Addressing the Burden of Antimicrobial Resistance in Vietnamese Hospitals by Vu Quoc, Dat
Open Research Online
The Open University’s repository of research publications
and other research outputs
Addressing the Burden of Antimicrobial Resistance in
Vietnamese Hospitals
Thesis
How to cite:
Vu Quoc, Dat (2020). Addressing the Burden of Antimicrobial Resistance in Vietnamese Hospitals. PhD
thesis The Open University.
For guidance on citations see FAQs.
c© 2020 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
 
 
 
 
 
 
 
 
 
ADDRESSING THE BURDEN OF ANTIMICROBIAL 
RESISTANCE IN VIETNAMESE HOSPITALS 
 
 
 
 
 
Vu Quoc Dat 
School of Life, Health and Chemical Sciences 
The Open University 
Affiliated Research Centre: Oxford University Clinical Research Unit (OUCRU) 
Viet Nam 
  
A thesis submitted for the degree of Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
 
 
December 2019
i 
 
 
Abstract 
Hospital acquired infections (HAIs), especially ventilator associated respiratory 
infection (VARI) cause significant morbidity and mortality, and disproportionally so in low- 
and middle-income countries (LMICs), including Vietnam, where infection control in 
hospitals is often neglected. The management of HAIs in these settings is challenging 
because of the high proportions of antimicrobial drug resistance and limitations of 
laboratory diagnostics, financial and human resources in terms of knowledge and skills for 
antimicrobial stewardship and infection prevention and control.  
Because resistance is driven by use of antimicrobials, my thesis started with a question 
on use and cost of antimicrobials in public hospitals in the country followed by a detailed 
assessment of use and cost of antimicrobials in the management of ventilator associated 
respiratory infections (VARI). I obtained detailed bids from hospitals and provincial 
departments of health representing 28.7% (1.68 / 5.85 billion US$) of the total hospital 
medication budget in Vietnam. Antimicrobials represented 28.6% of these costs. 
Antimicrobials were stratified using the Access, Watch, Reserve (AWaRe) groups proposed 
by WHO in 2017. I showed that the most commonly used antimicrobials across sites were 
second generation cephalosporins (20.3% of total procured defined daily dose, DDD) 
followed by combinations of penicillins and beta-lactamase inhibitors (18.4% of total 
procured DDD). The most expensive antimicrobials are the last resort antimicrobials, which 
can considerably increase the cost of treatment for patients with HAIs caused by multidrug 
resistant pathogens in critical care units in Vietnam. In recognition of this problem, I 
estimated the excess cost of management of VARI using a costing model study. At the 
current incidence rate of 21.7 episodes per 1000 ventilation-days, I estimated there were 
34,428 episodes of VARI nationally, associated with a direct cost of more than US$ 40 
million per year. Our studies showed the need for an affordable and scalable intervention 
in critical care units to reduce the burden of VARI and provide cost savings for national 
health expenditure. 
My studies also showed that antimicrobial costs are a major component of the excess 
cost of VARI management in Vietnam (51.1%) and that a one day reduction in the duration 
of antimicrobial therapy can save US$ 1.72 million. Therefore, my thesis has focused on 
interventions to prevent VARI and to shorten antimicrobial therapy. In recognition of 
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human resources constraints in Vietnam, including for microbiology diagnostics and critical 
care nursing, I have studied automatic technology and equipment, including matrix assisted 
laser desorption ionization-time of flight mass spectrometry (MALDITOF-MS) for rapid 
identification of pathogens and continuous automatic cuff pressure control device to 
prevent VARI. To examine effectiveness of these intervention, I conducted 2 randomised 
controlled trials to evaluate the clinical effectiveness of matrix assisted laser desorption 
ionization-time of flight mass spectrometry (MALDITOF-MS) in optimizing antimicrobial 
therapy and to evaluate the effectiveness of continuous cuff pressure control in preventing 
VARI. For the latter, pending unblinding and final results I describe the implementation of 
the trial and report the incidence of hospital acquired bloodstream infection during this 
trial.  
A diagnostic randomised controlled trial (RCT) was conducted to evaluate the impact of 
MALDITOF-MS versus conventional diagnostics in improving antimicrobial use in patients 
with confirmed infection. Although MALDITOF-MS provided more rapid identification of 
invasive bacterial and fungal pathogens than conventional microbiology, the proportion of 
patients on optimal therapy at 24 or 48 hours after growth of specimen did not increase. 
These findings showed that without human resources and an effective antimicrobial 
stewardship programme, technology alone cannot provide a solution for antimicrobial 
overuse in hospitals in LMICs.  
A randomized controlled clinical trial was conducted to evaluate the effectiveness of 
continuous cuff pressure control versus daily manual cuff measurement (VARI-prevent). In 
this study I recruited and followed-up 597 adult patients who were admitted to ICUs and 
were intubated within 48 hours of admission. The patients were randomised to receive 
either continuous or manual cuff pressure measurement and control and were followed 
for occurrence of VARI during ICU stay and up to 90 days after randomisation. The study 
has completed recruitment and follow-up and final analysis is ongoing. The overall rate of 
VARI and VAP in eligible patients was 23.7% (140/591) and 17.3% (102/591) respectively. 
The data from this trial (VARI-prevent) was analysed to estimate the incidence density rate 
of hospital acquired bloodstream infection (HABSI) in 3 ICUs in Vietnam for the first time. 
The most common pathogens causing HABSI were Klebsiella pneumoniae followed by 
Pseudomonas aeruginosa, Acinetobacter baumannii and Coagulase-Negative 
staphylococci. Polymicrobial culture results were reported in 6.8% (3/44) patients with 
iii 
 
culture confirmed HABSI. The rate of HABSI and central line associated BSI (CLABSI) were 
7.4% (44/591) and 9.3% (31/333), respectively. The incidence density rate of HABSI and 
CLABSI were 3.76 per 1000 patients-days and 8.43 per 1000 catheter-days, respectively. 
This suggests that the implementation of infection prevention and control bundle including 
catheter care is important to reduce the high incidence of HABSI in Vietnam. 
The findings in my thesis are relevant to healthcare professionals and policy 
stakeholders. It demonstrates the magnitude of HAI burden and creates awareness of 
potential beneficial interventions. Results of my trials will be helpful to inform decisions to 
establish the antimicrobial stewardship programmes and infection prevention and control 
bundles to improve patients’ outcomes. 
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: General introduction 
1.1. The global antimicrobial resistance threat 
1.1.1. The role of the hospital and ICUs in the cycle of antibiotic resistance 
The discovery of antibiotics is arguably the greatest medical achievement in the history 
of mankind (Ferriman, 2007). Since their introduction into patient care, antibiotics have 
saved millions of lives and enabled advances in many other fields of medicine, including 
critical care, surgery, transplantation and cancer treatment (Spellberg et al., 2011). 
However, we are now at the dawn of the post-antibiotic era where the continued 
effectiveness of antibiotics is waning along with an estimated global loss of 10 million lives 
a year and 100 trillion USD by 2050 due to antibiotic resistance (O’Neill, 2014). 
Antibiotics are classified as original natural compounds produced by fungi and 
saprophytic bacteria or derived or chemically synthesized from natural compounds 
(Demain and Sanchez, 2009). The emergence and spread of antibiotic resistance reflects an 
ancient, natural phenomenon of antibiotic resistance gene distribution (D'Costa et al., 
2011) and a classic Darwinian selection process accelerated by the widespread mass use of 
antibacterial drugs by humans in healthcare and food production.  
The terms overuse, misuse and inappropriate use are applied for antibiotic prescription 
without or with minimal benefit to patients (Smith et al., 2018). Global antibiotic resistance 
is affected by multiple ecological and social drivers in different environments, including use 
(appropriate or inappropriate) in human healthcare settings, but also use in animals for 
food production in the agricultural and aquacultural environments – representing the 
majority of use globally (Andersson and Hughes, 2014, Centers for Disease Control and 
Prevention (CDC), 2013a). 
Hospitals, particularly intensive care units (ICUs) present a conducive environment for 
emergence, spread and selection of antimicrobial resistance (AMR) (Figure 1-1). High 
selective pressure favouring resistant bacteria is exerted by the intensive and frequent 
antibiotic use in the hospital environment (Fortin et al., 2014), whilst poor quality infection 
control programmes and other conditions such as a high density of extremely vulnerable 
population with immunocompromised conditions enable transmission of these resistant 
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bacteria (Nicolle and World Health Organization. Anti-Infective Drug Resistance 
Surveillance and Containment Team., 2001). Therefore, hospitals act as amplification 
vessels for resistance genes and resistant pathogens, which may continue to spread to the 
community. Indeed, infections acquired within the hospital setting (hospital acquired 
infections) are generally associated with bacteria that are resistant to more antibiotics than 
infections acquired in the community.  
 
Figure 1-1. The cycle of antibiotic resistance (Centers for Disease Control and Prevention 
(CDC), 2013a). 
 
Among hospitalised patients, those in ICUs receive more broad-spectrum antibiotics at 
prolonged treatment durations, and undergo more invasive medical procedures putting 
them at higher risk of infection with drug resistant bacteria (Voor In 't Holt et al., 2014). 
Currently, carbapenem resistant Gram-negative bacteria, especially Enterobacteriaceae, 
are recognised as the greatest threat to patient safety in hospitals (European Centre for 
Disease Prevention and Control, 2019). In a systematic review and meta-analysis of studies 
published between 1987 and 2012, important significant risk factors for carbapenem-
resistant Pseudomonas aeruginosa infection were prior administration of carbapenems 
(OR = 7.09, 95% CI 5.43–9.25), medical devices (OR = 5.11, 95%CI 3.55–7.37), and ICU 
admission (OR= 3.02, 95%CI=1.62–5.61). Other statistical significant factors were other 
antibiotic use, underlying diseases and length of hospital stay (Voor In 't Holt et al., 2014). 
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The US National Nosocomial Infections Surveillance showed that in 1996 among 262 
hospitals higher rates of antibiotic use corresponded to higher antibiotic resistance among 
Escherichia coli for ceftriaxone, P. aeruginosa for ceftazidime and piperacillin/tazobactam 
and enterococci for vancomycin in ICUs in comparison with non-ICU settings (Fridkin et al., 
1999). The mean proportion of resistance among selected important pathogen-
antimicrobial pairings was highest among ICU patients (21%), followed by non-ICU 
inpatients (17%) and lowest among outpatients (12%) (Zhang et al., 2006). In a study 
conducted between 2011 and 2013 in Europe and North America, susceptibility of 
Enterobacteriaceae was lower in ICUs than non-ICU wards for all antibiotics tested using 
the Clinical and Laboratory Standards Institute (CLSI) guidelines (MDR rate was 16.4% in 
ICU vs 11.4% in non-ICU) (P < 0.05) in 18 European countries and in Canada and the USA 
(except for ciprofloxacin and levofloxacin) (Lob et al., 2015).  
Hospitals play an important role in persistence and spread of antimicrobial resistance 
(Figure 1-2). On dry surfaces, most nosocomial bacteria can survive from days to months 
(4-5 months for Acinetobacter spp and Enterococcus spp, 16 months for E. coli and P. 
aeruginosa and more than 30 months for Klebsiella spp) (Kramer et al., 2006). Exposure to 
antibiotics will favour the survival of resistant isolates over their susceptible counterparts. 
This can increase the risk for acquisition of a resistant pathogen for a newly hospitalised 
patient from the prior room occupant (Mitchell et al., 2015). Additionally, many hospital 
pathogens can produce biofilms during their colonisation of surfaces, facilitating prolonged 
survival, colonisation of medical devices, and subsequent device-related infections (Donlan 
and Costerton, 2002, Donlan, 2001). The hospital water environment can contribute to the 
chain of transmission by serving as a reservoir of nosocomial pathogens. Water was 
reported as an important source of nosocomial outbreaks in the USA, associated with 
nearly 1400 deaths from P. aeruginosa pneumonia alone each year (Anaissie et al., 2002). 
Carbapenemase- or extended-spectrum β-lactamase-producing Enterobacteriaceae can 
contaminate sinks in hospital and cause transmission between sinks, to healthcare worker’s 
hands and in turn to patients in ICUs (Lowe et al., 2012, De Geyter et al., 2017, Snitkin et 
al., 2012, Clarivet et al., 2016).  
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Figure 1-2. Major route of transmission of nosocomial antimicrobial resistant pathogens 
in hospitals.  
Adapted from Arias et al (Arias and Murray, 2012). 
 
In many low- and middle-income countries (LMIC), antimicrobial drug resistance poses 
an increasing burden on already stretched healthcare systems (Okeke et al., 2005), and the 
proportion of resistant bacteria is growing more rapidly in these countries. In a study of 
antibiotic resistance across 3 countries in different geographic and economic zones, the 
proportion and increase of resistant pathogens was highest in China (22% increase from 
1994 to 2000, data from China's National Center for Antimicrobial Resistance), followed by 
Kuwait (17% increase from 1999 to 2003, data from a single large teaching hospital, 
Mubarak Al-Kabeer Hospital,) and the USA (6% increase from 1999 to 2002, data from 
National Nosocomial Infections Surveillance System (NNIS) for hospital-based resistance 
and the U.S. Active Bacterial Core Surveillance (ABC)) (Zhang et al., 2006). Many factors can 
contribute to the increase of drug resistance in the hospitals in LMICs, including 
(inappropriate) use of antibiotics, lack of knowledge about infectious diseases and 
microbiology, lack of diagnostics, understaffing, overcrowded hospitals, lack of effective 
infection prevention and control and in some the growing phenomenon of medical tourism 
(Okeke et al., 2005, World Health Organization. Anti-Infective Drug Resistance Surveillance 
and Containment Team., 2001, Hsu et al., 2017, McNulty et al., 2018).  
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1.1.2. Aetiology and drug resistance profile of common pathogens causing 
hospital acquired infections 
Many microorganisms can cause nosocomial (hospital acquired) infections, including 
different viruses, bacteria, fungi and parasites. Bacteria are the most common causative 
pathogens, and E. coli and the ESKAPE bacteria (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, P. aeruginosa and Enterobacter 
spp) are the most important species associated with hospital acquired infections in the 
world (Boucher et al., 2009). In 2013, the United States of America’s Centers for Disease 
Control and Prevention (US CDC) raised awareness of antibiotic resistance threats that 
required urgent actions to respond. They described 18 priority bacteria-drug combinations 
in both health care and community settings focusing on incidence, clinical and economic 
impacts, availability of current treatment and prevention (Centers for Disease Control and 
Prevention (CDC), 2013a). These pathogens were categorized into one of three levels of 
antibiotic resistance: urgent, serious and concerning. carbapenemase-producing 
Enterobacteriaceae (CPE) were assigned to the urgent category along with Clostridium 
difficile and cephalosporin resistant Neisseria gonorrhoeae (Table 1-1). 
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Table 1-1. The US CDC’s priority pathogens list of antibiotic-resistant bacteria (Centers 
for Disease Control and Prevention (CDC), 2013a) 
 Antibiotic Resistance Threats 
 Threat Level of Urgent 
• Clostridium difficile 
• Carbapenem-resistant Enterobacteriaceae 
• Drug-resistant Neisseria gonorrhoeae  
Threat Level of Serious 
• Multidrug-resistant Acinetobacter (resistant to three or more drug classes) 
• Drug-resistant Campylobacter 
• Fluconazole-resistant Candida 
• Extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs) 
• Vancomycin-resistant Enterococcus (VRE) 
• Multidrug-resistant Pseudomonas aeruginosa (three or more drug classes) 
• Drug-resistant non-typhoidal Salmonella 
• Drug-resistant Salmonella Typhi 
• Drug-resistant Shigella 
• Methicillin-resistant Staphylococcus aureus (MRSA) 
• Drug-resistant Streptococcus pneumoniae 
• Drug-resistant tuberculosis 
Threat Level of Concerning 
• Vancomycin-resistant Staphylococcus aureus (VRSA) 
• Erythromycin-resistant Group A Streptococcus 
• Clindamycin-resistant Group B Streptococcus 
Nosocomial pathogens are in bold. 
 
In 2017, WHO released a global priority pathogens list of 12 pairings of bacteria and 
antibiotic resistance phenotypes for research and development of new treatments and 
stratified these into three priority levels as critical, high and medium (World Health 
Organization, 2017a). The critical group includes nosocomial multidrug resistant bacteria: 
carbapenem-resistant A. baumannii, carbapenem-resistant P. aeruginosa and 
carbapenem/3rd generation cephalosporin-resistant Enterobacteriaceae (see Table 1-2).  
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Table 1-2. The WHO’s priority list of antibiotic-resistant bacteria for research and 
development (R&D) of new and effective antimicrobial treatments (World Health 
Organization, 2017a) 
 Antibiotic-resistant microorganism 
 Priority 1: CRITICAL 
• Acinetobacter baumannii, carbapenem-resistant 
• Pseudomonas aeruginosa, carbapenem-resistant 
• Enterobacteriaceae, carbapenem-resistant, ESBL-producing 
Priority 2: HIGH 
• Enterococcus faecium, vancomycin-resistant 
• Staphylococcus aureus, methicillin-resistant, vancomycin-intermediate and 
resistant 
• Helicobacter pylori, clarithromycin-resistant 
• Campylobacter spp., fluoroquinolone-resistant 
• Salmonellae, fluoroquinolone-resistant 
• Neisseria gonorrhoeae, cephalosporin-resistant, fluoroquinolone-resistant 
Priority 3: MEDIUM 
• Streptococcus pneumoniae, penicillin-non-susceptible 
• Haemophilus influenzae, ampicillin-resistant 
• Shigella spp., fluoroquinolone-resistant 
Nosocomial pathogens are in bold. 
 
In 2015 and 2018, WHO released the reports of the Global Antimicrobial Resistance 
Surveillance System (GLASS) for selected priority specimen and pathogens (see Table 1-3) 
(Organization, 2015, World Health Organization, 2018a). This part of the thesis will focus 
on the critical group of prioritized bacteria defined by the WHO’s priority pathogens list as 
all of these represent enormous challenges in Vietnamese hospitals.  
1.1.2.1. Acinetobacter baumannii  
Acinetobacter are Gram-negative, strictly aerobic coccobacilli, and the genus comprises 
17 named species and 15 genomic species (gen. sp.) designated by DNA–DNA hybridization, 
among which Acinetobacter baumannii is the most clinically important species (Dijkshoorn 
et al., 2007). 
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Table 1-3. WHO priority specimens and pathogens for surveillance of AMR 
Specimen Case definition Prioritized pathogens for surveillance  
Blood  Isolation of pathogen from blood E. coli 
K. pneumoniae  
A. baumannii 
S. aureus 
S. pneumoniae 
Salmonella spp 
Urine Significant growth in urine 
specimen 
E. coli 
K. pneumoniae 
Faeces Isolation of Salmonella spp. or 
Shigella spp. from stools 
Salmonella spp. 
Shigella spp. 
Urethral and 
cervical swabs 
Isolation of N. gonorrhoeae  N. gonorrhoeae 
 
The natural habitat of Acinetobacter species consists of soil, water, and vegetables and 
many members of the genus Acinetobacter have been recovered from human skin 
(Dijkshoorn et al., 2007). However, the proportion of individuals carrying A. baumannii on 
healthy human skin is usually low (0.5%-10.4%) and community A. baumannii isolates are 
often susceptible and unrelated (Seifert et al., 1997, Zeana et al., 2003) whilst the 
proportion of A. baumannii colonisation in hospital ranged from 32.4% to 64% and most 
hospital isolates are multidrug resistant and closely related (Zeana et al., 2003, Lee et al., 
2010). A. baumannii can easily contaminate healthcare workers’ gowns, gloves, and hands 
and seems more easily transmitted than other multidrug resistant pathogens such as P. 
aeruginosa, MRSA or VRE (Morgan et al., 2010). A. baumannii can cause a spectrum of 
nosocomial infection in critically ill patients, of which the majority are ventilator-associated 
respiratory infections with other manifestations including bloodstream infection, catheter-
associated urinary-tract, wound infections and meningitis (Peleg et al., 2008). These 
demonstrate the important role of the A. baumannii reservoir and transmission in 
outbreaks of nosocomial infection. 
The resistance of A. baumannii to carbapenem has increased globally since 2006 (Peleg 
et al., 2008). The report from National Healthcare Safety Network (NHSN) in the USA 
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showed the overall proportion of carbapenem resistance in A. baumannii was 33% in 2006–
2007 (Hidron et al., 2008). During the period of 2011 to 2014, NHSN reported a higher 
frequency of resistance among A. baumannii strains than in 2006 and with a wide variability 
among types of infections. In 2014, the prevalence of carbapenem resistance in A. 
baumannii was 64% among isolates causing catheter-associated urinary tract infections, 
55% in ventilator-associated pneumonias (VAPs), 46.4% from central line-associated 
bloodstream Infections, and 33.3% in surgical site infections (SSIs) (Weiner et al., 2016). In 
the MYSTIC programme in 11 European countries from 1997-2000, among 490 tested 
isolates, A. baumannii was highly susceptible to meropenem (97–100%) and imipenem 
(93–100%) in all countries except Italy, Turkey and the UK (susceptibility of 66-77% to 
meropenem and 62-78% to imipenem) (Turner and Greenhalgh, 2003). 
The proportion of carbapenem-resistance in clinical isolates of A. baumannii in South-
east Asia (SEA) may be the highest in the world (Hsu et al., 2017). The SEA region consists 
11 countries, including 2 high income economies (Gross national income, GNI per capita of 
US$ 12,376 or more, including Singapore and Brunei), 2 upper middle income economies 
(GNI per capita of US$ 3,996 and US $12,375, including Malaysia and Thailand) and 7 lower-
middle income economies (GNI per capita between US$ 1,026 and US$ 3,995, including 
Myanmar, Cambodia, Indonesia, Laos, Philippines, Timor-Leste and Vietnam) (World Bank, 
2019). Among upper middle- and high- income SEA countries, where national hospital-
based antimicrobial resistance surveillance has been established, the proportion of 
carbapenem resistance in A. baumannii was 61% in Malaysia (2016) (Institute for Medical 
Research, 2016) and 71% in Thailand (2016) (National Antimicrobial Resistance Surveillance 
Center, 2016). In Singapore, the proportion of carbapenem resistance in A. baumannii was 
49.6% in a national survey (Hsu et al., 2007) and it remained unchanged during the period 
of 2011-2015, in Singapore’s largest hospital (Teo et al., 2016) (in the absence of publicly 
available recent national data). For other SEA countries with low- and lower middle-
incomes, in a systematic review from the period 2002-2016, carbapenem resistance among 
A. baumannii isolates was reported as 43%-92% in Vietnam, 50-85% in Indonesia, 54.1% in 
the Philippines and 5.9% in Cambodia. Data were not published for the remaining countries 
in the region, including Myanmar, Laos, Brunei and Timor-Leste (Hsu et al., 2017). 
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Table 1-4. Antimicrobial susceptibility profiles of common nosocomial carbapenem-resistant pathogens in Vietnamese ICUs 
Study Study period Study setting Clinical specimen A. baumannii  P. aeruginosa  K. pneumoniae E. coli  
(Johansson et al., 2011) 1/2007-3/2008 3 ICU with a total 
of 62 beds 
Blood, respiratory aspirate 
and urine* 
69.1% 
(105/152) 
55.7%  
(69/124) 
2.9%  
(3/103) 
0% 
(0/61) 
(Van et al., 2014) 2009 Single ICU with 15 
beds 
Blood, respiratory aspirate 
and pus 
92.1% 
(52/68) 
   
(Kiratisin et al., 2012) 4-7/2010 3 hospitals* Isolates from intra-
abdominal, bloodstream, 
and pneumonia infections 
89.5% 46.7%   
(Phu et al., 2016) 10/2012-9-2013 15 adult ICUs Isolates from pneumonia, 
bloodstream, surgical site 
and urinary tract infection 
89.2% 55.7% 14.9%  
(Le et al., 2016) 10/2012-9-2013 6 paediatric ICUs  67% 71% 55% 42% 
(Tada et al., 2013) 2008-2011 2 ICUs Respiratory, blood and pus  51% 53%   
(Le Minh et al., 2015) 1/2011-6/2012 Single ICU Tracheal aspirate 84%    
(Biedenbach et al., 2016) 2012–2014 5 hospitals respiratory tract specimens 92.5% (904) 42.9% (529)   
(Nhu et al., 2014) 11/2012 to 9/ 
2013 
2 paediatric 
hospitals 
 67% 71% 55% 42% 
(Tran et al., 2017) 11/2014 – 
9/2015 
Single ICU Bronchoalveolar lavage 
(BAL) fluid 
93.2% 86.2% 25.6%  
(Tuan Anh et al., 2017) 2012-2014 3 hospitals  Sputum, pus, blood and 
fluid aspirates 
86.7%    
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1.1.2.2. Pseudomonas aeruginosa 
P. aeruginosa are non-fermenting Gram-negative bacilli living in soil and aqueous 
environments (Gellatly and Hancock, 2013). P. aeruginosa is not commonly part of the 
normal human flora, with an estimated 5% of individuals colonised (Kropec et al., 1993). 
However, high colonisation rates are associated with a risk of severe P. aeruginosa infection 
in patients with long term hospitalisation and/or immunocompromising conditions, such 
as cystic fibrosis, bronchiectasis, severe burns, hematologic malignancies or critical illness. 
In a study among 1314 patients in 10 ICUs in France, P. aeruginosa colonisation developed 
in 11-21% of patients admitted to ICU during their stay and the risk factors for P. aeruginosa 
acquisition were increased age, history of previous acquisition, duration of mechanical 
ventilation for more than 10 days and exposure to non-antipseudomonal antibiotics and 
contaminated water (Venier et al., 2014). In SEA in 2010, the proportion of carbapenem 
resistant P. aeruginosa among isolates in hospitalised patients was lowest in Singapore 
(23.3%) and highest in Vietnam (46.7%) (Suwantarat and Carroll, 2016). 
P. aeruginosa is resistant to a broad range of antimicrobials through intrinsic, acquired 
and adaptive mechanisms and its additional swarming motility and biofilm-forming 
capacity causes difficulty in treating infections (Breidenstein et al., 2011). Carbapenem is 
only second choice empirical antipseudomonal treatment after ceftazidime, and should not 
be used as monotherapy because of rapid resistance development. Data from the 
European Antimicrobial Resistance Surveillance Network (EARS-net) and a global WHO 
network, including both non-ICU wards and ICUs with a mean number of 5160 isolates per 
year, showed the proportion of carbapenem resistance in P. aeruginosa has increased from 
6.8 to 28.8% during 1996–2015 (Karampatakis et al., 2018).  
1.1.2.3. Enterobacteriaceae 
Enterobacteriaceae are a large family of important Gram-negative bacilli that are part 
of the normal flora in the human gastrointestinal tract and include multiple genera among 
which Escherichia, Klebsiella, Enterobacter, Serratia, Proteus, and Citrobacter are most 
frequently encountered in a clinical setting. These organisms cause both community and 
hospital acquired infection. In the past 2 decades, the global emergence and spread of 
antimicrobial drug resistance among Enterobacteriaceae was mostly associated with 
extended-spectrum β-lactamases (ESBLs) and carbapenemases (Lynch et al., 2013). New 
Delhi Metallo-β-lactamase-1 (NDM-1) is a gene encoding for a carbapenem hydrolysing 
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enzyme which was first described in 2009 in Klebsiella and E. coli isolates from a Swedish 
patient who had travelled to and was hospitalised in New Delhi, India (Yong et al., 2009). 
The first case with NDM-1-producing Enterobacteriaceae was reported in Vietnam in 
September 2010 (Hoang et al., 2013).  
During April – July 2010, data from 4 countries in SEA (Philippines, Singapore, Thailand 
and Vietnam) in hospitalised patients showed that the proportion of ESBL positive 
Enterobacteriaceae ranged from 19.8% (Singapore, 96 isolates) to 55.1% (Vietnam, 71 
isolates) whilst the proportion of carbapenem resistant Enterobacteriaceae ranged from 
2.9% (Philippines, 70 isolates) to 5.6% (in Vietnam) (Suwantarat and Carroll, 2016).  
In a national antimicrobial resistance surveillance program between 2011 and 2015, the 
proportion of carbapenem resistant K. pneumoniae increased from 2% to 12% in Singapore, 
from 6% to 11.9% in Philippines, from 0.5% to 1.6% in Malaysia and 0.3% to 4.9% in Thailand 
(Hsu et al., 2017). In the same period, the proportion of carbapenem resistant E. coli rose 
from 0% to 5% in Singapore whilst it remained unchanged in Philippines (6%) and in 
Thailand (0.8% to 0.9%) and decreased from 0.5% to 0.2% in Malaysia (Hsu et al., 2017). 
Data on CRE in other countries in SEA (Brunei, Cambodia, Timor-Leste and Laos) was not 
available (Hsu et al., 2017). 
 
1.2. The growing crisis of hospital acquired infections  
1.2.1. Overview of hospital acquired infections (HAIs) 
A hospital acquired infection or nosocomial infection is defined as one acquired in 
hospital by a patient who was admitted for other reasons and that infection is not 
presented or not in incubation on admission (Ducel et al., 2002). A cut-off point of 48 hours 
after admission is widely used to distinguish between community and hospital acquired 
infections. In addition, the term healthcare-associated infection (HCAI) was originally 
proposed to refer to infections, which occur in patients on admission or within 48 hours of 
admission having had previous exposure to invasive procedures or healthcare facilities 
(such as nursing homes, outpatient treatment facilities etc) (Friedman et al., 2002). 
Currently, such facilities are uncommon in Vietnam and many LMICs and thus this thesis 
will only focus on HAIs.  
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HAIs are classified into anatomical site-specific infections and device related infections: 
surgical site infections, urinary tract infections (UTIs and UTIs related to urinary catheters) 
respiratory infections (hospital acquired pneumonia (HAP) and respiratory infection related 
to an endotracheal or tracheostomy tube), vascular catheter site infections (both 
peripheral and central) and blood stream infections (BSIs and those related to vascular 
catheters ) (Centers for Disease Control and Prevention (CDC), 2013b, Ducel et al., 2002). 
The US Centers for Disease Control and National Healthcare Safety Network (CDC/NHSN) 
has grouped HAIs into 14 major categories with 55 infection types (Centers for Disease 
Control and Prevention (CDC), 2013b) whilst the European Centre of Disease Prevention 
and Control (ECDC) defined 56 types of HAIs in ICUs. At a minimum, reporting is required 
for bloodstream infection and pneumonia, urinary tract infections and catheter-related 
infections may be added optionally (European surveillance of healthcare-associated 
infections in intensive care units, 2015). Nomenclature and definitions vary between these 
two organisations and Vietnam has utilised both. 
Hospital acquired infections affect all health care facilities in the world and have 
become a major cause of mortality and morbidity among inpatients and represent an 
important patient safety issue (Allegranzi et al., 2011). HAIs impact on length of stay, cost 
of treatment and outcome. However, the management of HAI is complex, in terms of 
clinical diagnosis, microbiological diagnostics, the growing proportion of antimicrobial 
resistant pathogens and the selection of appropriate empiric antimicrobials, particularly in 
patients requiring mechanical ventilation (Harmanci et al., 2002). The accurate aetiological 
diagnosis of HAIs, particularly in LMICs, is challenging because of the need for high quality 
microbiological investigations on specimens from all possible sites of infection.  
Hospital acquired respiratory infections are sub-classified depending on whether they 
are related to mechanical ventilation and intubation. Ventilator associated pneumonia 
(VAP) is a term used for pneumonia that occurs at least 48 hours after endotracheal 
intubation; ventilator associated tracheobronchitis (VAT) is a term used for other lower 
respiratory tract infections, such as tracheobronchitis or tracheitis without evidence of 
pneumonia (Centers for Disease Control and Prevention (CDC), 2013b).  
VAP is a particular problem in ICUs throughout the world. The development of VAP 
involves multiple factors and a complex interaction between the endotracheal tube, 
patient’s immunity and pathogen invasion into the lower respiratory tract. Pathogens can 
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spread to the lower respiratory mucosa causing infection via different mechanisms through 
(1) aspiration of infected respiratory secretions or gastric contents, (2) direct extension of 
a nearby infection, (3) inhalation of contaminated air or (4) by hematogenous 
dissemination from other remote local infection (Safdar et al., 2005a). Pathogenic bacteria 
may be acquired through endogenous routes (caused by host pathogenic flora) or 
exogenous routes (acquisition of bacteria from health care activities, invasive interventions 
or hospital environment). Based on understanding of these mechanisms, several strategies 
for preventing VAP have been developed as discussed later in this thesis. 
Differentiation of colonization and infection is important in diagnosis of HAI and making 
decisions on antibiotic therapy but is challenging in clinical practice (Figure 1-3). For 
example, Gram-positive bacteria are often isolated from the upper respiratory tract whilst 
the lower respiratory tract is considered sterile and therefore any significant isolates from 
the lower respiratory tract will be treated as pathogens (Robinson, 2004). However, the 
challenge is that specimens from the trachea and lung are often contaminated with 
organisms from the upper respiratory tract, or that have colonised the endotracheal tube, 
as the specimen is obtained. Both invasive and non-invasive diagnostic methods are widely 
used for diagnosis of VAP. As recommend by the American Thoracic Society since the first 
consensus statement on management of HAP in adults, blood cultures were used in an 
investigation of aetiological agents but positivity of bloodstream infection in an episode of 
VARI varied from 8-20% (American Thoracic Society, 1996). The microbiological diagnosis 
of VARI can be made by non-invasive methods, such as endotracheal aspiration (ETA) or 
invasive methods, such as protected specimen brush (PSB) or bronchoalveolar lavage (BAL) 
(Kalil et al., 2016). The clinical judgement of colonization or infection, backed by 
microbiological methods such as the identification of inflammatory cells in samples and the 
absence of epithelial cells (associated with the mouth and oropharynx) and use of (semi-) 
quantitative culture play important roles in the decision to start antibiotic treatment (Nseir 
et al., 2010). Additionally, distinguishing new clinical infection from colonization is required 
to measure the incidence of HAI which is the gold standard for HAI surveillance in past 
decades, although it is time consuming and expensive (Zingg et al., 2014). Thus, collection 
of samples and bacteria alone is insufficient for the accurate recording of HAI rates, 
particularly in the respiratory tract. Quantitative culture of respiratory samples is often 
used to differentiate between infection and colonization with widely accepted thresholds 
for the diagnosis of pneumonia as follows: ETA samples ≥105–106 colony forming units 
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(CFU)/ml; PSB samples ≥103 CFU/ml and BAL samples ≥104 CFU/ml (Ioanas et al., 2001). A 
Cochrane systematic review of five RCTs comparing respiratory samples processed 
quantitatively or qualitatively with 1367 patients showed no clinical advantage (in terms of 
reduction in mortality, ICU length of stay and duration of mechanical ventilation) of invasive 
diagnostics or quantitative cultures of respiratory secretions over non-invasive diagnostics 
or qualitative cultures in patients with suspected VAP (Berton et al., 2012). The complex 
diagnostic definitions for VAP which often require radiological, clinical and microbiological 
evidence make both high-quality epidemiology and research challenging and lead to bias 
due to the subjectivity in these definitions.  
 
Figure 1-3. Pathogenesis of ventilator-associated respiratory infection (VARI).  
Adapted from Craven and Kollef (Craven et al., 2009, Craven and Steger, 1995, Kollef, 1999).  
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1.2.2. Epidemiology of hospital acquired infection (HAI) 
Limitations in design and the low quality of data may result in poor estimates of HAI 
burden in LMICs. In a systematic review of health-care-associated infection in LMICs, 
118/220 (54%) of reviewed articles from 1995 to 2008 in Medline were graded as low 
quality (Allegranzi et al., 2011). The pooled prevalence of HAIs was double to triple that in 
high-income settings as Europe and the US (15.5 vs 7.1 and 4.5 per 100 patients, 
respectively). In this review, Pseudomonas (29%), Enterobacteriaceae (21%) and 
Acinetobacter species (24%) were leading causes of ventilator associated pneumonia (VAP) 
whilst bloodstream infections (BSI) were caused largely by Staphylococcus aureus (19%), 
Acinetobacter species (18%), Coagulase-negative staphylococci (17%) and 
Enterobacteriaceae (18%) (Allegranzi et al., 2011). Recent data from 43 countries with 
different income levels, including 503 ICUs in 2007-2012 showed high overall HAI 
prevalence (the overall rate of VAP per 1,000 mechanical ventilator days was 14.7 (95% CI, 
14.5-14.9)) (Rosenthal et al., 2014). 
We performed a literature search of 2 database (Embase and Ovid) from  January 1990 
to August 2017 for VAP in Asia for studies with period prevalence data, incidence density 
data, microbiology data and any data on costing of VAP (Bonell et al., 2018). Asian countries 
were defined according to the World Bank classification of income level at the time the 
study was published and further defined as tropical or non-tropical based on their 
geographical latitude. Period prevalence was highest in upper middle income countries 
(UMIs) and lowest in high income countries (HICs) (prevalence rate by country and region 
was shown in Figure 1-4). In this systematic review using data from 14 countries in Asia 
from 1990 to 2017, the point incidence density of VAP was 15.1 episodes per 1000 
ventilator-days (95%CI 12.1–18.0) (Bonell et al., 2018). The incidence density of VAP was 
high in both LMICs and UMICs, and there was no indication of a reduction over time on 
meta-analysis. However, the incidence density of VARI in LMICs was higher than in HICs 
(18.5 vs 9.0 per 1000 ventilator-days; P = 0.035) (Bonell et al., 2018).  
From this review, we concluded that VAP is a major contributor to HAIs in Asia.  Among 
14,295 organisms were identified, A. baumannii was the most common (26%), followed by 
P. aeruginosa (22%], K. pneumoniae (14%), and S. aureus (14%). In LMICs, A. baumannii 
was the most common. In tropical regions, A. baumannii was the most common species 
whilst S. aureus was a more common in - regions. Given the large expansion of ICUs in these 
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settings, the at-risk population can be expected to rise substantially in the immediate 
future, compounding the problem. 
 
Figure 1-4. The prevalence rates of ventilator-associated pneumonia in Asia.  
 
Southeast Asia is a region with high population density. The burden of HAIs in this 
region is not well documented, with even less literature concerning the lower income 
countries within this region (Ling et al., 2015). The overall prevalence of HAIs in Southeast 
Asia was reported as 9% in a recent meta-analysis, which is lower than in high income 
countries (15.5%), potentially due to systematic errors in reporting (Ling et al., 2015).  
In Thailand, the average point prevalence of HAIs was 6.5%, with the highest prevalence 
observed in ICU (22.6%) (Danchaivijitr et al., 2007). The most common HAIs were hospital 
acquired pneumonia/VAP, urinary tract infection and bloodstream infection. VAP was the 
most common device-associated infection with incidence densities of 10.8-13.6/1,000 
ventilator days (Reechaipichitkul et al., 2013, Danchaivijitr et al., 2007). Pathogens were 
isolated from around 70% of all HAIs and there was a predominance of Gram-negative 
bacteria (70% of isolates) (Reechaipichitkul et al., 2013). The types of HAI and detected 
bacterial isolates were similar in different studies. The most commonly isolated bacteria 
from patients with HAP and VAP were P. aeruginosa and A. baumannii (Reechaipichitkul et 
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al., 2013, Werarak et al., 2010). HAP and VAP were associated with a 30-day mortality of 
45.9% compared to 2.7% in those without infection (Werarak et al., 2010). Hospital 
acquired blood stream infection (HABSI) also were associated with higher ICU mortality in 
Thailand where overall mortality was 28.3%. The leading HABSI pathogens were E. coli 
(17.4%), S. aureus (15.2%), K. pneumoniae (12.3%) and P. aeruginosa (10.3%). Although the 
prevalence of HABSI decreased from 15.5/1000 (in 1987) to 12.2/1000 hospitalizations (in 
2003), the mortality remained unchanged, perhaps partly due to the increasing occurrence 
of multidrug resistant pathogens (Hortiwakul et al., 2012). Results from the point-
prevalence studies in Southeast Asia are presented in Table 1-5. 
 
Table 1-5. Overall type of hospital acquired infections from point-prevalence studies in 
selected countries in Southeast Asia 
HAIs Thailand 
(Danchaivijitr 
et al., 2007) 
Malaysia 
(Hughes et 
al., 2005) 
Vietnam 
(Phu et al., 
2016)  
Singapore 
(Cai et al., 
2017) 
Study setting 20 hospitals 
in 2006 
Single site 
in 2001 
15 adult ICUs 
in 2012-2013 
13 hospitals 
in 2015-2016 
Study population (patients) 9865 747 3287 5415 
Type of HAIs     
Hospital acquired pneumonia (HAP) 36.1% 21.4% 79.4% 24.8% 
Urinary tract infection (UTI) 25.5% 12.2% 2.9% 6.7% 
Bloodstream infection (BSI) 9% 12.2% 4.4% 8.7% 
Surgical site infection 11.0% 11.2% 4.2% 17.3% 
Skin and soft tissue infection 7.7% 4.0% 1.5% 7.2% 
Pathogens identified 70.8% 68% 59.6% 45.5% 
Etiology of HAIs     
P. aeruginosa 13.4% 21.4% 13.8% 11.5% 
Acinetobacter species 10.7% 3.43 24.4% 6.7% 
MRSA 5% 9.1% 5.4% 7.5% 
K. pneumoniae 10.9% 5.1% 11.6% 10.2% 
E. coli 6.9% 4.6% 5.4% 10.4% 
MRSA: Methicillin-resistant Staphylococcus aureus. 
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1.2.3. Economic burden of hospital acquired infections  
The excess cost associated with HAIs varied among different countries. A systematic 
review of the economic impact of HAIs on the US health care system in 2012 showed that 
the annual hospital costs of 5 major HAIs (surgical site infections, central line-associated 
bloodstream infections, catheter-associated urinary tract infections, ventilator-associated 
pneumonia and C. difficile infections) was US$ 9.7 billion. In which the estimated cost 
attributable to VAP was US$ 40,144 per case (95% CI 36,286–44,220), with a total economic 
burden of US$ 3.1 billion (95% CI US$ 2.8-3.4 billion) (Zimlichman et al., 2013). Meanwhile, 
the additional amount of money spent for an episode of VAP in Europe is estimated to be 
around US$ 13,000–15,000 (Arefian et al., 2016a, Wyncoll and Camporota, 2012). For Asian 
countries, data on the cost of VAP management was limited. In our recent systematic 
review, we found only 5 studies reporting the economic burden of VAP with different 
methodologies (Bonell et al., 2018). Three studies compared the average cost between 
patients with and without VAP, respectively which was US$6,251 vs. US$2,599 in India 
(Mathai et al., 2015), US$8,925 vs. US$6,626 in Taiwan (Tzeng et al., 2015) and 3.04 
purchasing power parity (PPP, a measure of the total amount of goods and services that a 
single unit of a country’s currency can buy in another country) per day vs. 1.23 PPP per day 
in Iran (Karkhane et al., 2016). One study in India calculated that the average excess cost of 
antibiotics used to treat VAP was US$433 (Misal et al., 2017) and one study in Thailand 
reported the average hospital cost per patient admitted to ICU before and after 
implementation of the care bundle for VAP $4,769 and $2,378 respectively 
(Apisarnthanarak et al., 2007). In Vietnam, the excess cost of HAI ranged from US$ 865 to 
US$ 1,131 in the period of 2008 to 2010 (Ha and Ha, 2012, Thi Anh Thu et al., 2015) and in 
a study of 3 Vietnamese tertiary referral hospitals from 2013 to 2015, the cost difference 
between patients with and without VAP was estimated at US$ 2,189 (Phu et al., 2017).  
Given the differences in methodologies and in country incomes among these studies, 
the economic impact on the healthcare systems can only be compared in a limited way. 
The variations in excess cost may be due to differences in costing of used resources and the 
healthcare systems. Estimating the excess cost associated with HAIs could help inform 
policy makers in planning and implementing necessary changes in infection prevention and 
control, antibiotic stewardship programmes, resource allocation and other relevant 
policies with the final purpose to reduce the incidence and burden of HAIs (Graves, 2004, 
Arefian et al., 2016b). A number of studies have been conducted across the world to answer 
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the question regarding the excess financial cost of treating HAIs, with certain variations in 
methods or definitions. The approaches to estimate the economic burden of HAIs have 2 
major limitations: lack of a distinction between cost attributable to the management of 
HAIs and cost attributable to the management of the causes of initial hospital admission 
and lack of an adequate method for calculating indirect costs (e.g. lost wages, 
incapacitation, lost future wages or premature death) (Gianino et al., 2007, Marchetti and 
Rossiter, 2013). 
Costs attributable to HAIs can be estimated using the concurrent method (examining 
individual patients and itemising all resources used during an HAI episode) or comparative 
method (comparing the cost of patients with HAIs and patients without HAIs or “controls”) 
(Haley, 1991). The first method is time consuming and requires detailed protocols to 
determine the events which are attributable to HAIs (Haley, 1991, Graves et al., 2010). The 
latter method is less time-consuming but has 2 difficulties: 1) several factors (e.g. 
comorbidity) can prolong the hospital stay regardless of HAI but these factors are hard to 
match and 2) for matching these factors, it increases number of matching factors and 
therefore can exclude the patients with HAI because the controls is exhausted (Graves et 
al., 2010).  
These costs include the hospital costs, hospital charges, resources used and actual re-
imbursement, and the hospital cost is a useful indicator as they reflect the actual economic 
burden of HAI (R. Douglas Scott II, 2009). For each episode of HAI, this cost should take into 
account the length of stay associated with HAIs, type and dosage of medication 
administered to treat the infections and number and type of services for diagnostics of the 
HAI episode (Gianino et al., 2007). 
 
1.2.4. Diagnostics of hospital acquired infections 
Microbiological diagnostics play an important role in the control of HAIs in 3 ways: 
screening, detection and surveillance. In screening, diagnostics help to identify patients 
with colonisation of resistant pathogens and these patients can be placed under stricter 
infection prevention and control measures, such as standard precautions and isolation to 
prevent the spread of resistant organisms (Siegel et al., 2007). In detection, rapid high 
quality laboratory diagnostics play an important role in the management of infection by 
28 
 
enabling accurate diagnosis of aetiology and antimicrobial susceptibility, guiding 
appropriate treatments for individual patients and informing locally relevant guidelines, 
(Petti et al., 2006, Caliendo et al., 2013). Diagnostics are also important in facilitating 
stewardship and enabling surveillance of antimicrobial resistance (AMR) (Tsalik et al., 
2016).  
LMICs, where the burden of HAIs and AMR is highest, often lack laboratory capacity, 
both in terms of equipment and highly trained laboratory staff, required to provide 
accurate microbiological diagnoses, resulting in lack of trust in results and underuse of 
microbiological diagnostics (Petti et al., 2006, Peterson et al., 2001). This leads to limited 
knowledge of the causes of HAIs, of the spread and significance of antimicrobial resistance 
and may lead to inappropriate use of antibiotics with impacts on both AMR and mortality 
and morbidity. Advanced diagnostics are needed for addressing the antimicrobial 
resistance threats and reducing operational requirements in LMICs (Ming et al., 2019). 
The rapid detection and identification of bloodstream pathogens is important to 
establish the diagnosis of bacteremia and guide treatment. However, blood culture detects 
pathogens in < 50% of patients with sepsis (Kayange et al., 2010, Heffner et al., 2010). 
Increased time to notification of positive blood culture is associated with increased length 
of hospitalization (Beekmann et al., 2003). The early, accurate identification of bloodstream 
infection assists in rapid deployment of optimal antibiotic therapy for these patients with 
life threatening infections.  
Microbiological molecular methods have potential advantages over conventional 
techniques, in terms of speed, throughput, sensitivity, quantitation and automation (Ecker 
et al., 2010). Current available new techniques for identification of pathogen in blood are 
often based on the detection of proteins (such as Matrix-assisted laser desorption 
ionization-time of flight mass spectrometry (MALDITOF-MS) or nucleic acids (such as 
fluorescence in situ hybridization (FISH), microarray and real-time PCR) (Loonen et al., 
2014).  
MALDITOF-MS has been recognized as a revolution in microbiological diagnostics since 
it was first developed by Nobel laureate Koichi Tanaka in the 1980s (Tanaka et al., 1988). In 
the hospital setting, the rapid availability of accurate identification and susceptibility 
testing of bacterial (and fungal) pathogens is important to guide appropriate therapy. A 
diagnostic system that is robust, accurate, rapid and has low running costs, could be cost 
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saving and improve patient outcomes. MALDITOF uses a proteomic method to identify 
pathogens by analyzing microbial colonies which grow from culture media, blood culture 
broth, cerebrospinal fluid (CSF) or urine (Clark et al., 2013). The sample is prepared by 
addition to a matrix of a laser energy-absorbent, low mass organic compound in the 
MALDITOF metal target plate and air dried at room temperature for co-crystallization 
before insertion into a mass spectrometer. The sample-matrix crystal is bombarded by an 
ultraviolet laser causing sublimation and ionization. The mass analyzer detects 
characteristics of sample protein ions through their movement in the time of flight (TOF) 
tube to produce a spectrum of mass-to-charge (m/z) ratios. The pathogen protein profile is 
as distinctive as a fingerprint and is matched to either identical or the closest spectra in a 
reference database to identify genera, species and even strain types (Clark et al., 2013, 
Bizzini and Greub, 2010, Singhal et al., 2015). In addition to replacing the need for expert 
microbiologists and expensive reagents, MALDITOF also offers the valuable advantage of 
reducing the time to identification of pathogens (TTD) over conventional biochemical 
methods of identification in LMICs (see Supplementary Table 2). It allows to identify 
pathogens from positive blood cultures within 20 minutes. 
 
1.3. Interventions to reduce AMR and HAI in hospital 
1.3.1. Antimicrobial stewardship programmes (ASP) 
Antimicrobial stewardship is described as a healthcare-system-wide approach to 
judicious use of antimicrobials to preserve their future effectiveness (National Institute for 
Health and Care Excellence (NICE), 2015). It includes coordinated interventions designed to 
improve and measure the appropriate use of antimicrobials by optimising its dose, duration 
of therapy, route of administration and maximising clinical outcomes whilst minimising 
toxicity and selection of resistant organisms (Barlam et al., 2016, World Health 
Organization. Regional Office for South East Asia, 2011). 
There is a correlation between antimicrobial resistance and antimicrobial consumption 
(Davies and Davies, 2010). Antibiotic prescription data from outpatients in 18 European 
countries between 1997 to 2002 showed a significant correlation between prevalence of 
penicillin-resistant S. pneumoniae and consumption of penicillin, with higher resistance 
rates in higher consuming countries (Goossens et al., 2005). A similar trend between 
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pneumococcal resistance rates and consumption of beta-lactam and macrolide antibiotics 
was reported between 1998 and 1999 in another study utilising 482 laboratories from 23 
countries in the European Antimicrobial Resistance Surveillance System (EARSS) and 
national outpatient sales data for antibiotics gathered from 13 member states of the 
European Union (Bronzwaer et al., 2002).  
The hospital setting is an important one for AMR as it is the setting where antibiotic use 
and resistance rates are highest. As a result of antibiotic use prior to and on admission to 
hospitals, infections acquired within the hospital setting (hospital acquired infection) tend 
to be associated with bacteria that are resistant to more antibiotics than those acquired in 
the community. The likelihood is that if ‘untreatable’ bacteria are to arise, it will be in the 
hospital setting, more than likely within the intensive care department where broad-
spectrum antibiotic use is highest and patients are extremely vulnerable. A recent study 
looking at Dutch travellers who acquired faecal carriage of resistant bacteria whilst abroad 
found a 12% risk of spread of ESBL producing Enterobacteriaceae from the traveller to 
household members on return (Arcilla et al., 2016) If similar levels of transmission in the 
household are seen in hospital discharges from LMICs, and carriage is sustained, then rapid 
spread of resistance to the community should be anticipated, further emphasising the 
importance of controlling AMR in the hospital setting. 
In hospital settings, broad-spectrum antibiotic consumption was also reported as 
associated with high resistance rates among the Gram-negative bacilli and Gram-positive 
cocci (Loeffler et al., 2003, Hsu et al., 2010). The exposure to many antibiotics in the 
hospital environment results in selective pressure, encouraging the emergence, 
persistence and transmission of multidrug resistant pathogens. Antibiotic restriction and 
cycling strategies have been implemented and may contribute to decreasing the total 
number of antibiotic-resistant pathogens causing HAI (Gruson et al., 2000, Lai et al., 2015) 
or bringing resistance rates back to baseline levels, although their efficacy in improving 
clinical outcome has been inconclusive (Brown and Nathwani, 2005).  
In 2016, the Infectious Diseases Society of America (IDSA) and the Society for 
Healthcare Epidemiology of America (SHEA) recommended 5 fundamentals of 
antimicrobial stewardship (Barlam et al., 2016). Firstly, administrative interventions include 
the use of audit and feedback, development and implementation of facility specific 
guidelines targeting common infections, education, routine prescriber-led review of 
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antibiotic prescribing and use computerized clinical decision support systems. Secondly, 
optimisation of antibiotics use is recommended by implementing PK monitoring and 
adjustment programs for aminoglycosides and vancomycin and using the shortest effective 
antibiotic therapy duration. Thirdly, the microbiology and laboratory diagnostics is 
recommended by developing stratified antibiograms and selective and cascaded reporting 
of antibiotics, using rapid diagnostics testing in additional to conventional cultures and 
serial procalcitonin measurements. Fourthly, measurement of interventions should include 
monitoring antibiotic use and its cost and measurement of interventions on clinical 
outcomes. Finally, antimicrobial stewardship needs to be considered in some special 
populations of neonates, immunocompromised patients and hematology-oncology 
patients. 
1.3.2. Infection prevention and control interventions  
HAI prevention strategies often focus on implementing standard precautions among 
health care staff to limit transmission of pathogens, controlling the risk of infection from 
the hospital environment and invasive medical interventions, and promoting optimal 
antibiotic therapy in hospital and training staff (Ducel et al., 2002).  
In ICUs, the most common HAI are ventilator associated respiratory infections (VARIs) 
(Ling et al., 2015, Allegranzi et al., 2011). A substantial reduction in this would provide direct 
benefit to patients and potentially reduce the exposure to very broad-spectrum antibiotics, 
limiting the generation of resistance to them and potentially delaying the emergence of 
completely resistant bacteria. In high income settings ‘care bundles’ have been developed 
to deliver improvements in many aspects of critical care, including prevention of VAP. Care 
bundles for VAP prevention may include essential components of surveillance, diagnosis, 
treatment and prevention for VAP, based on available evidence and expert opinion, and 
combined in an effort to improve compliance in implementation. In general, 
implementation of VAP care bundles has been shown to be feasible, with compliance 
increasing over time since their first introduction and now achieved in more than 70% of 
units in some high income countries (Sen et al., 2016, Morris et al., 2011, Bird et al., 2010, 
Alsadat et al., 2012). Implementation of VAP care bundles was associated with a significant 
reduction in VAP rate (reduced from 10.2 cases/1000 ventilator days to 3.4 cases/1000 
ventilator day) (Bird et al., 2010) and in antibiotic use (Morris et al., 2011), saved cost (Bird 
et al., 2010) and contributed to a decrease in the incidence of MRSA colonization (from 
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10% to 3.6%) (Sulis et al., 2014, Morris et al., 2011) (see further discussion on care bundles 
in Chapter 7, 7.1.Introduction). However, there is little data on the effectiveness of even 
the components of such bundles in the SE Asian resource constrained setting, where 
staffing levels are often substantially different, the opportunity for isolation lacking, 
background levels of antimicrobial resistance higher, and some interventions proven to 
work in developed world settings, such as semi-recumbent patient positioning, have failed 
to demonstrate effectiveness when scrutinized in these settings (Loan et al., 2012).  
In 2014, the Society for Healthcare Epidemiology of America (SHEA) and the Infectious 
Diseases Society of America (IDSA) released recommendations on VAP prevention, 
updating guidance from 2008 (Klompas et al., 2014) with the most recent update in 2016 
(Kalil et al., 2016). Recommendations of VAP prevention was presented in Table 1-6. Among 
16 interventions recommended to prevent VAP and other ventilator-associated events, 
5/16 recommendations were graded “low quality of evidence”. These will require more 
attention from researchers to develop sufficient evidence to improve further strategies to 
prevent VAP.  
Maintenance of endotracheal cuff pressure through continuous control of 
endotracheal cuff pressure is listed as an approach to reduce VAP through prevention of 
the aspiration of contaminated oropharyngeal secretions. This would be an ideal strategy 
for a resource constrained setting as the technique involves a reduction in the nursing input 
(as compared with subglottic suction which requires an increase in nursing interventions) 
and has little cost in terms of disposable items (as compared to innovative endotracheal 
tubes, which carry a high disposable cost and would require a change in culture to minimize 
wastage). However, previous studies (see Table 1-6) have not established sufficient 
evidence to recommend this intervention. Of note, many strategies, including continuous 
control of endotracheal cuff pressure, have not been shown conclusively to impact on 
antibiotic use, a crucial feature when trials are unblinded, and ‘VAP prevention’ may simply 
be the result of re-categorisation of HAI into another, non-respiratory, diagnosis (Nseir et 
al., 2011, Lorente et al., 2014).  
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Table 1-6. Summary of recommended strategies for preventing Ventilator-Associated 
Pneumonia (VAP) (Klompas et al., 2014, Alvarez Lerma et al., 2014, Coffin et al., 2008) 
Intervention Impact on VAP rate Quality of 
evidence 
Ref 
General strategy: 
Education and training Reduced VAP rate by 57.6%-59% Moderate (Zack et al., 2002, 
Apisarnthanarak 
et al., 2007) 
Hand hygiene  Reduced VAP rate 50.6% (29.8%-
65.5%) 
Moderate (Ma et al., 2014) 
Use of non-invasive 
positive pressure 
ventilation in selected 
populations 
Reduced VAP rate 38% (20%-73%) High (Hess, 2005) 
Facilitate early mobility Reduced VAP rate from 2.14 
 0.95/1000 ventilator-days to none 
Moderate (Titsworth et al., 
2012) 
Bed head elevation  A benefit favored to the 45° bed 
head elevation (RR = 0.47, 95% CI = 
0.19-1.17) in reducing VAP rate 
Low (Niel-Weise et al., 
2011) 
Prophylactic probiotics Reduced VAP rate (RR 0.75; 95%CI 
0.59–0.97) 
Moderate (Petrof et al., 
2012) 
Strategies to prevent micro-aspiration 
Utilize endotracheal 
tubes with subglottic 
suctioning 
Reduced VAP rates by 55% (46-66%) Moderate (Muscedere et al., 
2011) 
Automated control of 
endotracheal tube cuff 
pressure 
Reduced VAP rate from 26.2% to 
9.8% 
Low (Nseir et al., 
2011) 
Maintain an 
endotracheal cuff 
pressure of at least 20 
cm H2O 
Persistent intracuff pressure below 
20 cm H20 increased VAP (RR=4.23, 
95% CI 1.12-15.92) 
Low (Rello et al., 1996) 
Ultrathin polyurethane 
endotracheal tube  
Reduced VAP rate by 50% Low (Poelaert et al., 
2008) 
Strategies to reduce colonization of the aerodigestive tract 
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Intervention Impact on VAP rate Quality of 
evidence 
Ref 
Regular oral care with 
chlorhexidine 
Reduced VAP rate by 60% (47%-77%) Moderate (Shi et al., 2013) 
Strategies to minimize contamination of equipment 
Change the ventilator 
circuit only if visibly 
soiled or malfunctioning 
No change in VAP rate High (Kollef et al., 
1995) 
 
Whilst attention has focused on VAP, it is important to understand that in many settings 
in SEA ventilator associated tracheobronchitis (VAT) is also treated with antibiotic therapy, 
with the aim of preventing the development of VAP and prolonged ventilation time. Whilst 
this may be considered as contentious by some, there is some evidence behind this 
approach (Nseir et al., 2011). Interventions that prevent VAP should also prevent VAT, due 
to their shared aetiological pathway, and thus the target for such interventions can 
reasonably be considered as Ventilator Associated Respiratory Infections (a combination of 
VAP and VAT) (Martin-Loeches et al., 2015, Craven and Hjalmarson, 2010). 
A randomized controlled trial will provide an opportunity to robustly evaluate the 
impact of continuous pressure control, not just in preventing ventilator associated 
respiratory infections but also in reducing antibiotic use.  
 
1.4. Situation of hospital acquired infections, antimicrobial use 
and resistance in Vietnam 
Vietnam is ranked by the World Bank as a lower middle-income country and, with a 
population of 91 million people, it is the 13th most populous country in the world and the 
third-largest population in Southeast Asia (World Bank, 2016). The number of annual 
hospital admissions ranges from 6,000-14,000 per hospital of which critical care admissions 
usually account for 5-18% of all admissions. The number of critical care unit (CCU) beds 
accounted for 4-11% of total hospital beds whilst the number of doctors and nurses per 
actual CCU bed was 0.22 and 0.56, respectively (Dat et al., 2017a). Along with the lack of 
human resources, hospital overcrowding and inappropriate antimicrobial use, there are 
also gaps in the available infection control policies, low compliance with hand hygiene 
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among healthcare workers and a lack of surveillance systems together contributing to the 
spread of antibiotic resistance and hospital acquired infection in Vietnamese hospitals 
(Johansson et al., 2011, The GARP Vietnam National Working Group, 2010). 
Several studies have assessed antibiotic use and resistance and HAI incidence in 
hospitals and in ICUs and shown increasing trends. I have summarised these studies below. 
A point prevalence study among 36 hospitals in Vietnam (2 national-level, 18 provincial-
level and 16 district hospitals) showed that 64.7% of hospitalised patients were receiving 
antibiotics and 30.8% of these were considered inappropriate (Thu et al., 2012). The 
antimicrobial use was even higher in ICU patients (85%) in our multi-ICU study (Phu et al., 
2016).  
In 2007, in a one-day cross sectional study among 7,571 patients in 36 hospitals in 
Vietnam, the HAI prevalence was 7.3% (553/7571) and HAP was the most common HAI 
(41.9%) followed by surgical wound infections (27.5%). Oral endotracheal intubation and 
tracheotomy were independent risk factors for respiratory infections (adjusted OR=1.6 and 
10.9, p values < 0.01 respectively) (Truong Anh Thu et al., 2009b). Data from a single ICU in 
a tertiary, referral 1400-bed hospital during this period showed 21.2% (172/808) patients 
had HAP and 492/808 patients (61%) were on ventilation. Of the 172 patients with HAP, 
144 (84%) were VAP. The most commonly detected isolates were A. baumannii (41.5%), P. 
aeruginosa (27.9%), and K. pneumoniae (9.5%). HAI was associated with increased hospital 
length of stay (26.6 days vs 11.5 days) and extra hospitalization costs (2,385 vs 1,114 US 
dollars) (Truong Anh Thu et al., 2009a).  
During an active surveillance study in seven large hospitals in Vietnam from 2008-2010, 
surgical site infection was observed in 5.5% of surgical procedures, with the highest rates 
in colon surgery (33.3%), limb amputation (25%) and vascular surgery (25%). Among 
pathogens isolated from surgical site infections, the most frequent isolates were E. coli 
(39%) with a carbapenem resistance rate of 20%, followed by Enterococcus spp. (10%) and 
A. baumannii (8%) (Viet Hung et al., 2016). 
From 2012-2013, HAI prevalence was reported as 29.5% in our multi-ICU study with the 
most common infection being HAP (79.4%), followed by blood stream infection (4.4%) and 
surgical site infections (4.2%). Gram-negative bacteria were responsible for 84.2% of all 
isolates. A. baumannii and P. aeruginosa were the most common pathogens causing 
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pneumonia (25% for A. baumannii and 15.7 % for K. pneumoniae) whilst A. baumannii and 
E. coli were frequently isolated in BSI (22.7% and 13.6% respectively) (Phu et al., 2016).  
Beside large multi-centre studies mentioned above, ICU based studies, mostly 
conducted in the National Hospital for Tropical Diseases in Hanoi and the Hospital for 
Tropical Diseases in Ho Chi Minh City reported high prevalence and high resistance rates of 
A. baumannii, P. aeruginosa and Enterobacteriaceae as a most common isolates from ETA 
and bloods in critically ill patients over past 10 years (see Table 1-4).  
In the Vietnamese hospital setting, the most highly resistant bacteria were 
Acinetobacter, Klebsiella species, E. coli and Pseudomonas species (Phu et al., 2016, Le et 
al., 2016, Johansson et al., 2011). The proportion of A. baumannii with carbapenem 
resistance ranged from 51-93.2% in ICU studies (Table 1-4). Two studies reported colistin 
resistance among A. baumannii at 11.2% (13/116) and 6% (6/101) (Tada et al., 2013, Tuan 
Anh et al., 2017) and notably, one hospital reported a high prevalence of colistin resistance 
at 31.6 % (12/38) (Tuan Anh et al., 2017). The proportion of P. aeruginosa isolates showing 
carbapenem resistance was from 42.9 to 86.2% (Table 1-4).  
A multi- centre paediatric ICU study reported high prevalence of carbapenem resistance 
in HAIs caused by P. aeruginosa (69% or 25/29), A. baumannii (67% or 24/36) and K. 
pneumoniae (55% or 23/42). Among 95 Enterobacteriaceae isolates, 88% were resistant to 
3rd-generation cephalosporins and 40% were resistance to both cephalosporins and 
carbapenems. The prevalence of methicillin-resistance among Staphylococcus aureus 
(MRSA) was 81% (13/16) (Le et al., 2016). 
In an 11 year retrospective study (2000 – 2010) in an infectious disease ICU in southern 
Vietnam, Acinetobacter was recognised as the most common pathogen (30.4%, n=206) 
isolated from tracheal aspirate samples in suspected VAP patients with an average annual 
increase of 6.6% (Nhu et al., 2014). From 2008, the proportional of Acinetobacter spp. 
isolates dramatically increased by 66% and carbapenem resistance was almost 80%.  
In a study in northern Vietnam at 3 ICUs with 62 beds from 2007-2008, Acinetobacter 
was identified in 112 (29.4%) respiratory tract isolates and 21 (14.4%) blood isolates, of 
which A. baumannii accounted for 88/112 (78.6%) and 16/21 (76.2%) isolates respectively. 
The resistance rate among Acinetobacter isolates to ceftazidime, ciprofloxacin, gentamicin 
and imipenem was 89%, 80.1%, 79.1% and 69.1% respectively (Johansson et al., 2011).  
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From October 2012 to September 2013, our monthly repeated point prevalence survey 
of 15 adult ICUs in Vietnam also showed the most frequent isolates in HAIs was A. 
baumannii (24.4%, 177/726) with the carbapenem resistant prevalence of 89.2% (149/167) 
(Phu et al., 2016).  
During a study period between 2012 and 2014, 119/160 (74.4%) A. baumannii isolates 
from 3 hospitals in southern Vietnam were classified as MDR (resistant to at least 1 agent 
in 3 or more antimicrobial families), of which 117/119 (98.3%) included imipenem 
resistance. Colistin resistance was exhibited in 13/116 (11.2%) isolates (Tuan Anh et al., 
2017).  
Vietnam reported the first cases of the New Delhi metallo-beta-lactamase 1 gene 
(NDM-1) producing E. coli and K. pneumoniae from 2 patients who admitted to a surgical 
hospital in September 2010 (Hoang et al., 2013). In a study of 2233 patients admitted to 12 
Vietnamese hospitals during 2017 and 2018, prevalence of CRE colonisation increased over 
time, with an increase in average of 4.2% per day and mean CRE colonisation rates 
increased from 13% on admission to 89% after 15 days of hospitalisation (Tran et al., 2019). 
Collectively these data show the increasing relevance and resistance of Acinetobacter 
in hospital acquired infections and the newly emerged and rapidly spreading severe clinical 
problem of carbapenem resistance among Enterobacteriaceae, often necessitating use of 
colistin (an expensive, hard to administer, suboptimal drug with many side effects). 
However, a limitation of most of these studies was that they were lacking clinical linkage 
between these isolates and patient centered outcomes. 
Given the limitations of the available HAI and VAP data in Vietnam, it is important to 
have clinical cohort studies to provide accurate, prospective data on the aetiologies of HAI 
and VAP, on the associated risk factors and also the impact of HAI and VAP on length of ICU 
stay, cost and mortality. Integration of such data collection within the proposed clinical 
trials, of antibiotic stewardship and VAP prevention interventions, will contribute to the 
establishment of evidence based, locally appropriate, recommendations for HAI/VAP 
prevention, antibiotic use and infection control program in Vietnam. 
1.5. Rationale for the project 
Infection control procedures and measures to prevent HAI and the transmission of 
resistant pathogens have been implemented in response to the threat of antimicrobial 
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resistance. A comprehensive programme (Storr et al., 2017) including strategies to limit 
transmission of pathogens between patients, control environment related factors for HAIs, 
use of appropriate treatment and optimal antibiotic prescribing, minimizing invasive 
intervention and implementation of surveillance and education has been implemented to 
varying degrees in different settings. Transmission of pathogens through health care 
worker’s hands has often been a target for intervention, however compliance to hand 
hygiene and other precautions is low among healthcare workers (Erasmus et al., 2010) and 
poor hand hygiene practice has been observed in patient contact (Johansson et al., 2011) 
and may not be highly effective in reducing ESBL-producing Enterobacteriaceae 
transmission (Schultsz et al., 2013). Other measures, recommended for routine use in 
intensive care to prevent VAP by bodies such as Infectious Diseases Society of America, and 
Spanish Societies of Intensive Care Medicine (Kalil et al., 2016, Alvarez Lerma et al., 2014), 
such as semi-recumbent body position did not show benefit in preventing ventilator 
associated pneumonia in Vietnamese patients with severe tetanus (Loan et al., 2012). 
Additionally, some interventions are probably not appropriate in limited resource settings, 
due to high costs and nursing requirements or the high levels of resistance already present 
(Gaillot et al., 2011). Thus, tailored interventions that are appropriate to the setting are 
required. 
High antibiotic consumption, lack of appropriate evidence-based interventions for 
infection prevention, and the high level of antimicrobial resistance underlie the importance 
of antimicrobial stewardship in Vietnamese hospitals. The research questions contained 
within this PhD project were developed to address the burden of antimicrobial resistance 
in Vietnamese hospitals, and in particular on the intensive care and VAP:  
1. What is the current use of antimicrobials in public hospitals in Vietnam? 
2. What is the direct cost of management of VARI in Vietnam? 
3. Can Matrix-assisted laser desorption ionization-time of flight mass spectrometry 
(MALDI-TOF MS) improve the proportion of patients treated with optimal therapy 
within 24 hours of positive culture, thereby contributing to Antimicrobial 
Stewardship? 
4. What is the incidence of hospital-acquired bloodstream infections, risk factors for 
their acquisition and their microbiological aetiology & susceptibility in 3 ICUs in 
Vietnam? 
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5. What is the effectiveness of continuous endotracheal cuff pressure control for the 
prevention of ventilator associated respiratory infections and reduction of 
antibiotic use in ICU? 
 
In 2013, Vietnam released a national action plan on combatting antimicrobial resistance 
(AMR) in the period from 2013 – 2020 (Ministry of Health, 2013). This was the first ever 
national plan to address the burden of AMR in the country by focussing on: 
1) raising awareness of community and health workers on antimicrobial resistance 
2) strengthening and improving national surveillance system on the use of antimicrobial 
and AMR 
3) ensuring adequate supply of quality medicines 
4) promoting proper safe use of antimicrobials 
5) promoting infection control 
6) promoting proper safe antimicrobial use in livestock, poultry, aquaculture and 
cultivation. 
My PhD project placed an emphasis on investigating the antimicrobial use in the 
country, providing the insights on the burden of hospital acquired infections (HAI) in term 
of morbidities and economic burden, focusing on feasible technological intervention efforts 
to reduce antimicrobials and prevent ventilator associated respiratory infection (VARI), the 
most common type of HAI in critical care units. My thesis focused on model evidence-based 
strategy with the aims of measuring the current situation of HAIs and seeking feasible 
approaches to address the burden of antimicrobial resistance in Vietnamese hospitals that 
are fit for purpose to the specific context in Vietnam, a lower middle-income country. These 
aims are in line with and contribute bullet points 2, 3 and 5 of the National Action Plan. 
As antimicrobial drug resistance is driven by all use of antimicrobials, whether 
appropriate or inappropriate, the starting point of my PhD thesis was to describe the use 
and cost of antimicrobials in Vietnam. Additionally, the data of cost of antimicrobials, 
especially the last resort antibacterials for treating multidrug resistant patients is used to 
identify the economical burden and morbidity of VARI in critical care units in Vietnam. To 
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address the burden of antimicrobial drug resistance in ICUs in Vietnam by focusing on VARI, 
the most common type of HAIs, I examined two potential strategies to reduce the 
antimicrobial use, including the early pathogen identification and prevention of the 
aspiration of contaminated oropharyngeal secretions. The thesis included 4 separate 
studies with primary objectives as below: 
• Study 1: Price and use of antimicrobials in hospitals in Vietnam 
‒ To describe the price and use of antimicrobials in hospital in Vietnam 
• Study 2: Excess direct hospital cost of treating adult patients with ventilator 
associated respiratory infection (VARI) in Vietnam 
‒ To estimate the base case cost of treating of VARI and annual total excess direct 
hospital cost of managing VARI in Vietnam 
• Study 3: MALDITOF Versus Routine Clinical Microbiology for Identifying Pathogens: a 
Randomized Diagnostic Trial (MALDITOF).  
‒ To compare the proportion of patients on optimal antibiotic treatment within 24 
hours of positive culture (first growth of an eligible specimen) in patients whose 
samples are processed using standard laboratory techniques and those whose are 
processed using MALDITOF.  
• Study 4: The VARI-prevent Trial: A randomised trial of continuous endotracheal cuff 
pressure control compared with intermittent manual pressure checks for the 
prevention of ventilator associated respiratory infections (VARI).   
‒ To determine the incidence of hospital acquired bloodstream infections in 
intubated patients admitted to ICUs in Vietnam 
‒ To determine whether automated cuff pressure control results in a reduction in the 
proportion of patients developing ventilator associated respiratory infections 
compared with routine care. 
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: Methodology 
This chapter described the methods and materials for 3 subsequent chapters in this 
thesis. It contains 4 individual study designs:  
i) a descriptive study of antimicrobial price and use in public hospitals in Vietnam 
(Chapter 3),  
ii) a modelling study of excess cost of ventilator associated respiratory infection (VARI) 
in critical care units in Vietnam (relating to Chapter 4);  
iii) a randomised controlled trial of matrix assisted laser desorption ionization-time of 
flight mass spectrometry (MALDITOF-MS) versus routine clinical microbiology for 
identifying pathogens (relating to Chapter 5) and  
iv) a randomised controlled trial of continuous versus intermittent endotracheal cuff 
pressure control for the prevention of ventilator associated respiratory infections (relating 
to Chapter 6 and Chapter 7). 
2.1. Method for Chapter 3: Price and use of antimicrobials in an 
emerging pharmaceuticals market in Vietnam 
2.1.1. Objective 
This study describes antimicrobial usage, expenditure and cost in public hospitals in 
Vietnam. 
2.1.2. Study design 
The process of bidding for contracts to supply medication to public health facilities 
follows Vietnam government guidance (Ministry of Health, 2016). Health facilities are 
reponsible for preparing an invitation to tender for medications based on their projected 
demand (usually largely based on the quantity used in the preceding year). The health 
facility is required to ensure the consumption of at least 80% of each medication purchased 
(Ministry of Health, 2016).  
In this study, antimicrobial consumption in public hospitals in Vietnam was estimated 
using data from successful tenders for the purchase of antimicrobials for 52/63 Provincial 
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Departments of Health, 23 secondary hospitals and 7 primary hospitals (outside the 52 
provincial departments) throughout Vietnam. As of December 2017, Vietnam had 13,583 
public healthcare facilities, including 1,085 hospitals with 308,400 patient beds, 579 
regional clinics and 11,830 medical service units in communes, wards, offices and state- or 
privately-owned enterprises (Vietnam Ministry of Health, 2016, General Statistics Office, 
2018). In the private sectors, there were 219 private hospitals in the country by 2018. The 
country’s healthcare system is divided into four technical categories: tertiary hospitals 
(under administrative control of or appointed by the Ministry of Health), secondary 
hospitals (under the Provincial Departments of Health (DoH) and catering to and receiving 
referrals from the province population), primary hospitals (district hospitals under 
Provincial DoH, catering to and receiving referrals from the district population, commune 
health stations), and commune health stations or medical service units) (Vietnam Ministry 
of Health, 2013, Dat et al., 2017a). Currently there are 75 tertiary hospitals, 491 secondary 
hospitals, 514 primary hospitals and 5 unclassified hospitals (Vietnam Ministry of Health, 
2016).  
2.1.3. Data resources 
Data on the cost of antimicrobials in Vietnam were taken from the successful tenders 
for medicines in 2018 for hospitals and provincial Departments of Health (DoH) in Vietnam 
as published on the website of the Drug Administration of Vietnam website (Drug 
Administration of Vietnam, 2018). DoHs will tender for the supply of medication to the 
secondary and primary hospitals under their jurisdiction. The bid winning tenders from 
provincial DoH may cover all or only some of the primary and/or secondary hospitals within 
that province and the data on precisely which hospitals, or the breakdown by type within 
each bid, were not available. I collected all available bid-winning tenders in 2018 for 23 
secondary hospitals, 7 primary hospitals and 52 provincial departments of health. The data 
for each tender included the name of the active ingredient, trademarks, strength, dosage 
and package, route of administration, registration identification, manufacturer, country of 
origin of manufacturer, measuring unit, bid quantity, unit price, total value, bidders, 
offerors and brand name/generic name (Ministry of Health, 2016). The list of antimicrobials 
in our analysis excluded antimicrobial medications which are nationally procured, such as 
those for the treatment of HIV, influenza, tuberculosis and malaria.  
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2.1.4. Estimation of antimicrobial procurement and the cost of 
antimicrobials 
All antimicrobials for systemic use were included in the analysis and classified using the 
Anatomical Therapeutic Chemical (ATC) Index with Defined Daily Doses (DDDs) 2018 (WHO 
Collaborating Centre for Drug Statistics Methodology, 2018). The DDD is recommended by 
WHO as a measurement unit of drug consumption (WHO International Working Group for 
DrugStatistics Methodology et al., 2003). It is the average maintenance dose of a drug per 
day for a 70 kg adult for its main indication. It provides an estimate and comparison of drug 
consumption between population groups and is widely used in pharmacoeconomical 
studies. The DDD for a given drug is assigned by ATC/DDD classification with a unique code 
and may be different for the routes of administration (oral and parenteral) of the same 
drug when there is a substantially difference of bioavailability. It is neither defined for 
topical products nor available for all drug combinations (WHO Collaborating Centre for 
Drug Statistics Methodology, 2017). Antibacterials were further classified by AWaRe 
categories following the 2017 revision of the WHO Model List of Essential Medicines (see 
Table 2-1) (World Health Organization, 2017c).  
Table 2-1. AWaRe antibacterial classification 
ACCESS group antibacterials 
amoxicillin 
amoxicillin + clavulanic acid 
ampicillin 
benzathine benzylpenicillin 
benzylpenicillin 
cefalexin 
cefazolin 
cloxacillin 
phenoxymethylpenicillin 
procaine benzyl penicillin 
amikacin 
chloramphenicol 
clindamycin 
doxycycline 
gentamicin 
metronidazole 
nitrofurantoin 
spectinomycin 
sulfamethoxazole + trimethoprim 
cefixime* 
cefotaxime* 
ceftriaxone* 
piperacillin + tazobactam*  
meropenem* 
azithromycin* 
ciprofloxacin* 
clarithromycin* 
vancomycin * 
WATCH group antibacterials 
Quinolones and fluoroquinolones 
3rd-generation cephalosporins (with or without beta-lactamase inhibitor) 
Macrolides 
Glycopeptides 
Antipseudomonal penicillins + beta-lactamase inhibitor 
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Carbapenems 
Penems 
RESERVE group antibacterials 
Aztreonam 
4th generation cephalosporins  
5th generation cephalosporins 
Polymyxins 
Fosfomycin (IV) 
Oxazolidinones 
Tigecycline 
Daptomycin 
*Antibacterials that are recommended as first or second choice treatments for a few, specific 
indications but also in the WATCH group (Sharland et al., 2018). Source: WHO model list of 
essential medicines, 20th list (March 2017, amended August 2017). 
 
I calculated the total DDD procured for an antimicrobial by multiplying the total 
procured at each dose-route of administration for this drug by the DDD conversion factor 
for the corresponding dose-route of administration. The average cost per DDD of an 
antimicrobial drug was calculated by dividing cost for that drug by the total number of DDD. 
The high/low ratio was used to compare the difference between the highest unit price and 
the lowest price of one DDD of each antimicrobial across all the tenders. All costs were 
converted from VND to US$ according to the annual average official exchange rates of the 
World Bank in 2017 (US$1 = 22,370.09 VND) (The World Bank Group, 2019). The average 
price of antimicrobials per DDD, the share of antimicrobials cost in the hospital drug budget 
and the number of DDD are used to compare in different levels of hospitals. Pareto chart 
(ABC analysis) was used to examine the consumption of antimicrobials and expenditures 
for procurement (Embrey and Management Sciences for Health (Firm), 2013). The ratio of 
the highest to the lowest price of antimicrobials per DDD (high/low (H/L) ratio) was 
calculated to report the variation of antimicrobials price (Management Sciences for Health 
(MSH), 2015). I used Spearman correlation coefficient to assess the association between 
variation of antimicrobials prices (high/low ratio) and number of manufacturers. 
Descriptive statistics was performed using Microsoft Excel (Office 365, version 1909, 
Microsoft Corporation, Redmond, Washington,). 
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2.2. Method for Chapter 4: Excess direct hospital cost of treating 
ventilator associated respiratory infection (VARI) in Vietnam 
2.2.1. Objectives 
This study aims to estimate the total excess annual cost to the National Health Service 
of the management of VARI in critical care units in tertiary hospitals throughout Vietnam. 
2.2.2. Study design 
I estimated the excess cost of VARI in Vietnam using a incidence-based cost-of-illness 
approach (Tarricone, 2006) from a healthcare sector perspective which included all costs 
covered by the governmental health insurance and co-paid by patients. I did not distinguish 
between ventilator associated pneumonia (VAP) and ventilator associated 
tracheobronchitis (VAT) as the pathogenesis and bacterial aetiology of the two entities are 
essentially the same and both are treated for a similar duration in Vietnam. A Vietnamese 
study analysing the costs of VAP and other VARI found little difference when similar patient 
groups were looked at (Phu et al., 2017). All direct medical costs were estimated as the 
product of number of services and their unit cost. Micro-costing methodology was used to 
cost the management of VARI which was composed of cost components of diagnostics, 
hospital stays and antimicrobials. By using this method, the direct costs were estimated as 
the product of number of services used and their unit cost. 
2.2.3. Data resources 
Based on my previous study in 2015, I used data of 25 provincial hospitals and 103 
district hospitals in Vietnam to derive the number of hospital beds with access to 
mechanical ventilation in Vietnam and the proportion of these ventilators in frequent use 
(Dat et al., 2017a). In this survey critical care beds accounted for a median of 4% (IQR 3-
5%) of the provincial hospital beds and for 9% (IQR 5-12%) of the district hospital beds. This 
corresponded to median critical care unit (CCU) sizes of 26 beds (IQR 17-33) and 12 beds 
(IQR 8-19) in provincial and district levels respectively. All provincial CCUs had ventilators 
with a median number of mechanical ventilators of 11 (IQR 6-16 or 0.4 per actual critical 
care bed (IQR 0.26–0.55)). However, only 73.6% of district hospitals had ventilators with a 
median of 0.08 (IQR 0.00-0.17) ventilators per actual critical care bed. Whilst most 
provincial hospitals have adequate capacity to deliver critical care services, district 
hospitals have limited capability in this respect, typically only ventilating patients prior to 
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transfer to a higher level of care (Dat et al., 2017a). I therefore include only central and 
provincial hospitals in modelling the burden of VARI. 
The prevalence and associated increased length of CCU stay of VARI were extracted 
from literature review (Table 2-2). Aetiology and susceptibility of VARI causing pathogens 
were extracted from a previous point-prevalence surveys in 15 hospitals in Vietnam (Table 
2-3) (Phu et al., 2016). Data on the unit costs of healthcare services in Vietnamese CCUs 
were taken from documents issued by the ministry of health regarding costs for medical 
services among hospitals at the same level across the country (Ministry of Health and 
Ministry of Finance, 2015, Ministry of Health, 2017). Costs for these services are inclusive 
of certain direct expenses (i.e. consumable materials, substitute items), expenses for 
electricity, water, fuel, waste, treatment, maintenance and replacement of equipment and 
employee allowances and salaries (Ministry of Health and Ministry of Finance, 2015). 
Assumptions for the costing model are shown in Table 2-2.  
 
Table 2-2. Assumptions of a costing model for ventilator associated respiratory infection 
(VARI) in Vietnam 
Assumption Value (range) Source(s)  
Number of critical care units (hospitals) 577 (Vietnam Ministry of 
Health, 2016) 
Number of ventilators per critical care units 11 (6-16) (Dat et al., 2017a) 
Proportion of patients with intubation ≥ 48 
hours  
88.9% (87.6%-90.2%) (Ha et al., 2015) 
Incidence density of VARI per 1000 
ventilation days 
21.7 (17.7 – 26.5) (Phu et al., 2017) 
Percentage of ventilators in frequent use 77% (± 10%) (Vietnam Medical Services 
Administration, 2015) 
The de-escalation rate 23% (21.3%-68%) (Alvarez-Lerma et al., 2006) 
Extra CCU length of stay for each episode of 
VARI (days) 
12 (± 2) (Phu et al., 2017) 
Extra duration of antibiotics (days) 12 (7-14) (Phu et al., 2017, Kalil et 
al., 2016) 
Excess duration of ventilation (days) 12 (± 2) (Phu et al., 2017) 
Range of aetiologies of VARI See Table 2-3 (Phu et al., 2016) 
 
47 
 
Data on the cost of antimicrobials in Vietnam was taken from the 2017 medication bid-
winning results of national and provincial hospitals in Vietnam as published on the Drug 
Administration of Vietnam website (Drug Administration of Vietnam, 2018). The bid-
winning price reflects the diversity in pricing of antimicrobials across 93 national and 
provincial hospitals in 27 provinces in Vietnam. The average price of antimicrobials was 
applied for the model.  
I developed a decision tree for antimicrobial treatment of VARI based on local data on 
the microbiological aetiology of VARI and internationally recognised recommendations for 
antimicrobial treatment (Torres et al., 2017, Kalil et al., 2016) which is aligned with the 
national guidelines issued by the ministry of health for use in Vietnamese hospitals 
(Ministry of Health, 2015). The local data for aetiology and associated antibiotic 
susceptibility was derived from a previous point-prevalence survey in Vietnam (Phu et al., 
2016) (Table 2-3) and used in conjunction with the guidelines of the Infectious Diseases 
Society of America and the American Thoracic Society (or where the treatment 
recommendation was not available for specific pathogens, the Sanford guide to 
antimicrobial therapy) to determine the antimicrobial treatment administered (David N. 
Gilbert et al., 2017, Kalil et al., 2016) (Figure 2-1).  
Table 2-3. Assumed aetiology of ventilator associated respiratory infections 
Name of microorganisms Proportion 
No identification of pathogens 61.5% 
Identification of pathogens 38.5% 
Enterobacteriaceae 6.7% 
Escherichia coli 1.3% 
Non-susceptible to the 3GCs and CARB 5.4% 
Susceptible to the 3GCs and non-susceptible to CARB 54.1% 
Susceptible to 3GCs and CARB 40.5% 
Klebsiella pneumoniae 4.5% 
Non-susceptible to the 3GCs and CARB 14.9% 
Susceptible to the 3GCs and non-susceptible to CARB 56.8% 
Susceptible to 3GCs and CARB 28.4% 
Klebsiella spp. 2.9% 
Non-susceptible to the 3GCs and CARB 5.7% 
Susceptible to the 3GCs and non-susceptible to CARB 62.3% 
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Name of microorganisms Proportion 
Susceptible to 3GCs and CARB 30.1% 
Other Enterobacteriaceae 3.3% 
Non-susceptible to the 3GCs and CARB 12.5% 
Susceptible to the 3GCs and non-susceptible to CARB 59.4% 
Susceptible to 3GCs and CARB 28.1% 
Non-fermenters 21.8% 
Acinetobacter baumannii 9.9% 
Non-susceptible to CARB 89.2% 
Susceptible to CARB 10.8% 
Pseudomonas aeruginosa 6% 
Non-susceptible to the 3GCs and CARB 55.7% 
Susceptible to the 3GCs and non-susceptible to CARB 44.3% 
Susceptible to 3GCs and CARB 
 
Acinetobacter spp. 3% 
Non-susceptible to CARB 89.2% 
Susceptible to CARB 10.8% 
Other Gram-negative bacilli 2.9% 
Gram-positive bacteria 3.8% 
Staphylococcus aureus 1.8% 
Methicillin-resistant Staphylococcus aureus (MRSA) 75.7% 
Methicillin-sensitive Staphylococcus aureus (MSSA) 24.3% 
Staphylococcus spp. 0.7% 
Non-susceptible to oxacillin 36.4% 
Susceptible to oxacillin 63.6% 
Enterococcus spp. 0.7% 
Vancomycin-resistant Enterococcus (VRE) 57% 
Vancomycin-susceptible Enterococcus (VSE) 43.0% 
Streptococcus spp. 0.6% 
Fungi (Candida spp.) 0.9% 
3GC: Third-generation cephalosporins; CARB: carbapenem 
Adapted from Phu et al (Phu et al., 2016). 
 
The cost of VARI included the costs of initial empirical and targeted therapy regimens. 
The initial broad-spectrum empirical therapy was modelled to cover P. aeruginosa and 
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ESBL-producing organisms, Acinetobacter spp. and methicillin-resistant Staphylococcus 
aureus (MRSA) for the setting with high rates of multidrug resistant pathogens (Torres et 
al., 2017, Kalil et al., 2016). The empirical therapy was assumed to last for 3 days and 
followed by the targeted therapy (Figure 2-1). 
Analysis was limited to adult patients because of limited data in the paediatric critical 
care population concerning the aetiology of VARI, provision and utilisation of critical care 
beds and difficulties accounting for the spectrum of ages to adjust antimicrobial doses.
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Figure 2-1. Decision tree for antibiotic treatment for ventilator associated respiratory infection (VARI).  
CEF, ceftriaxone; COL, colistin; FLU, fluconazole; IMP, imipenem-cilastatin; LEV, levofloxacin; LZD, linezolid; MER, meropenem; OXA, oxacillin; SAM, 
ampicillin-sulbactam; VAN, vancomycin. 
Identification of 
pathogens (61.5%) 
Other Gram-
negative bacteria 
 (57.9%) 
No-identification of 
pathogens (38.5%) 
Enterobacteriaceae 
(31.2%) 
Fungi (0.9%) 
VARI (ventilator 
associated respiratory 
infection) 
Empiric therapy 
IMP + VAN 
MER + COL (8.6%) 
IMP (77.5%) 
CEF (9.7%) 
IMP + COL (4.2%) 
IMP (30.2%) 
SAM (1.4%) 
LEV (1.7%) 
MER + COL (15.1%) 
IMP + COL (51.6%) 
IMP + VAN 
FLU 
Gram-positive 
bacteria (10%) 
CEF (15%) 
LZD (10.3%) 
VAN (37.2%) 
OXA (37.5%) 
De-escalation 
(23%) 
No de-escalation 
IMP + VAN 
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2.2.4. Estimation of the cost of VARI management and number of VARI 
episodes  
Estimates of the cost of VARI episodes were based on the excess direct medical costs 
of diagnostics, hospital stay, ventilation and antimicrobial treatment. All costs were at 2017 
prices and presented in US dollars (US$) based on the official exchange rate of 2016 (1 US$ 
= 21,935 Vietnam Dong) (World Bank, 2018b). The diagnostics for VARI included 
investigations for VARI (complete blood count, arterial blood gas, bedside chest 
radiography, endotracheal aspirate smear and culture, blood culture and antibiotic 
susceptibility when the pathogen was identified) (Torres et al., 2017, Kalil et al., 2016). 
These investigations are performed routinely in referral hospitals in Vietnam and 
recommended by the ministry of health for critical care units. All investigations were 
assumed to be performed at the time of VARI suspicion. The excess cost of hospital stay 
and ventilation was calculated by the quantity of extra days multiplied by their daily prices 
(Table 2-3 and Table 2-4). 
The antimicrobials cost per VARI episode was composed of the cost of three days of 
empirical therapy with imipenem-cilastatin (IMP) and vancomycin (VAN) and the cost of 
targeted therapy. For VARI without pathogen identification, we assumed that the empirical 
treatment continued for the whole course of VARI treatment in n days: 
Cemperical antimicrobials = n × (CIMP+CVAN) 
For cases with pathogen identification, in the absence of local data, we assumed that 
the de-escalation was 23% as reported in a prospective Spanish observational study 
(Alvarez-Lerma et al., 2006) and the empirical therapy remained unchanged in 77% of VAP 
patients. We calculated the proportion of antimicrobial regimens corresponding to the 
frequency of pathogenic isolates in patients with antimicrobial de-escalation therapy. The 
per-episode antimicrobial cost of microbiologically confirmed VARI cases was calculated as 
follows: 
Ctargeted antimicrobials = 3×(CIMP+CVAN) + ∑ (n-3)CkPk 
In which, n is the antimicrobial therapy duration (days), k is the antimicrobials regimen, 
C and P is the daily cost and proportion of usage of the specific regimens.  
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Table 2-4. Costs associated with management of ventilator associated respiratory 
infection (VARI) in Vietnam  
Item Average unit cost (min-
max) in USD 
Notes 
Cost for hospital beds US$ 21.87 (30.98-12.77) Daily cost  
Cost for mechanical ventilation US$ 22.35 (24.39-20.31) Daily cost  
Cost for diagnostics of VARI   
Complete blood cells US$ 3.09 (1.46-4.71) 1 time  
Air blood gas US$ 9.42 (9.15-9.70) 1 time  
Bedside chest X-ray US$ 2.91 (2.65-3.16) 1 time  
Blood cultures US$ 11.14 (9.15-13.13) 1 time 
Endotracheal aspirate culture US$ 11.14 (9.15-13.13) 1 time 
Endotracheal aspirate smear US$ 2.80 (2.61-3.00) 1 time 
Qualitative antibiotic susceptibility US$ 7.62 (7.09-8.14) If the pathogen is identified 
C-reactive protein (CRP) US$ 2.36 (2.29-2.42) 1 time 
Cost for antimicrobial treatment   
Linezolid 300 mg US$ 25.39 (8.62-42.16)  600 mg IV q12h  
Meropenem 1 g US$ 19.29 (3.17-35.41) 1 g IV q8h  
Colistimethate Sodium1 MIU US$ 14.05 (10.48-17.62) 5 mg/kg IV × 1 (loading dose) 
followed by 2.5 mg × (1.5 × 
CrCl + 30) IV q12h 
Fluconazole 200 mg US$ 11.65 (6.56-16.74) 400 mg q12h 
Imipenem + cilastatin 500/500 mg US$ 9.46 (2.61-16.31) 500 mg IV q6h  
Levofloxacin 500 mg US$ 7.75 (1.19-14.32) 750 mg IV q24h  
Vancomycin 1 g US$ 4.16 (0.33-7.99) 15 mg/kg IV q8–12h  
Ceftriaxone 1g US$ 3.92 (2.47-5.37) 1 gm IV q24h 
Ampicillin sulbactam 1g/0.5 g US$ 1.88 (0.44-3.33) 3 g IV q6hr  
Ceftazidime 1g US$ 1.69 (0.48-2.91) 2 g IV q8h  
Oxacillin 1g US$ 1.25 (0.65-1.85) 2 gm IV q4h  
 
The country’s annual number of VARI episodes was estimated from the incidence 
density of VARI (in cases per 1000 ventilation days) multiplied by the total number of 
ventilators in frequent use in all critical care units and the proportion of patients intubated 
for more than 48 hours (see Table 2-2).  
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2.2.5. Sensitivity analysis 
A one-way sensitivity analysis of the total cost of VARI treatment was performed by 
varying the country capacity for mechanical ventilation, incidence density of VARI, cost of 
diagnostics, critical care stay and antimicrobials, and duration of antimicrobial therapy. We 
performed one-way sensitivity analyses in which each factor was individually varied within 
the assumed plausible ranges as described above whilst all other factors remained at the 
central values.  
Among variables included in the costing model, the number of critical care units was 
considered as fixed value whilst the proportion of patients with intubation ≥ 48 hours and 
percentage of ventilators in frequent use were varied by ±10% from the average values. 
We varied the number of ventilators per critical care unit by the interquartile range as 
reported in the previous study in Vietnam (Dat et al., 2017a). Because the antimicrobial 
therapy de-escalation rate was not reported in Vietnam, we varied this rate by the values 
from the prospective study of 24 intensive care units in Spain (Alvarez-Lerma et al., 2006). 
Varying the incidence density of VARI was performed with the additional analysis of data 
from a previous prospective observational study in 4 CCUs in Vietnam (Phu et al., 2017). 
The extra duration of antimicrobial therapy was varied between 7-14 days to cover 2 
common antimicrobials regimens of 7-8 days and 10-14 days (Torres et al., 2017). The 
excess CCU length of stay and duration of ventilation was varied by ±2 days from the 
difference of length of stay (12 days) between patients with VAP and no VAP in a meta-
analysis (of studies largely in high income settings) and a prospective study in Vietnam 
(Melsen et al., 2013, Phu et al., 2017). The range of cost values is shown in the Table 2-2.  
2.3. Method for Chapter 5: Impact of MALDITOF diagnostic 
pathway on optimal antimicrobial therapy 
2.3.1. Objectives  
The primary objective of this study was to determine if MALDITOF-MS can improve the 
prescribing of antimicrobial therapy in patients with culture-confirmed infection. 
Secondary objectives were to establish the impact of MALDITOF-MS on patient centred 
outcomes and cost of treatment during hospitalisation. 
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2.3.2. Study design 
This was a randomised controlled trial conducted in 2 tertiary hospitals in Vietnam that 
specialise in infectious diseases: the National Hospital for Tropical Diseases (NHTD) in Hanoi 
and the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City. Both have ISO15189 
accredited microbiology laboratories. This trial compared the Matrix-assisted laser 
desorption ionization-time of flight mass spectrometry (MALDITOF-MS – the intervention 
arm) to the current standard microbiological methods (control arm) for identifying 
pathogens.  
2.3.3. Study population 
Recruitment was performed between January and December 2015 among patients with 
at least one pathogen cultured from an eligible sample. Eligible samples were blood 
cultures or aspirates from sterile compartments (‘other’ samples - cerebrospinal fluid (CSF), 
deep abscesses, joint fluid, peritoneal fluid, pleural fluid or deep tissue biopsies). All 
subsequent samples from sterile compartments from a patient with an eligible sample 
were to be analysed using the same diagnostic pathway (MALDITOF-MS or standard 
microbiological methods). A patient was not eligible for recruitment if, at the time of 
randomisation, they had already had an eligible sample processed during the same hospital 
admission. 
2.3.4. Study endpoints 
The primary endpoint was the proportion of patients on optimal antimicrobial 
treatment (OAT) within 24 hours of positive culture (first observed growth of an eligible 
specimen). Optimal antibiotic treatment was defined as an antibiotic treatment lasting for 
at least 48 hours since positive culture, targeted to the identified pathogen and later found 
to cover the organisms antimicrobial resistance profile, while avoiding unnecessary broad-
spectrum antibiotics (e.g. avoid carbapenems or multiple agents where other agents or 
single agents would provide sufficient coverage). Examples of optimal antibiotic treatment 
are for example: stopping vancomycin treatment when a Klebsiella spp is identified or 
starting melioidosis specific treatment in case Burkholderia pseudomallei is identified. In 
case another invasive pathogen was identified within 48 hours of administering the optimal 
treatment that was not covered in the antibiotic spectrum, then the treatment is not 
considered optimal.  
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The decision on whether therapy was optimal within 24 hours was made by an 
independent review committee, blinded to the allocated diagnostic arm. The committee 
individually reviewed a standard subset of data collected in the case report form (CRF) 
which included the admission and discharge diagnosis, the antibiotics used over the 
admission and the full microbiology results (including susceptibility testing) for that 
episode. These data, which were free of any evidence of the allocated arm, were 
scrutinised in retrospect for all cases to determine the following: OAT at 24 hours and 48 
hours or at any point during hospital stay. If antibiotic therapy was not optimal at 24 hours, 
the reason for this was grouped into: organism not covered; therapy too broad; and 
‘other’). Discrepancies between reviewers were resolved by consensus using international 
guidelines where available. Where review of the individual clinical scenario and the 
organism isolated led the independent review committee to feel that the microbiological 
result should not be the sole focus of antimicrobial therapy, this was recorded as 
‘unclassified’.  
Secondary ‘patient-level’ endpoints were: OAT within 48 hours of positive culture, the 
defined daily dose (DDD) of antibiotics prescribed to patients (calculated by summing all 
the defined daily doses of antibiotics used from enrolment to discharge), the total duration 
of antimicrobial treatment (calculated by summing each day when any antibiotic was given 
from enrolment to discharge), hospital and ICU length of stay and clinical outcome (divided 
into death, palliative discharge (a common practice in Vietnam when a patient was 
discharged home for palliative care with the expectation of an early death), survived with 
sequelae and recovered) and hospital care (in US Dollars derived from the hospital bill at 
the 2018 exchange rate US$1 = 21,935 Vietnam Dong (World Bank, 2018b)) . Patients with 
meningitis due to Cryptococcus neoformans had the costs of their care was supported by a 
clinical trial over the study period and consequently costs for these patients were not 
included (Beardsley et al., 2016). 
Secondary ‘specimen-level’ endpoints included the time from specimen collection and 
first growth from an eligible specimen to OAT and to discharge.  
2.3.5. Sample size  
We expected that with the rapid results produced by the MALDITOF-MS system, 
doctors would be able to administer optimal antibiotic treatment more rapidly. Specifically, 
we expected an increase in the proportion of patients on optimal antibiotic treatment 
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within 24 hours from first growth of an eligible specimen from 40% (standard diagnostics) 
to 60% (MALDITOF-MS) (Vlek et al., 2012). To detect such an increase with 90% power at 
the 2-sided significance level of 5%, a total sample size of 260 eligible specimens is required. 
To have sufficient power for a subgroup analysis of the trial in positive blood cultures for 
each hospital separately and accounting for some incomplete data, the trial was to 
continue enrolment at both hospitals until the slower recruiting hospital reached enrolled 
280 blood cultures as first specimen. We aimed to enrol all eligible specimens (blood or 
other) from both hospitals during that time frame but do not explicitly control the number 
of ‘other’ specimens. 
Based on data from NHTD and HTD we predicted we would be able to finish recruitment 
within one year. During a recent 12-month period, NHTD had approximately 282 positive 
blood cultures, and in the same period HTD had approximately 500 positive blood cultures. 
In the same period, we expected to be able to enrol ~150 other specimens at NHTD and 
~200 at HTD.  
Assuming that the total sample size includes data from approximately 1000 subjects, 
we would have 89% power to detect an increase in the primary endpoint from 40% (routine 
diagnostics or controls) to 50% (MALDITOF- MS) in the overall analysis of all specimens 
from both hospitals. Moreover, we were also be able to detect an increase from 40% to 
60% in the subgroup of other specimens from both hospitals with a power of >90%. 
2.3.6. Randomisation procedure 
When an eligible specimen from a patient showed growth of a pathogen, the diagnostic 
pathway was randomized to either MALDITOF-MS or routine microbiological diagnostics 
with a 1:1 allocation ratio and stratification by hospital and specimen type (blood vs. other). 
Isolates grown from all eligible specimens of the same patient were assigned to the same 
diagnostic pathway as the first randomized specimen of that patient.  
Allocation to diagnostic pathway was assigned by a web-based randomization program 
using a random variable block length of 4 or 6. When a pathogen was isolated from a 
positive eligible specimen, the laboratory technician logged onto the secure randomization 
program and entered the patient and specimen code. The random diagnostic pathway 
allocation then was generated, informed to the laboratory technician and logged in the 
study database. In the case of multiple specimens with pathogen growth for a single 
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patient, the unique patient code triggered the randomization program to generate the 
same diagnostic pathway allocation as the previous sample(s).  
2.3.7. Intervention 
Clinical specimens were collected according to routine practice. Briefly, blood culture 
bottles (aerobic) were incubated for up to five days in an automated culture system 
(Bactec, Becton-Dickinson, USA). Other samples were incubated on media allowing growth 
of aerobic, anaerobic and fastidious organisms and checked daily for growth. For the 
MALDITOF-MS arm, blood culture media or colonies from plates were sub-cultured onto 
blood agar until growth could be observed. Colonies were then analysed by MALDITOF-MS 
analysis twice per day. In the routine arm, methods for identification included: Gram stain, 
API test strips (bioMérieux), VITEK2 system (bioMérieux), and other biochemical and 
microbiological tests (e.g. oxidase, optochin sensitivity etc). Samples that yielded 
organisms that were not considered pathogens (e.g. coagulase-negative staphylococci, 
diphtheroids, isolated growth of viridans group streptococci) were not included in analysis. 
Treating physicians were not explicitly told of the allocated diagnostic pathway for the 
patients, but could have made deductions from the speed of results for that patient. 
2.3.8. Study assessment 
Both clinical and microbiological data for participants were collected prospectively, 
recorded onto a case Record Form (CRF), and checked for accuracy by research staff. These 
data included all antibiotic and antifungal medications prescribed, hospital related costs to 
the patient or their insurance incurred (through the hospital bill) and outcome. At least 24 
hours following the delivery of the written report on the pathogen identity to the ward, a 
member of the research team discussed with the clinical team whether the results in the 
report had changed management and if not, why not. Data were then anonymised and 
entered to an online, secure electronic database by single entry method.  
No other changes were made to the routine hospital procedures for the communication 
of microbiological culture results between the laboratories and the clinical teams. This 
involved telephoning of positive culture results where staffing permitted it and provision 
of written reports to the wards (no computerised reporting system was available at either 
site during the study period).  
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Table 2-5. Schedule of enrolment, interventions, and assessments in the MALDITOF-MS 
trial 
 STUDY PERIOD 
 Enrolment Allocation Post-allocation Close-out 
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ENROLMENT:       
Eligibility screen X      
Informed consent  X      
Randomisation  X     
INTERVENTIONS:       
MALDITOF-MS  X X    
Standard microbiological diagnostics 
(controls) 
 
X 
X 
  
 
ASSESSMENTS:       
Demographic data  X      
Type of specimen X      
Pathogen isolates   X    
Antimicrobial susceptibility   X    
Date and time of antimicrobial switches X X X X X  
Prescribed antimicrobials X X X X X X 
Defined daily dose (DDD)      X 
Diagnosis  X     X 
Mortality      X 
Length of stay      X 
Cost of microbiological testing      X 
Cost of stay      X 
Optimal antibiotic treatment review    X X  
 
2.3.9. Data management 
Both microbiological and clinical data were recorded onto a CRF and checked for 
accuracy by the clinical microbiologist on duty. Data was entered to an electronic database 
(CLIRES) by single entry method. Internal checks of the entered data were performed to 
look for outliers and errors. 
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2.3.10. Statistical Analysis 
2.3.11. Ethics approval and consent to participate 
The study was reviewed and approved by The Ethical Committee in Biomedical 
Research - Hospital for Tropical Diseases (Approval number 16/HDDD-QD), the Institutional 
Review Board – National Hospital for Tropical Diseases (Approval number 698/QD-NDTW) 
and the Oxford Tropical Research Ethics Committee (OXTREC Reference: 55-14) with 
respect to scientific content and compliance with applicable research and human subject 
regulations. The trial was registered with Clinicaltrials.gov (NCT02306330). 
In NHTD, patients admitted to the participating hospitals received an information sheet 
with details about the study. This sheet informed patients of the purpose and procedures 
of the study as well as their right to refuse participation and how to get more information 
or withdraw from the study. Any patient who requested not to be included in the study had 
their specimens labelled accordingly and diagnosis proceeded in the standard way. At HTD, 
in accordance with the Ethical Committee approval at that site, patients (or their legal 
representatives) who had growth in an eligible sample were seen by study staff, fully 
informed of the study, and asked for written consent before participation. Only those who 
provided consent were recruited.  
 
2.3.12. Statistical Analysis 
For analysis of the primary outcome, we used a logistic regression model of the primary 
endpoint depending on the treatment groups, with additional adjustment for the first 
specimen type (blood vs. other) and study site. As a conservative measure, subjects with 
an ‘unclassified’ primary endpoint were labelled as ‘non-optimal’, as were subjects that 
were discharged or died within 24 hours unless OAT had been started before 
death/discharge. We planned the following subgroup analyses: specimen type 
(blood/other); study site (hospital); type of pathogen (fungi, Gram positive or negative 
bacteria); final diagnosis of meningitis and non-meningitis. These subgroup analyses and 
the secondary endpoint of OAT within 48 hours of positive culture were performed in the 
same way as for the whole population. Comparisons of the secondary endpoints of total 
antibiotics prescribed and hospital stay were performed using a linear regression model 
with treatment as the main covariate and adjustment by specimen type and study site. 
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Where the outcome was right skewed the endpoint was log-transformed prior to analysis 
leading to a comparison of geometric rather than arithmetic means. Hospital and ICU 
length of stay were analysed using Cox proportionate hazards, stratified by specimen type 
and study site. A summary of these endpoints for survivors only is also provided. Outcome 
was categorised as death or palliative discharge, survived with sequelae (including intra-
hospital transfers other than palliative ones) and recovered. The ordinal outcome was 
compared between the two diagnostic arms using a proportionate odds cumulative logit 
model with adjustment by specimen type and study site. A non-prespecified analysis of 
outcome as a binary variable was also conducted (death and palliative discharge versus 
other) using a logistic regression model adjusted for specimen type and study site. Time 
from first growth and collection of sample to OAT were analysed using a standard Cox 
regression analysis with competing risks (death or discharge without OAT) treated as right-
censored at time infinity to indicate that they never received OAT. Time from first growth 
and sample collection to issue of the pathogen identification report in the laboratory were 
descriptively summarised by diagnostic arm as median (lower and upper quartiles) with the 
formal statistical comparison. Analyses were performed using R (Version 3.4.0). P values 
below 0·05 were considered significant (two-sided). 
2.3.13. Funding 
The study was funded by the Wellcome Trust Asia Programme grant and the Li Ka Shing 
Foundation.  
2.4. Method for Chapter 6: Hospital acquired blood stream 
infection in intubated patients in 3 Vietnamese ICUs and Chapter 7: 
Descriptive analysis of ventilator associated respiratory infections 
in a randomised controlled trial in the ICUs 
2.4.1. Objectives 
The objectives of both chapters five and six were met through a single study. These 
objectives were as follows: 
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2.4.1.1. Objectives of Chapter 6  
The objective of this chapter is to estimate the incidence of hospital acquired 
bloodstream infection (HABSI) and central line associated bloodstream infection (CLABSI) 
among intubated patients, the aetiology and risk factors for HABSI of these patients. 
2.4.1.2. Objectives of Chapter 7 
The primary objective of this study was to determine if continuous endotracheal cuff 
pressure control (CPC) can reduce the incidence of ventilator associated respiratory 
infection (VARI) in adults. Secondary aims included establishing whether CPC leads to an 
increase in proportion of ventilated days in ICU not on antibiotics or a reduction in 
antibiotic costs, a reduction in the frequency of hospital acquired infection (HAI) as a whole 
during ICU stay, length of ventilation, length or cost of ICU and hospital stay, as well as any 
local complications of the endotracheal cuff and mortality at 28 and 90 days post 
randomisation and at discharge from ICU. In this thesis, I also present a brief data analysis 
plan and demographics of patients with VARI.  
2.4.2. Study design  
This was an open-label, randomised controlled trial (RCT) comparing continuous 
endotracheal cuff pressure control via an automated electronic device, with intermittent 
manual pressure control for the prevention of VARI in ICU. For the purpose of this study a 
stand-alone CPC device was be used (Tracoe reference 701) for the intervention. The RCT 
also provided opportunity to monitor the occurrence of hospital acquired infection 
prospectively. Although recognition and diagnosis of HAIs and intervention at early stage 
are expected to impact the mortality, length of stay and treatment cost, it is clear that there 
are important differences between surveillance definitions and actual clinical definitions. 
Therefore, the observational study of hospital acquired infections can be integrated in the 
trial to provide insight on the real-life diagnosis and treatment of HAIs. 
2.4.3. Study population 
Patients were recruited over an 18-month period from the two ICUs in the Hospital for 
Tropical Diseases (HTD), the general ICU in Trung Vuong Emergency Hospital (TVH) in Ho 
Chi Minh City and the National Hospital of Tropical Diseases (NHTD) in Hanoi. HTD and 
NHTD are referral centres for the management of patients with infectious diseases. Both 
receive patients with infectious diseases directly from their local populations as well as 
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transferred from other hospitals in southern and northern Vietnam. TVH is a provincial 
hospital serving the general medical needs of the local population in HCMC. 
Patients were considered eligible for inclusion in the study if they were at least 18 years 
of age, had been intubated for ≤ 24 hours at the time of randomization (either orally or 
through tracheostomy) and for active treatment (i.e. the physician caring for patient would 
prescribe an antibiotic if the patient developed an infection). Exclusion criteria were 
previous enrolment in the study, having been previously intubated within the last 14 days, 
known tracheal stenosis, tracheomalacia or stridor that is suspected secondary to physical 
tracheal injury. Patients were only enrolled following written informed consent from 
themselves or their legal representatives. 
Patients were stratified by clinical diagnosis of tetanus or non-tetanus, as patients with 
tetanus represent a distinct subgroup: usually they present without significant premorbid 
disease or systemic inflammatory response, often undergo primary tracheostomy and have 
a prolonged duration of intubation and ICU stay. Whilst rare in high-income settings, in 
many countries tetanus patients represent a significant burden of disease with high rates 
of HAI and high consumption of ICU resources (Thwaites and Farrar, 2003). Thus, any study 
attempting to address the problem of HAI in this setting also needs to specifically address 
tetanus without allowing it to dominate the picture. In view of this patients with tetanus 
were limited to 30% of the total enrolment. 
2.4.4. Study endpoints 
The primary endpoint was the occurrence of VARI which was defined as Ventilator 
Associated Pneumonia (VAP) or Ventilator Associated Tracheobronchitis (VAT) during ICU 
stay up to a maximum of 90 days post randomisation as evaluated by an independent 
endpoint adjudicator, blinded to the randomisation arm and independent of patient care. 
For both VAP and VAT, it was a core requirement that the patient had been intubated for 
at least 48 hrs, and that the tube was in place within the 48 hours before the infection 
occurs. An additional core criterion for all cases was that a decision has been made to start 
new antibiotics or change the antibiotic regimen to treat a new infection. In addition to 
these core criteria, the endpoint diagnosis of VAT further required new onset of purulent 
respiratory secretions or change in character of sputum or increase in volume of sputum 
plus either (1) temperature >38 °C or < 36 °C or (2) white blood cell count <4.0 x 109/L or 
≥12 x 109/L with no other recognised cause. The endpoint diagnosis of VAP was met when 
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the core criteria were met and there were new or progressive changes on chest 
radiography plus two of following three criteria (1) temperature >38 °C or < 36 °C, (2) white 
blood cell count <4.0 x 109/L or ≥12 x 109/L with no other recognised cause and (3) a new 
onset of purulent respiratory secretions or change in character of sputum or increase in 
volume of sputum. 
Secondary endpoints included microbiologically confirmed VARI (defined as VARI plus 
bacterial growth of ≥105 colony forming units (CFU)/ml (endotracheal aspirate) or 
equivalent semi-quantitative growth), clinical and microbiologically confirmed VAP, 
proportion of intubated days receiving antibiotics, incidence of other HAI, including 
hospital acquired bloodstream infection (defined as either (1) least one positive blood 
culture for a recognised pathogen or (2) at least two positive blood cultures for a common 
skin contaminant (from two separate blood samples within 48 hours) and either fever (> 
38 °C) or chills or hypotension (as defined by the European Centre for Disease Prevention 
and Control (ECDC)) (European surveillance of healthcare-associated infections in intensive 
care units, 2015) whilst intubated, total number of days ventilated/in ICU, cost of 
ICU/hospital stay, cost of antibiotics during ICU/hospital stay and mortality at 28 and 90 
days after randomisation, and at ICU. Safety data including in-hospital re-intubation, 
tracheomalacia, tracheal stenosis and other local complications of ET placement were 
collected up to 90 days post randomisation, or up to hospital discharge, whichever was 
later. The time periods over which endpoints or censoring events were elicited is shown in 
Table 2-6. 
2.4.5. Sample size  
Based on local data and that from a large point-prevalence study in Vietnam (Phu et al., 
2016) the estimated period prevalence of VARI (the primary outcome) in non-tetanus and 
tetanus ventilated patients is 20% and 30% over the course of their admission respectively. 
Based on previous small studies we expected an effect size of a 50% reduction in VARI using 
CPC, but wished to be able to detect a 40% reduction (Lorente et al., 2014, Nseir et al., 
2011). This effect size was expected to be the same in both tetanus and non-tetanus 
patients. To preserve the generalisability of the study for settings where tetanus is less 
common, whilst still demonstrating the utility of the intervention in this patient group, we 
stratified randomisation to ensure that 30% of our recruited patients had a diagnosis of 
tetanus. Thus, we might expect to reduce VARI rates from 20% to 12% in non-tetanus and 
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from 30% to 18% in tetanus patients). In a study population with 30% tetanus patients, this 
corresponds to an absolute risk reduction from 23% to 13.8%. To detect this reduction with 
80% power at the two-sided 5% significance level, 278 patients were required in each arm. 
Allowing for 8% loss to follow up we aimed to recruit 600 patients in total (420 non-tetanus, 
180 tetanus).  
Table 2-6. Follow up periods for all study endpoints.  
Endpoint Beginning of follow 
up 
End of follow up/censoring event 
(soonest event applies except where 
specified) 
Primary:   
VARI Randomisation ICU discharge/death/transfer or 90 days 
Secondary:   
Microbiologically confirmed 
VARI 
Randomisation ICU discharge/death/transfer or 90 days 
Clinical & Microbiologically 
confirmed VAP 
Randomisation ICU discharge/death/transfer or 90 days 
Intubated days receiving 
antibiotics 
Randomisation ICU discharge/death/transfer or 90 days 
Incidence of HAI Randomisation Extubation/death/transfer/discharge 
from ICU or 90 days 
Days ventilated/in ICU Randomisation ICU discharge, death, transfer 
Cost of ICU stay ICU admission ICU discharge/death/transfer 
Cost of antibiotics in ICU stay ICU admission ICU discharge/death/transfer 
Cost of hospital stay Hospital admission Hospital discharge 
28-day mortality Randomisation 28 days after randomisation 
90-day mortality Randomisation 90 days after randomisation 
ICU mortality Randomisation Discharge from ICU or death/palliative 
discharge from it 
Hospital mortality Randomisation Discharge from hospital or 
death/palliative discharge from it 
 
2.4.6. Randomisation procedure 
Randomisation was 1:1 stratified by site and whether or not the patient had a clinical 
diagnosis of tetanus at the time of randomisation. A stratified, computer-generated 
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randomisation list was created using block randomisation with variable block length and 
incorporated into secure internet accessible software that implements the randomisation. 
Once an eligible patient had consented, the initials and date of birth of the patient were 
entered into the software by study staff. Based on the randomisation list, the software 
produced the treatment allocation, which was displayed and recorded in the study 
database. All entries and outputs of the software were auditable.  
2.4.7. Intervention 
Depending on the results of randomisation patients received either manual, 
intermittent endotracheal cuff pressure control, which was checked and adjusted 8 hourly 
(standard care), or automatic, continuous endotracheal CPC (intervention group). Target 
pressure in both groups was 25 cm H20 as a default. Changes to this target were recorded 
and the clinical reason for the change noted. 
2.4.8. Study assessment 
On a daily basis, the attending physicians assessed whether there was a new infection 
in a patient who had been intubated for ≥ 48 hours and in whom the tube was still in place 
or had been removed within the previous 48 hours. If the answer was ‘yes’, a standard 
battery of tests including complete blood count, procalcitonin, arterial blood gas, blood 
culture, sputum/endotracheal aspirate microscopy and culture, urine culture and chest x-
ray was performed regardless of the suspected site of infection. Test results and clinical 
details from up to 5 days previous, the day of the HAI evaluation and subsequent 2 days 
were collected, including maximum/minimum temperature, changes in ventilation 
parameters (fractional inspired oxygen, positive end expiratory pressure), changes in 
sputum colour or volume, new inotrope or vasopressor requirements. The treating 
clinicians provided their own diagnosis of the aetiology of the infection according to ECDC 
criteria and prescribed antibiotic and other therapies as per routine care. However, for the 
primary endpoint, an endpoint reviewer, blinded to the treatment allocation and 
independent of clinical involvement with the patient, reviewed the complete case report 
form and radiology of patients completing the study at the end of each month to determine 
whether they met the primary or appropriate secondary endpoint criteria.  
Enrolled patients had cuff pressure controlled in accordance with the allocated study 
arm for the entire duration of their intubated time on ICU. Follow up for the primary 
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outcome was until transfer to another facility, death, discharge from ICU or 90 days 
following randomisation, whichever was soonest. Patients that required re-intubation 
during the same stay in ICU continued in the study, using the same cuff pressure control 
measures originally allocated to them. Patients discharged from ICU but requiring return 
to ICU and re-intubation were not re-enrolled and were managed in accordance with 
standard care. At the end of the hospital stay the costs of the stay as billed were recorded 
(including bed, ventilator and other supportive therapies costs, drugs including antibiotic 
costs, but not including labour as per Vietnamese Ministry of Health guidance). 
Additionally, as a part of secondary endpoints assessment, study staff telephoned patients 
or their relative at 28 and 90 days after randomisation if they were no longer inpatients in 
order to assess mortality and complications related to intubation. Study procedures with a 
schedule of enrolment, interventions and assessments in Table 2-6.  
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Table 2-7. Schedule of enrolment, interventions, and assessments 
 STUDY PERIOD 
 Enrolment Allocation Post-allocation Close-out 
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ENROLMENT:          
Eligibility screen X         
Informed consent  X         
Randomisation  X        
INTERVENTIONS:          
Continuous endotracheal 
cuff pressure control 
 
X 
       
Intermittent endotracheal 
cuff pressure control (q8h) 
 
X 
       
ASSESSMENTS:          
Demographic data  X         
Charlson Comorbidity Index 
& APACHE II 
X         
PEEP and FiO2  X X X      
HbA1c  X        
Chest x-ray   X  X      
Cuff pressure measurement  X X       
Complete Blood Count  X  X      
Arterial blood gas analysis  X  X      
Procalcitonin    X      
Blood and urine culture    X      
Respiratory secretions 
microscopy & culture 
   
X  
    
Risk factors for VARI 
Use of sedative agents  
Use of paralytic agents 
Feeding  
Use of PPI  
  X    
   
Mortality   X   X X X X 
Endotracheal tube cuff 
related complications  
  
X  
 
X X X X 
Cost of stay      X X   
Cost of antibiotics      X X   
 
2.4.9. Data management  
Relevant data was recorded onto a case report form (CRF) and checked for accuracy. 
After the follow up was finished, the CRFs were deidentified by removing patient identifiers 
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and telephone numbers. Selected staff were trained on how to enter all clinical data from 
the CRFs and from laboratory source documents into a computerised data entry system 
using double data entry. Data will be retained for at least 15 years after completion of the 
study (last patient followed up for 90 days). Original paper documents will be maintained 
for at least 5 years, thereafter digital copies will be retained. All stored records are kept 
secure and confidential.  
All personal information reviewed as a part of this study was remain confidential. 
Patient names or identifiers were not appeared in any database. Data cleaning was 
performed to detect and edit ambiguous or missing data. The database was locked and 
statistical analysis plan was agreed before final analysis and unblinding study arms. 
2.4.10. Statistical Analysis 
2.4.10.1. Data analysis for Chapter 6 
Standard descriptive statistics were calculated for categorical (in percentage) and 
continuous variables (median and interquartile, IQR). Bivariate analyses were performed 
using Pearson’s chi-squared test or Fisher’s Exact Test for categorical variables as 
appropriate. Cox proportional-hazards regression was used to identify variables that 
predict the occurrence of HABSI and clinical outcomes. Cox’s proportional hazards 
regression was performed to analyse factors associated with all-cause in-hospital mortality. 
All tests were two-tailed and differences were considered statistically significant at p values 
≤0.05. 
2.4.10.2. Data analysis for Chapter 7 
Among patients who were enrolled for the clinical trial, I calculated standard descriptive 
statistics for categorical (in percentage) and continuous variables (median and 
interquartile, IQR) for baseline characteristics of all patients and the subgroup of patients 
with VARI and VAP. No statistical tests were performed to test statistical significance of 
characteristics among different groups. The statistical analysis plan is being finalised prior 
to unblinding of the trial and analysis of data.  
2.4.11. Ethics approval and consent to participate 
Patients who required intubation at the study site on or after arrival or who had been 
intubated prior to transfer, or their legal representatives, were approached as soon as 
possible in line with prioritising patient care, fully informed and invited to consent to the 
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study. Consent was obtained by study or hospital staff trained in good clinical practice 
(GCP) and the consent procedure. Randomisation then took place and patients were 
managed in the appropriate manner. Patient care was never delayed for consent or 
randomisation procedures. Where consent was provided by a patient’s representative and 
they later regained the capacity to provide consent, the patient was approached and given 
the opportunity to withdraw from the study.  
This study protocol and the template informed consent forms were reviewed and 
approved by the Ethical Committee in Biomedical Research - Hospital for Tropical Diseases 
(Approval number 30/QĐ-BVBNĐ), the Institutional Review Board – National Hospital for 
Tropical Diseases (Approval number 22/HDDD-NDTU), the Ethical Committee in Biomedical 
Research Trung Vuong Hospital (Approval number 670—BVTV) and the Oxford Tropical 
Research Ethics Committee (OXTREC Reference: 26-16) with respect to scientific content 
and compliance with applicable research and human subjects regulations. The trial was 
registered with Clinicaltrials.gov (NCT02966392). 
2.4.12. Reporting of Adverse Events & Monitoring 
As adverse events are relatively common in critically ill patients intubated on the ICU, 
safety reporting focused on events of potential relevance to cuff pressure control. The 
events being reported to the ethical committees were (1) all unexpected serious adverse 
events, (2) all serious adverse events judged to be related or possibly related to cuff 
pressure and (3) all deaths or palliative discharges (discharge home of a patient where 
ongoing care was considered futile to permit the patient to die at home, a commonly 
preferred alternative to dying in hospital in Vietnam). Reporting to the ethical committees 
was in accordance with GCP.  
An independent Data and Safety Monitoring Board (DSMB) was established consisting 
of expert Vietnamese and international researchers and doctors, with the necessary 
clinical, research and statistical knowledge. The DSMB reviewed the protocol, a DSMB 
charter outlines its responsibilities and how it operates. All DSMB reports were sent to the 
responsible ethical committees including the site ethical committees, the Oxford Tropical 
Research Ethics Committee for consideration. Recruitment was continued at active sites 
during the DSMB review period. No interim analyses were planned for the primary 
endpoint, however, safety analyses was be conducted after 30 patients were recruited and 
subsequently at points decided by the DSMB. 
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The study was monitored by a team at OUCRU, independent of study design and 
management. Central monitoring took place regularly with on-site monitoring occurring 
prior to commencement of the study, after the recruitment of 25 patients in total, at 12 
months and at intervals prior to and after 12 months depending on the results of early 
monitoring visits. 
2.4.13. Funding 
The study was funded by the Wellcome Trust Asia Programme grant (grant code 
106680/Z/14/Z).
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: Price and use of antimicrobials in an emerging 
pharmaceuticals market in Vietnam 
3.1. Introduction 
Despite concerted international efforts, antimicrobial use continues to rise in both 
humans and animals. Data on antibiotic sales from 76 countries (including Vietnam) 
between 2010 and 2015 estimated global antibiotic consumption in humans has increased 
by 65% over this period, reaching 42 billion defined daily doses (DDDs) every year (Klein et 
al., 2018). Global consumption is forecast to increase by a further 200% between 2015 and 
2030 if there are no changes in current practice (Klein et al., 2018). Overall antibiotic 
consumption (in DDDs per 1 000 population per day) differs 3 fold between countries with 
an up to 16 fold variation in volumes of quinolones and cephalosporins among the mostly 
high-income member states of the Organisation for Economic Co-operation and 
Development (OECD) (OECD, 2017). Antibiotic consumption was positively correlated with 
growth in per capita gross domestic product (GDP) (Klein et al., 2018) and low- and middle-
income countries (LMICs) are disproportionately responsible for driving the rise in global 
antibiotic consumption (Van Boeckel et al., 2014). From 2000 to 2010, Brazil, Russia, India, 
China and South Africa (BRICS) contributed 30% of global population growth but 76% of the 
increase in global antibiotic consumption (in number of doses) in the same period (Van 
Boeckel et al., 2014).  
There is a positive correlation between antibacterial consumption and levels of 
bacterial resistance to antibiotics (Goossens et al., 2005). WHO introduced the AWaRe 
classification of antibacterials (Access, Watch and Reserve groups) to promote 
antimicrobial stewardship at local, national and global level, and address the challenge of 
increased antimicrobial resistance. The ‘Access’ group includes first and second choice 
antibacterials for the empirical treatment of common infectious syndromes which should 
be widely available in all healthcare settings. The ‘Watch’ group includes antibacterial 
classes that have higher resistance potential and are recommended for a specific, limited 
number of indications. Finally, the ‘Reserve’ or last resource group includes antibacterials 
that are recommended for highly specific patients when all alternatives have failed (see 
appendix 1 for detailed classification) (World Health Organization, 2017c). WHO 
72 
 
recommends that countries monitor the consumption of the Watch and Reserve 
antibacterials carefully as part of their AMR strategy (World Health Organization, 2017c) 
and to timely inform policies to optimize the use of antibacterials (World Health Assembly, 
2015).  
Access category antibacterials comprise more than 50% of total consumption (in DDD 
per 1000 inhabitants per day) in 49/65 reported countries in the period of 2015-2016 , 
whilst the Reserve category accounted for less than 2% of total antibacterial consumption 
in DDD/1000 person days in most high-income countries. In the European region, the 
Reserve category was rarely used, amounting to a median of 0.2% of all antibacterial use 
in 45 countries surveyed (World Health Organization, 2018d).  
Vietnam is a lower middle-income country (LMIC) with a population of 94.6 million and 
GDP per capita of US$2,171 (World Health Organization, 2018c). In 2016, health 
expenditure accounted for 5.7% of GDP, corresponding to annual per capita health 
expenditure of US$122.8, 45% of which was out of pocket spending (World Health 
Organization, 2018c). However, data on antibiotic consumption from LMICs are still limited, 
especially for countries from South East Asia (World Health Organization, 2018d). In 
addition to quantifying consumption of antimicrobials, understanding relative costs and 
spending on antimicrobials is important since antimicrobial consumption is associated with 
antimicrobial resistance but a high price of medication may act as a barrier to access, 
reducing consumption. Our study aimed to estimate antimicrobial usage, expenditure and 
cost in public hospitals in Vietnam. 
3.2. Materials and Methods 
Data on antimicrobial procurement were obtained from tender-winning bids from 
52/63 provincial health authorities and 30 public hospitals across Vietnam from 2018. 
Antimicrobials were classified using the Anatomical Therapeutic Chemical (ATC) Index and 
the WHO Access, Watch, Reserve (AWaRe) groups. Volume was measured in number of 
Defined Daily Doses (DDD). Antimicrobial cost were presented per DDD. The detail of 
method was presented in Chapter 2. 
3.3. Results  
We included tender-winning results totalling US$1.68 billion from 23 secondary 
hospitals, 7 primary hospitals and 52 provincial departments of health in Vietnam. With 
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estimation of total pharmaceutical sales in Vietnam in 2018 was US$ 5.85 billion (Business 
Monitor International Ltd., 2016), our analysis (US$1.68 billion) may represent 28.7% of the 
national budget for medication. The overall budget for systemic antibacterials and 
antifungals accounted for 28.6% (US$482.6 million) of the total drug budget for the study 
hospitals (Table 3-1).  
Among antibacterials for systemic use (J01), there were a total of 77 different 
substances (ATC 5th level) in 23 chemical subgroups (ATC 4th level) procured over all sites. 
Antibacterials procured according to their AWaRe categories are presented in Figure 3-1. 
Overall, 25.8% of DDD (178.658.638 DDD) procured were unclassified by the AWaRe index, 
among which 78.5% were 2nd generation cephalosporins (J01DC), 13.4% were 1st 
generation cephalosporins (J01DB), 5.4% were macrolides (J01FA) and 2.7% were other 
substances. The Access group, Access and Watch group and Watch group antibacterials 
accounted for 42.9%, 23.4% and 7.7% of procured number of antimicrobial DDD 
respectively whilst the Reserve group accounted for 0.3% of antibacterials procured. The 
proportion of Access group, Watch group and Reserve group provided by domestic 
manufactures were 83.2%, 83.7% and 43.1% respectively.
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Table 3-1. Budget and number of DDD 
 Department of Health 
(n=52) 
Secondary hospital 
(n=23) 
Primary hospital 
(n=7) 
All sites 
J01_antibacterials 
for systemic use 
Total budget (%) US$430,713,755  
(29.50%) 
US$47,888,882  
(22.01%) 
US$1,426,924  
(18.49%) 
US$480,029,561 
(28.48%) 
Number of DDD (%) 636,851,337  
(93.26%) 
51,468,583  
(95.32%) 
4,036,865  
(96.62%) 
692,356,785  
(93.43%) 
J02_antimycotics 
for systemic use 
Total budget (%) US$1,750,265  
(0.12%) 
US$815,819  
(0.37%) 
US$13,898  
(0.18%) 
US$2,579,982  
(0.15%) 
Number of DDD (%) 2,342,056  
(0.34%) 
US$219,822 
(0.41%) 
20,798  
(0.50%) 
2,582,676  
(0.35%) 
P01_antiprotozoals Total budget (%) US$940,694  
(0.06%) 
US$17,942  
(0.01%) 
US$1,577  
(0.02%) 
US$960,214  
(0.06%) 
Number of DDD (%) 9,657,984  
(1.41%) 
406,181  
(0.75%) 
34,875  
(0.83%) 
10,099,040  
(1.36%) 
P02_anthelmintics Total budget (%) US$436,790 
(0.03%) 
US$68,622  
(0.03%) 
US$2,369  
(0.03%) 
US$507,781  
(0.03%) 
Number of DDD (%) 4,735,531  
(0.69%) 
590,841  
(1.09%) 
17,250  
(0.41%) 
5,343,622  
(0.72%) 
Other medications Total budget (%) US$1,026,229,647  
(70.29%) 
US$167,855,286  
(77.16%) 
US$6,225,722  
(80.66%) 
US$1,188,532,427  
(70.52%) 
Total Total budget (%) US$1,460,071,152  
(100.00%) 
US$217,553,353  
(100.00%) 
US$7,718,581 
(100.00%) 
US$1,685,343,086  
(100.00%) 
Number of antimicrobial DDD (%) 682,893,636  
(100.00%) 
53,994,079  
(100.00%) 
4,178,096  
(100.00%) 
741,065,810  
(100.00%) 
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Figure 3-1. Proportional antibacterial procurement in DDD (%) by AWaRe classification 
Oral antibacterials accounted for 91.4% of total DDD of antibacterials (J01) across all 
sites (Figure 3-2). Parenteral antibacterials represented 11.2% of the procured antibacterial 
DDDs in secondary hospitals, 3.8% in primary hospitals and 8.5% in bids by DoH. The most 
common oral antibacterial across all sites were the second generation cephalosporins 
(J01DC) (19.8% of total DDD). When stratifying by the site of procurement, the most 
common consumed oral antibacterials in secondary hospitals were combinations of 
penicillins and beta-lactamase inhibitors (J01CR) (29%) and in primary and departments of 
health hospitals were the second generation cephalosporins (J01DC) (21.8% and 20.3% 
respectively). For parenteral antibacterials, the most common antibacterials were the third 
generation cephalosporins (J01DD) (29.1%). The details of antibacterial procurement in 
DDD is shown in Table 3-2. 
The cost shares of antibacterials procurement are shown in Table 3-2. The second 
generation cephalosporins (J01DC), combinations of penicillins, including beta lactamase 
inhibitors (J01CR), penicillins with extended spectrum (J01CA), third generation 
cephalosporins (J01DD) and fluoroquinolones (J01MA) covered 76.6% of the total quantity 
of DDD, reaching 65.7% of the total costs (Table 3-2). However, carbapenems (J01DH) only 
accounted for 0.3% of antibacterial use but 10.2% of the total antibacterial costs.  
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Figure 3-2. The cost shares and number of DDD of antimicrobials for systemic antibacterial (J01) by route of administration in hospitals in 
Vietnam. 
  
Number of DDD Budget ($) Number of DDD Budget ($) Number of DDD Budget ($) Number of DDD Budget ($)
All settings Departments of Health Secondary hospitals Primary hospitals
Parenteral formulations 119,680,725 615,425,972 53,943,996 269,559,621 5,744,034 37,571,344 152,333 582,020
Oral formulations 1,265,032,844 344,633,150 582,907,341 161,154,134 45,724,549 10,317,538 3,884,532 844,903
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Table 3-2. The proportion of DDD number and budget shares of the antibacterials for systemic (J01). 
 Department of Health  Secondary hospitals  Primary hospitals  All sites 
 % DDD % budget  % DDD % budget  % DDD % budget  % DDD % budget 
J01DC_Second generation cephalosporins 20.29% 16.52%  19.66% 8.06%  21.81% 15.87%  20.25% 15.67% 
J01CR_Combinations of penicillins, incl. beta 
lactamase inhibitors 16.31% 15.77%  26.33% 15.22%  18.35% 24.10%  17.06% 15.74% 
J01CA_Penicillins with extended spectrum 15.78% 2.94%  10.67% 0.91%  11.89% 2.21%  15.38% 2.74% 
J01DD_Third generation cephalosporins 12.23% 23.02%  19.73% 23.31%  8.55% 24.86%  12.77% 23.05% 
J01MA_Fluoroquinolones 11.33% 11.56%  12.89% 14.89%  11.54% 7.94%  11.45% 11.89% 
J01DB_First generation cephalosporins 9.00% 8.16%  0.80% 0.57%  15.00% 8.52%  8.43% 7.40% 
J01FA_Macrolides 8.22% 3.41%  4.05% 1.31%  9.20% 8.81%  7.91% 3.22% 
J01AA_Tetracyclines 1.79% 0.07%  1.78% 0.47%  2.13% 0.08%  1.79% 0.11% 
J01CE_Beta lactamase sensitive penicillins 1.59% 0.08%  0.07% 0.00%  0.39% 0.03%  1.47% 0.07% 
J01EA_Trimethoprim and derivatives 0.97% 0.18%  0.22% 0.01%  0.11% 0.01%  0.91% 0.16% 
J01GB_Other aminoglycosides 0.86% 1.63%  1.45% 1.27%  0.72% 0.84%  0.90% 1.59% 
J01XD_Imidazole derivatives 0.40% 1.29%  0.48% 0.81%  0.05% 0.22%  0.40% 1.24% 
J01CF_Beta lactamase resistant penicillins 0.39% 0.90%  0.18% 0.29%  0.05% 0.13%  0.37% 0.83% 
J01FF_Lincosamides 0.22% 0.74%  0.22% 0.93%  0.00% 0.00%  0.22% 0.76% 
J01DH_Carbapenems 0.18% 9.18%  0.50% 18.74%  0.04% 1.27%  0.20% 10.12% 
J01DE_Fourth generation cephalosporins 0.15% 2.25%  0.29% 3.43%  0.05% 2.04%  0.16% 2.37% 
J01MB_Other quinolones 0.14% 0.05%  0.01% 0.00%  0.04% 0.04%  0.13% 0.05% 
J01XX_Other antibacterials 0.05% 0.69%  0.37% 3.09%  0.04% 0.76%  0.08% 0.93% 
J01XA_Glycopeptide antibacterials 0.05% 0.69%  0.23% 2.78%  0.03% 1.05%  0.06% 0.90% 
J01BA_Amphenicols 0.03% 0.03%  0.00% 0.00%  0.01% 0.01%  0.03% 0.02% 
J01XB_Polymyxins 0.01% 0.84%  0.07% 3.90%  0.01% 1.19%  0.02% 1.15% 
 The cells were colorized with red-yellow-green color scale by column. The highest values in a column were red, the average values were yellow, and the 
lowest values were green. DDD= Defined Daily Dose. 
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Figure 3-3. ABC analysis of the quantities of procured antibacterials (in DDD) and the cost.  
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Figure 3-4. Number of antimicrobial manufacturers in Vietnam 
 
By AWaRe categories, the average cost per DDD of Reserve group antibacterials was 
the highest (US$12.38 per DDD), followed by the Watch group antibacterials (US$2.15 per 
DDD), antibacterials in both Watch and Access group (US$0.74 per DDD), as unclassified 
antibacterials (US$0.64 per DDD) and Access group antibacterial (US$0.36 per DDD). We 
presented the cost of antimicrobials (ATC 5th level) in Table 3-4. The top three of the most 
expensive antimicrobials were caspofungin (J02AX04) (US$284.5 per DDD), doripenem 
(J01DH04) (US$85.3 per DDD) and tigecycline (J01AA12) (US$65.4 per DDD). There is a large 
variability of antimicrobial price per DDD range which is represented as a ratio of the 
highest to lowest price of antimicrobial per DDD (H/L ratio) from very high (H/L ratio up to 
82 for oral formulation or 40.26 for parenteral formulation) or no discrepancy (H/L=0) for 
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the branded forms (Table 3-4). Twenty seven of thirty-eight oral forms (71.3%) and 10/55 
parenteral forms (18.2%) of antimicrobials had H/L ratio above 10. 
Whilst almost all (59/77 or 76.6%) antibacterials for systemic use (ATC 5th level, 
chemical substance) were dispensed from both domestic and international manufacturers, 
18 were procured from either international or domestic manufactures (Figure 3-4 and 
Table 3-3). 82.7% of antibacterials were supplied by domestic producers (67 companies, 
supplied 572,698,014 DDDs) whilst 212 international manufactures from 35 countries 
supplied the remainder (119,658,771 DDD). Antibacterials supplied by international 
manufacturers accounted for 54.5% of the total costs (US$261,754,116) and 17.3% of the 
total DDD procured. Among 35 countries with pharmaceutical companies sharing the 
antibacterial market in Vietnam, India and Cyprus contributed the highest proportions of 
total DDD, together supplying 8.4% of total antibacterial (58,142,107 DDDs) in all sites, 
corresponding to 48.6% of total foreign antibacterials (J01) procured (28.6% by India and 
20.1% by Cyprus).  
Table 3-3. Source of manufacturers for selected antibacterials 
Antibiotic procured by only 
domestics manufactures  
norfloxacin and tinidazole (J01RA13) 
lomefloxacin (J01MA07) 
streptomycin (J01GA01) 
lincomycin (J01FF02) 
ciprofloxacin and tinidazole (J01RA11) 
ceftibuten (J01DD14) 
tetracycline (J01AA07) 
pefloxacin (J01MA03) 
benzylpenicillin (J01CE01) 
chloramphenicol (J01BA01) 
nalidixic acid (J01MB02) 
ticarcillin and beta lactamase inhibitor (J01CR03) 
oxacillin (J01CF04) 
gentamicin (J01GB03) 
spiramycin and metronidazole (J01RA04) 
Antibiotic procured by only 
international manufactures 
tigecycline (J01AA12) 
ertapenem (J01DH03) 
parenteral azithromycin (J01FA10) 
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Table 3-4. Prices of antimicrobials 
Antimicrobials All Oral formulation Parenteral formulation 
 
No. Mfr. Average price 
per DDD 
High/low 
ratio 
No. Mfr. Average price 
per DDD 
High/low 
ratio 
No. 
Mfr. 
Average price 
per DDD 
High/low 
ratio 
J02AX04_caspofungin 1 284.53 1.10 -   1 284.53 1.10 
J01DH04_doripenem 4 85.31 1.56 -   4 85.31 1.56 
J01AA12_tigecycline 1 65.36 1.00 -   1 65.36 1.00 
J01XB01_colistin 5 49.98 2.18 -   5 49.98 2.18 
J01CR03_ticarcillin and beta 
lactamase inhibitor 
2 40.87 3.56 -   2 40.87 3.56 
J01DH51_imipenem and cilastatin 21 35.71 6.33 -   21 35.71 6.33 
J01CA12_piperacillin 2 34.88 1.80 -   2 34.88 1.80 
J01DH02_meropenem 21 30.98 12.90 -   21 30.98 12.90 
J01DC01_cefoxitin 13 26.57 8.32 -   13 26.57 8.32 
J01DH03_ertapenem 1 24.69 1.00 -   1 24.69 1.00 
J01CR05_piperacillin and beta 
lactamase inhibitor 
14 18.51 3.90 -   14 18.51 3.90 
J01DE02_cefpirome 9 18.00 3.59 -   9 18.00 3.59 
J01XA02_teicoplanin 5 17.75 2.23 -   5 17.75 2.23 
J01DD62_cefoperazone and beta 
lactamase inhibitor 
21 16.56 27.33 -   21 16.56 27.33 
J01DC03_cefamandole 8 15.88 4.35 -   8 15.88 4.35 
J01DB03_cefalotin 4 14.55 1.77 -   4 14.55 1.77 
J01CR01p_ampicillin and beta 
lactamase inhibitor 
12 11.55 6.06 -   12 11.55 6.06 
J02AA01_amphotericin B 2 11.30 12.10 -   2 11.30 12.10 
J01DC09_cefmetazole 8 10.06 3.06 -   8 10.06 3.06 
J01XX01_fosfomycin 8 9.12 2.81 2 5.13 1.52 6 10.31 2.62 
J01DD07_ceftizoxime 15 7.95 6.18 -   15 7.95 6.18 
J01DD12_cefoperazone 15 7.83 12.68 -   15 7.83 12.68 
J01FA10p_azithromycin 6 7.62 6.90 -   6 7.62 6.90 
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Antimicrobials All Oral formulation Parenteral formulation 
 
No. Mfr. Average price 
per DDD 
High/low 
ratio 
No. Mfr. Average price 
per DDD 
High/low 
ratio 
No. 
Mfr. 
Average price 
per DDD 
High/low 
ratio 
J01XA01_vancomycin 15 7.57 2.57 -   15 7.57 2.57 
J01DE01_cefepime 16 7.18 19.53 -   16 7.18 19.53 
J01MA14_moxifloxacin 16 6.93 37.69 7 0.92 5.38 9 12.09 3.06 
J01CR02p_amoxicillin and beta 
lactamase inhibitor 
12 6.58 6.52 -   12 6.58 6.52 
J01DB12_ceftezole 10 6.07 2.90 -   10 6.07 2.90 
J01DD02_ceftazidime 26 5.07 11.56 -   26 5.07 11.56 
J01GB07_netilmicin 9 4.99 3.43 -   9 4.99 3.43 
J01XX08_linezolid 8 4.67 40.45 4 1.70 1.57 4 24.76 3.68 
J01XD02_tinidazole 4 4.61 2.98 -   4 4.61 2.98 
J01DD04_ceftriaxone 28 3.51 40.26 -   28 3.51 40.26 
J01DC07_cefotiam 10 3.05 4.00 -   10 3.05 4.00 
J01DD01_cefotaxime 29 2.77 12.18 -   29 2.77 12.18 
J01DB04_cefazolin 9 2.46 4.18 -   9 2.46 4.18 
J01FF01_clindamycin 13 2.40 39.58 10 0.43 9.11 3 5.26 3.93 
J01DD14_ceftibuten 2 2.37 2.46 2 2.37 2.46 -   
J01GB06_amikacin 12 2.25 8.33 -   12 2.25 8.33 
J01CF02_cloxacillin 9 2.05 34.20 3 0.95 5.18 6 4.76 4.94 
J01XD01_metronidazole 13 1.93 4.52 -   13 1.93 4.52 
J01GB01_tobramycin 16 1.26 8.75 -   16 1.26 8.75 
J02AC02_itraconazole 11 1.12 308.00 10 0.71 6.33 1 82.61 1.00 
J01CF04_oxacillin 6 0.85 11.50 3 0.59 2.50 3 1.67 3.14 
J01MA12_levofloxacin 39 0.81 495.43 20 0.27 72.13 19 5.07 12.04 
J01DD13_cefpodoxime 27 0.76 27.03 27 0.76 27.03 -   
J01DC04_cefaclor 21 0.64 65.52 21 0.64 65.52 -   
J01DD15_cefdinir 19 0.64 29.79 19 0.64 29.79 -   
J01CA01_ampicillin 6 0.63 7.10 1 0.12 1.00 5 0.63 2.88 
J01MA06_norfloxacin 6 0.61 18.73 6 0.61 18.73 -   
J01CE01_benzylpenicillin 4 0.61 5.40 -   4 0.61 5.40 
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Antimicrobials All Oral formulation Parenteral formulation 
 
No. Mfr. Average price 
per DDD 
High/low 
ratio 
No. Mfr. Average price 
per DDD 
High/low 
ratio 
No. 
Mfr. 
Average price 
per DDD 
High/low 
ratio 
J02AC01_fluconazole 18 0.60 142.46 16 0.46 80.30 2 12.02 1.47 
J01MA03_pefloxacin 5 0.58 12.50 3 0.14 1.71 2 1.10 1.27 
J01MA02_ciprofloxacin 39 0.56 1899.69 24 0.08 42.81 15 8.85 31.10 
J01BA01_chloramphenicol 9 0.52 5.25 8 0.46 2.02 1 1.34 1.14 
J01FA02_spiramycin 17 0.45 9.07 17 0.45 9.07 -   
J01DB09_cefradine 8 0.43 12.76 5 0.42 12.76 3 0.74 3.62 
J01CR02o_amoxicillin and beta 
lactamase inhibitor 
33 0.38 23.70 33 0.38 23.70 -   
J01DB05_cefadroxil 24 0.37 24.89 24 0.37 24.89 -   
J01DD08_cefixime 31 0.34 52.05 31 0.34 52.05 -   
J01DB01_cefalexin 20 0.31 16.47 20 0.31 16.47 -   
J01MA01_ofloxacin 18 0.27 677.97 14 0.04 10.17 4 8.42 6.53 
J01FA09_clarithromycin 23 0.27 19.19 23 0.27 19.19 -   
J01FA10o_azithromycin 27 0.26 38.66 27 0.26 38.66 -   
J01DC02_cefuroxime 39 0.25 28.92 28 0.21 28.92 11 0.58 9.54 
J01MB02_nalidixic acid 5 0.25 1.83 5 0.25 1.83 -   
J01FA01_erythromycin 10 0.20 82.00 10 0.20 82.00 -   
J01FF02_lincomycin 1 0.17 1.67 1 0.16 1.00 - 0.27 1.00 
J01GA01_streptomycin 1 0.16 1.00 -   1 0.16 1.00 
J01GB03_gentamicin 9 0.15 2.24 -   9 0.15 2.24 
J01EA01_trimethoprim 23 0.12 70.00 23 0.12 70.00 -   
J01FA06_roxithromycin 14 0.11 17.14 14 0.11 17.14 -   
J01CA04_amoxicillin 21 0.11 26.52 21 0.11 26.52 -   
J01AA07_tetracycline 9 0.04 1.76 9 0.04 1.76 -   
J02AB02_ketoconazole 2 0.03 1.19 2 0.03 1.19 -   
J01CE10_benzathine 
phenoxymethylpenicillin 
7 0.03 2.74 7 0.03 2.74 -   
J01AA02_doxycycline 11 0.01 6.25 11 0.01 6.25 -   
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3.4. Discussion 
Our study represents the first effort to describe the use and cost of antimicrobials in 
healthcare facilities in Vietnam, a country with a high burden of drug resistant infections. 
In a previous study of antibiotic sales in 76 countries between 2000 and 2015, Vietnam 
ranked 11th in antibiotic consumption per capita with 32 DDDs per 1,000 inhabitants per 
day (Klein et al., 2018). However, the use of antimicrobials by ATC index and by the route 
of administration in public hospitals has not been published. Additionally, we found that 
antibacterials proportion of total medication expenditure was high - comprising 28.5% of 
the total budget for medications in all study sites. 
We found that a quarter of antimicrobials (in DDD) were unclassified by AWaRe 
classification system. Similarly, a large proportion of unclassified antibacterials was also 
reported in other countries, for example 60.3% in Finland in a survey of prescriptions 
among hospitalised children in 56 countries in 2015 (Hsia et al., 2019). Thus, the current 
AWaRe system, fails to classify many of the most commonly used drugs. This limitations of 
AWaRe classification system was acknowledged the WHO Essential Medicines List Working 
Group and may require further revision (Sharland et al., 2018). 
By classes of antibacterials, we found that cephalosporins were the most commonly 
prescribed in Vietnam. In healthcare sectors in Europe, where the resistance levels are low, 
the most common antibacterials were beta-lactams, penicillins (J01C) (European Centre for 
Disease Prevention and Control, 2018) whilst in China, where the resistant levels are similar 
to Vietnam, 3rd-generation cephalosporins were the most consumed antibiotic in hospitals 
(Yin et al., 2017). In the first surveillance report by WHO on antibiotic consumption in 65 
countries during the period of 2016-2018, the Philippines was the only country from 
Southeast Asia providing data on national consumption of antimicrobials using IQVIA and 
import database (World Health Organization, 2018d). In Philippines, the most frequently 
consumed antibiotics were tetracyclines and penicillins with each contributing 30% of total 
consumption of antibiotics (in DDD per 1000 inhabitants per day).  
My study provides important data concerning costs of antimicrobials used in Vietnam. 
The majority of antibiotic costs related to the cost of the most commonly used antibiotics 
according to DDD. However, a small number of antimicrobials accounted for a 
disproportionately large high expenditure. Carbapenems were only a small number of 
antimicrobials prescribed according to DDD, but a significant proportion of costs. Data on 
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the national expenditure on antimicrobials is often limited and there are few data from 
other countries for comparison but it is likely that the situation of last resort antibiotics is 
similar in other settings. For example, in the US in 2015, the antibiotic expenditures were 
largest for daptomycin (1.3 billion or 14.7% of total expenditure), and although no data are 
provided on daptomycin usage, it is likely that this is a relatively infrequently used 
antibiotic.  
With a total of 290 manufacturers sharing the antimicrobial market in Vietnam, 
currently, there are numerous manufacturers with different forms and formulation of 
antimicrobials on the Vietnamese market. For example, there were eight US Food and Drug 
Administration–approved manufacturers for Cefuroxime 250 mg tablet in US (Alpern et al., 
2017) whilst there were 20 manufacturers approved by Vietnam government for the same 
formulation and strength in Vietnam. This large number of domestic and international 
manufacturers likely leads to increased complexity and cost in ensuring the quality of 
medications and regulating their manufacture and distribution. 
My study has shown high variability in cost of antimicrobials. Measurement of price and 
availability of antimicrobials is essential to inform policies about accessibility and 
affordability to the population. In a survey of the prices, availability, and affordability of 42 
core medicines (including eight antibiotic substances) in 5 provinces in Vietnam in 2005, 
the prices of innovator drugs and the lowest priced generics were 47 times and 11 times 
higher than the international reference prices (MSH), respectively (Nguyen et al., 2009). 
The medicine prices in the public sectors were higher than in private sectors (Nguyen et al., 
2009). The International Medical Products Price Guide by Management Sciences for Health 
(MSH) is recommended as a most useful reference for medicine prices (World Health 
Organization, 2008) and the 2015 version is the latest (Management Sciences for Health 
(MSH), 2015). Among antibacterials in the Reserve group, the high/low ratio of cefepime 
according to MSH 2015 (4.39) was much lower than the one in my study (19.53) 
(Management Sciences for Health (MSH), 2015). However, no data for other antibacterials 
in the Reserve group were available for cross reference. 
The pharmaceutical market in Vietnam is import-reliant and was estimated to reach 
US$5.2 billion in 2017 (Business Monitor International Ltd., 2016). Ninety percent of the 
country’s medication expenditure was on imported medicines (Angelino et al., 2017). The 
European Union was the most important pharmaceutical manufacturer providing 
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medications to Vietnam with a value of US$1.1 billion or 51 % of Vietnam’s total 
pharmaceutical imports in 2014, in which France, Germany, Italy shares US$579 million or 
73 % of total pharmaceutical imports from the EU (Vu, 2016). We confirmed that Europe 
were the leading exporters to Vietnam in term of values of antibiotics expenses whilst Asian 
countries (mainly India) exported the largest quantities. However, the majority of 
antimicrobial consumption was met by domestic manufacturers, which was part of 
strategic plan for developing the Vietnam pharmaceutical industry by 2020 as the 
government set objectives to produce 80% of total annual medication consumption in the 
country (The Prime Minister, 2014). 
Our study has some limitations. Firstly, I was unable to obtain data from all healthcare 
institutions in Vietnam due to bids being published elsewhere, e.g. an institutional website. 
Based on the previous estimation of national drug expenditure (US$ 5.85 billion), we 
estimated our data represents at least 28.7% but this may be an underestimate because 
the total pharmaceutical sales of 5.85 billion included community pharmacies. 
Furthermore, of the data that were available, of antibacterial use from all sites were not 
complete because hospitals may have extra calls for bids or not use all of the antibiotics 
purchased from these bids. However, the successful bids were based on the previous year’s 
actual (total) consumption and the institutions were required to use at least 80% of 
antimicrobials purchased in these bids, therefore our estimate, whilst not exact, is likely to 
be a reasonable estimate of use. Our estimates of antimicrobial usage in hospitals may be 
biased and underestimate exact usage because medications for hospitalised patients can 
also be purchased directly by patients, especially in primary and secondary hospitals 
because many Watch and Reserve antibacterials are not reimbursed by the national 
insurance programme and consequently not available in hospital pharmacies (Viet Nam 
Ministry of Health, 2018). Additionally, there is some uncertainty about the number of 
hospitals included in this study as the bid by DoH covered the tenders of different public 
hospitals in the province and the number of hospitals joining the provincial bidding was 
unidentifiable.  
In future with the advent of an electronic health record (currently being implemented 
in Vietnam), it may be possible to obtain more accurate data and cross reference purchased 
drugs with prescribed drugs. Finally, this study did not include private sector consumption. 
As the Vietnamese Government launched a strategy to increase the share of private 
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hospital beds to 20% by 2020 (Vietnam's Prime Minister, 2013), the growth of the private 
healthcare system may contribute significantly to consumption of antimicrobials.  
3.5. Conclusions 
Antimicrobials accounted for a third of budget for medication in public hospitals in 
Vietnam. The pattern of antibacterial consumption by AWaRe categories was similar to 
other countries. The high cost of Reserve group antibacterials suggests a need for national 
pricing policies to ensure accessibility and the importance of implementation of 
antimicrobial stewardship. This high cost, however, may be seen as a barrier to 
inappropriate use of these antibiotics and may contribute to antibiotic stewardship. 
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: Excess direct hospital cost of treating ventilator 
associated respiratory infection (VARI) in Vietnam 
4.1. Introduction 
In recognition of the complexity of antimicrobial costs, in this chapter I provide some 
understanding on the cost of management of patients with ventilator associated 
respiratory infection (VARI) in Vietnam.  
Hospital acquired infections (HAIs) are a major concern in healthcare institutions world-
wide. HAI prevalence ranges from 4% in the United States (Magill et al., 2014) to 7.1% in 
Europe (Zarb et al., 2012). In a literature review of 6 countries from 41 studies in Southeast 
Asia between 2000 and 2012, HAI occurred in 20 patients per 1000 intensive care unit-days 
with the highest incidence density attributed to ventilator-associated pneumonia (14.7 per 
1000 ventilator-days) (Ling et al., 2015). In critical care units (CCUs), approximately 30% of 
patients acquire HAI during their stay: (Vincent, 2003) the most common being ventilator-
associated pneumonia (VAP) and ventilator-associated tracheobronchitis (VAT) . VAP and 
VAT can be grouped together as Ventilator Associated Respiratory Infections (VARI), a term 
that then encompasses the spectrum of respiratory infections that clinicians in Vietnam 
and many parts of the world treat with antibiotics (Craven et al., 2011). VARI is associated 
with excess length of stay, prolonged duration of ventilation, increased cost and, (in some 
studies) increased mortality (Melsen et al., 2013, Arabi et al., 2008). Incidence densities of 
3.2-56.9 per 1000 ventilator-days have been reported in resource constrained setting 
(Allegranzi et al., 2011). 
The direct financial costs of such infections have been reported to be high (Stone et al., 
2005, Zimlichman et al., 2013), and it is important to improve our understanding of these 
costs in order to mobilise resources for prevention and control measures. In a systematic 
review of publications between 2001 and 2004, mostly in high-income settings, the mean 
excess cost of VAP was US$ 9,969 ± 2,920 (Stone et al., 2005). A more recent estimate from 
the USA found that the average excess cost per VAP case for an adult inpatient was $40,144 
(36,286-44,220) (Zimlichman et al., 2013). In lower and middle income countries, the case-
based cost is considered significantly lower but not well described (Mathai et al., 2015, Ling 
et al., 2015). However the incidence is higher (Allegranzi et al., 2011) and a greater 
proportion of the costs may be met out of pocket, leading to substantial impacts on the 
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patients and their families (Global Burden of Disease Health Financing Collaborator 
Network, 2017). 
Vietnam is a lower-middle income country with a population of 93 million and a gross 
national income (GNI) per capita of US$ 2,060 in 2016 (World Bank, 2018a) . As of July 2016 
Vietnam had 13,571 healthcare facilities, including 1,132 general and specialized hospitals 
with 305,700 in-patient beds (General Statistics Office, 2017, Vietnam Ministry of Health, 
2016). This figure includes 75 central hospitals (including 38 national hospitals) that receive 
referrals from outside of the local province, 502 provincial or equivalent hospitals that 
receive referrals from within the local province, 548 districts hospitals and 7 unclassified 
hospitals that receive patients only directly from the community (Vietnam Ministry of 
Health, 2016).  
 Although in Vietnam, VARI is an increasing concern, little is known about its economic 
impact. High levels of antibiotic resistance (Phu et al., 2016) and infection control 
programmes which are often inadequate means this is increasingly important, and VARI 
has been shown to be a particular problem (Duong and McLaws, 2017, Phu et al., 2017).  
The aim of this study was to estimate the total annual excess cost associated with VARI 
in critical care units in Vietnam. Such an estimate will help policy makers in planning and 
implementing necessary changes in infection control, antibiotic stewardship and other 
relevant policies. To address this, a costing model was constructed to evaluate the excess 
cost of diagnostics and treatment of VARI in Vietnam from a healthcare sector perspective 
using the incidence-based cost-of-illness approach 
4.2. Materials and methods 
I constructed a costing model to evaluate the excess cost of diagnostics and treatment 
of VARI in Vietnam. Model inputs included costs for extra lengths of stay, diagnostics, VARI 
incidence, utilisation of ventilators and antibiotic therapy. Cost for healthcare services were 
obtained from the national ceiling price of medical services in published hospitals by 
Ministry of Health and cost for antimicrobial was calculated from the 2017 medication bid-
winning results of national and provincial hospitals in Vietnam. A sensitivity analysis was 
used to examine how the different cost of treatment components affect cost of VARI 
management under the current incidence rate of VARI. The detail of method was presented 
in Chapter 2.  
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4.3. Results 
The average excess cost of VARI management in national and provincial hospitals in 
Vietnam was US$ 1,174.90 per episode (range from US$ 682.10 - 1,667.60) with the cost of 
antibiotic treatment comprising US$ 600.20 (US$ 247.60 - 952.90) or 51.1% of the total cost 
of VARI episode. The share of average cost components per VARI episode were shown in 
Figure 4-1.  
 
 
Figure 4-1. The share of cost components per VARI episode. 
Based on assumptions presented in Table 2-2, the estimated number of cases of VARI 
in Vietnam was 34,428 episodes annually, at a VARI incidence of 21.7/1,000 ventilation 
days (Figure 4-2). The estimated excess cost of VARI nationwide was US$ 40,447,469 (range 
US$ 23,482,151 - 57,412,787). An absolute reduction in VARI incidence density of 1% led to 
a decrease of 1,578 episodes per year and a saving of US$ 1.86 million nationally.  
The cost of 12 days antimicrobial therapy for VARI contributed US$ 20,664,650 (US$ 
8,524,541-32,804,759) to the national cost and a decrease in cost of US$ 1.72 million per 
one day reduction in the duration of antimicrobial therapy (assuming no impact on 
outcome). The average daily cost of antimicrobial to treat carbapenemase-producing 
Gram-negative bacteria was US$ 172 (US$ 110-235.3) versus US$ 28.3 (US$ 7.7-48.9) to 
treat carbapenem susceptible Gram-negative bacteria. Based on current data on the 
aetiology and resistance patterns of bacteria causing VARI (Phu et al., 2016), the proportion 
of VARI caused by carbapenemase-producing Enterobacteriaceae (CPE) organisms was 
16.4% (corresponding to 5,633 VARI episodes per year). However, the costs of antimicrobial 
treatment alone of these episodes amounted to US$ 11,733,107, accounting for to 29% of 
the total national cost of VARI management.   
$262.5, 22.3%
$268.2, 22.8%
$600.2, 51.1%
$43.9, 3.7%
Additional cost for hospital stay
Additional cost for ventilation
Additional cost of antimicrobials
Additional cost of diagnostics
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The dash lines show the current national annual cost at the VARI incidence density of 21.7/1000 
ventilation days. 
Figure 4-2. Annual excess cost for VARI in Vietnam. 
 
The tornado diagram (Figure 4-3) shows that the greatest impact on the national cost 
of VARI management was through the price of antimicrobials and the number of VARI 
episodes (the national cost varied from US$ 28,307,360 - 52,587,578). The variance of VARI 
incidence density is associated with a smaller cost variance (from US$ 32,991,714-
49,394,375). Variance in the costs of VARI diagnostics, ventilation duration and the 
proportion of patients with intubation for more than 2 days had minor effects (Figure 4-3). 
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Figure 4-3. Sensitivity of modelled total costs associated with ventilator associated 
respiratory infection (VARI) diagnosis and treatment in Vietnam. 
4.4. Discussion 
Our study estimated excess direct medical cost of VARI management across the whole 
of Vietnam, a lower-middle income country with a high rate of antibiotic resistance and 
hospital acquired infections. We estimated the excess cost of VARI to the Vietnamese 
health care system to be tens of millions of US Dollars, a high proportion of which was due 
to the cost of antibiotics.  
The estimation of VARI cost per case in our study is comparable to previous studies in 
Vietnam but significantly lower than in high-income settings (Stone et al., 2005, Zimlichman 
et al., 2013). The excess cost of HAI in Vietnam was reported as US$ 865 in a tertiary 
neonatal intensive care unit (ICU) in 2008 (Ha and Ha, 2012) and US$ 1,131 in tertiary ICU 
in 2010 (Thi Anh Thu et al., 2015). In a study of 4 ICUs in 3 Vietnamese tertiary referral 
hospitals from 2013 to 2015, the median ICU related costs associated with admission were 
US$ 4,723 for patients developing VARI over their stay and US$ 2,534 for those that did not 
(Phu et al., 2017), corresponding to a cost difference of US$ 2,189. The lack of distinction 
between the attributed cost before and after VARI is a limitation of a non-matched cohort 
study (Graves et al., 2010, Phu et al., 2017).  
In a recent systematic review of the estimated economic impact of HAI on the US health 
care system it was shown that the most costly HAI was central line–associated bloodstream 
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infection (US$ 45,814 in 2012 US$ per case), followed by VAP (US$ 40,144; 95% CI 36,286-
44,220) (Zimlichman et al., 2013). The regional or national excess cost for VAP in Europe is 
estimated to be around US$ 13,000-15,000 per episode (Wyncoll and Camporota, 2012, 
Arefian et al., 2016a). However, the differences in incomes and healthcare systems make 
between countries comparisons relatively unedifying. However, given the current 
Vietnamese per capita health expenditure of US$ 117 (in 2015) (World Health Organization, 
2018b), the estimated cost attributed to VARI management (US$ 1174.9) is a high economic 
burden to the healthcare system in Vietnam (in comparison to the ratio of US per capita 
health expenditure to attributable cost of US$ 9,536/US$ 40,144 (Zimlichman et al., 2013). 
These differences in cost may be attributed to differences in costing and the healthcare 
systems (in Vietnam some healthcare costs are borne ‘out of pocket’ and these were not 
included as they are very hard to quantify), similarly some costs for hospital infrastructure 
are subsidised by the government in Vietnam and many European countries. However, 
there are also substantially lower costs for human resources in Vietnam and a tendency to 
use fewer and cheaper disposable items and blood tests.  
Our data showed high variability in antimicrobial prices and a high proportion of costs 
related to antimicrobials (51.1%). In a matched control study of VAP in US, the attributed 
cost of VAP was US$ 39,828 per episode whilst the cost of antibiotics contributed to US$ 
9,367 (23.5%) of the total cost (Kollef et al., 2012). The findings in our study likely relate to 
disproportionately high antibiotic costs in Vietnam (World Health Organization. Vietnam 
country office, 2011), very high antibiotic resistance levels and long courses of treatment 
in Vietnam. 
Despite growing healthcare insurance coverage in Vietnam, these high costs of 
treatment are often not fully covered by insurance. Thus the high cost of VARI may 
contribute to putting patients and their families into severe debt and act as a barrier to 
accessing treatment for life threatening conditions (Pekerti et al., 2017). Our study 
highlights the savings that could be made from even small gains in the reduction of VARI 
incidence and any safe reduction in the length of therapy for VARI. These are even without 
potential gains through reducing exposure of the patient and the CCU environment to 
broad spectrum antibiotics. 
Our estimate does not include non-medical direct costs including other out-of-pocket 
costs incurred by the patients and families for travelling, food and accommodation during 
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hospitalization and consultations. It also does not include indirect costs associated with loss 
of income and productivity due to absence from work and premature mortality. Few data 
on these societal costs are available in Viet Nam. One study estimated that whilst the costs 
to the health sector averaged US$ 190 and US$ 300 for treating pneumonia and meningitis 
respectively, in children under 5 years old admitted to a tertiary hospital, the total direct 
non-medical costs (transportation cost, lodging, soap, diapers, etc) ranged from US$ 50 to 
US$ 156 and the indirect costs (defined as the productivity loss of caregivers based on the 
number of working hours lost and monthly income) ranged from US$ 60 to US$ 140 for 
pneumonia and for meningitis respectively (Le et al., 2014).  
One systematic review including three matched cohort studies reported a short 
attributable ICU length of stay related to VAP (a mean of 6 days, 95% CI, 5.32– 6.87), (Safdar 
et al., 2005b) whilst one individual participant data meta-analysis from randomised trials 
assessing VAP prevention measures showed the overall difference of ICU length of stay was 
12 days between VAP and non-VAP patients (Melsen et al., 2013). One prospective study 
in Vietnam showed the difference of ICU stays for VAP and non-VAP was 11 days (Phu et 
al., 2017). We selected 12 days for our model because it reflects the longer duration of 
antimicrobial therapy used in Vietnam.  
As there are no data for antimicrobial de-escalation rate in Vietnam, we assumed that 
the de-escalation was similar to studies in US and Europe (Kollef et al., 2006, Alvarez-Lerma 
et al., 2006). This is likely to represent an overestimate of the proportion that are de-
escalated, in part due to limited opportunities to do so because of the high rates of 
antimicrobial resistance. Our model showed that variation in the proportion of patients de-
escalated has a small impact on the total cost of VARI management. 
Our study has several limitations. Firstly, resistance rates are increasing and the etiology 
and susceptibility data used may already be out of date, leading to an under-estimate of 
the attributable costs. Secondly, as a result of the increasing need for critical care to provide 
for an aging population with an increasing prevalence of underlying non-communicable 
diseases, the number of ventilated days nationally may rise leading to underestimation of 
the number of VARI episodes, in turn underestimating the total national cost of treatment. 
Furthermore, the studies quoted have focused on the first episode of VARI, potentially 
underestimating the incidence through exclusion of subsequent episodes. Thirdly, the 
critical care usage, the capacity of investigations of HAI (including microbiological testing) 
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and the antibiotic prescription are difficult to extrapolate across Vietnam, as a nationwide 
CCU registry and quality improvement systems have not been established. Therefore, data 
on transfer of patients, proportion of patients ventilated for more than 48hrs and 
antimicrobial prescribing patterns may vary substantially across hospitals.  
4.5. Conclusions 
Our study found that the direct medical cost for VARI in Vietnam is substantial. 
Interventions targeting these infections, such as the implementation of infection control 
and antimicrobial stewardship in critical care units, could provide direct cost savings in 
addition to their beneficial effect on the generation of antibiotic resistance and should be 
systematically implemented and evaluated. 
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: Impact of MALDITOF diagnostic pathway on 
optimal antimicrobial therapy 
5.1. Introduction 
As shown in Chapter 4, VARI management required microbiological diagnostics for 
rapid identification of pathogens to make decisions on antimicrobials treatment. In this 
chapter, we focused on the impact of a novel diagnostic method on antimicrobial use. 
In the light of the crisis in antimicrobial resistance, antimicrobial stewardship programs 
are critical to optimizing antimicrobial use in order to maintain effectiveness, improve 
patients’ safety and minimise costs (MacDougall and Polk, 2005). Techniques in diagnostic 
microbiology could potentially contribute to stewardship programs through timely 
bacterial identification and generation of susceptibility profiles, improving appropriate 
antibiotic selection and reducing broad spectrum antibiotic use.  
The rapid detection and identification of a bloodstream pathogen is important to 
establish the diagnosis of bacteremia and guide treatment. However, blood culture detects 
pathogens in < 50% of patients with sepsis. Increased time to notification of positive blood 
culture is associated with increased length of hospitalization (Beekmann et al., 2003). The 
early, accurate identification of bloodstream infection assists in rapid deployment of 
optimal antibiotic therapy for these patients with life threatening infections. Clinical 
microbiological laboratories in resource constrained settings often lack good testing 
systems and expertise for correct identification of bacterial pathogens. Due to these 
constraints, time to identification and reporting of bacterial pathogens can be protracted, 
which may impact on patient care and outcome. Correct and rapid bacterial identification 
and susceptibility testing is important for providing appropriate antibiotic therapy as soon 
as possible. A diagnostic system that is robust, accurate, rapid and with low running costs, 
could be cost saving and improve patient outcome. 
Recognising this, investment in hospital laboratory infrastructure and capacity building 
in LMICs has attracted international attention (Wertheim et al., 2010, Yao et al., 2010, Kinh 
et al., 2017). The limited resources available need to be used efficiently to develop 
laboratory capacity optimally, strengthen diagnostics and improve patient outcomes 
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(Nkengasong et al., 2010). Novel technologies have been developed to improve the speed 
and accuracy of bacterial diagnosis of aetiology and susceptibility, but many are expensive 
(Davies et al., 2017, Petti et al., 2006). Most of these technologies have been developed in 
and for high income countries (Malkin, 2007). Systematic evaluation of the introduction of 
novel laboratory diagnostics is also necessary in resource constrained settings to show their 
value in clinical decision-making and quality of care. 
MALDITOF-MS can accurately identify bacteria and fungi within a few minutes (Dixon 
et al., 2015, Scott et al., 2016) at a reasonable cost (excluding machine purchase costs and 
maintenance) without the same level of expertise needed for standard microbiological 
diagnostics. Whilst the hardware is expensive (approximately 250,000 USD) it has very low 
per assay costs (1-1.5 USD/sample) and requires minimal skills (Bizzini and Greub, 2010, 
Scott et al., 2016, Dixon et al., 2015). Reagents have long expiry dates, unlike traditional 
biochemical identification systems (leading to regular use of expired reagents is common 
in LMICs) (Ombelet et al., 2018). Besides the identification of common bacteria, studies 
have shown that it can also be used for species that are difficult to identify, such as yeasts, 
anaerobes, and fastidious microorganisms, though a limitation of MALDITOF-MS is mis-
identification of some rare specific pathogens due to a limited database (see 
Supplementary Table 1). Therefore, MALDITOF-MS is an important new technology that is 
becoming routine in developed countries. As yet there is no robust data exploring the 
impact of MALDITOF on patient centered outcomes such as mortality and morbidity, and 
little on stewardship related outcomes such as time to optimal antibiotic therapy and 
antibiotic costs in resource-limited countries. 
Previous studies in high-income settings, where MALDITOF has been combined with an 
antimicrobial stewardship programme (ASP), have shown clinical impact on reduced time 
to optimal antibiotic therapy (Huang et al., 2013, Perez et al., 2014), increased proportion 
of appropriate antibiotic treatment after culture positivity (Vlek et al., 2012) and reduced 
length of hospital stay (Lin et al., 2016, Perez et al., 2014, Wenzler et al., 2016, Perez et al., 
2013). In settings where ASPs were already well established, the results have been less 
clear.  
To date no randomised controlled trials have been performed exploring the benefit of 
MALDITOF in relation to improving the time to optimal therapy, nor have there been any 
studies of its use in LMIC settings where antimicrobial stewardship is less well implemented 
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and the prevalence of resistance is often high. We therefore aimed to determine whether 
MALDITOF (Maldi Biotyper, Bruker, Germany) reduced the time to OAT compared to 
standard microbiological identification using VITEK2, API (two bacterial diagnostic systems 
that require bacterial growth to perform identification) and biochemistry tests in patients 
with microbiologically confirmed infection in two infectious diseases referral hospitals in 
Vietnam with limited antimicrobial stewardship. 
5.2. Methods 
This was a parallel arm randomised controlled trial conducted in 2 tertiary hospitals in 
Vietnam. The patients were recruited from January and December 2015 among patients 
with at least one bacterial or fungal pathogen cultured from a normally sterile sample. 
Eligible samples were blood cultures or aspirates from sterile compartments (cerebrospinal 
fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, pleural fluid or deep tissue biopsies).  
The standard procedure was applied for clinical specimen collection as per the 
participating hospital’s usual practice. The first positive growth of pathogenic organisms 
was randomly assigned (1:1) to identification by either MALDITOF-MS (Microflex LT/SH, 
Bruker, Germany, library DB4613) or identification by convention methods, including 
Gram-staining, API test strips, VITEK2 (bioMérieux, Marcy l’Étoile, France) and other tests 
as required. 
The primary outcome was the proportion of patients, with growth of pathogenic 
organisms from normally sterile sites, on optimal antimicrobial therapy within 24 hours of 
positive culture, determined by a blinded independent endpoint review committee. For the 
formal comparison between the two diagnostic groups, we used a logistic regression model 
of the primary endpoint depending on the treatment groups, with additional adjustment 
for the first specimen type (blood vs. other) and the hospital. The main effect measure is 
an odds ratio of optimal antibiotic treatment within 24 hours between treatment groups 
and a corresponding two-sided 95% confidence interval (CI) and p-value. Analyses were 
performed using R (Version 3.4.0). P-values ≤0.05 (two-sided) were considered significant. 
Full details of the methods are presented in chapter 2. 
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5.3. Results 
5.3.1. Study population 
The trial recruited between 1st December 2014 and 15th January 2016. There were 1005 
patients with a positive sterile site culture randomised, with 377 patients excluded due to 
hospital discharge or death prior to the sample becoming positive, or samples growing 
contaminants. The final analysis included 628 patients, with 326 patients received 
identifications of pathogens by MALDI-TOF and 302 patients received identifications of 
pathogens by standard microbiological procedure (Figure 5-1).  
 
Figure 5-1. Flow chart of participants. 
 
The median age of patients was 47 years old (IQR 32-59) and 64.3% (404/628) were 
male. Baseline characteristics of patients are shown in Table 5-1 and were not significantly 
different between the two arms. A quarter of patients (161/628) were admitted to critical 
care, with the most common sites of infection on randomisation being central nervous 
system infection (CNSI) (170/628, 27.1%) and intra-abdominal infection (164/628, 26.1%). 
Among the 628 samples, 421 (67%) were blood, 154 (24.5%) CSF, 46 (7.3%) peritoneal fluid, 
6 (1.0%) deep abscess samples, and 1 (0.2%) pleural fluid (Table 5-2).  
  
Total patients randomized 
N=1005 
MALDI-TOF  
N=495 
Control 
N=510 
169 excluded: 
Contaminant: 153 
Discharged before sample positive = 16 
208 excluded: 
Contaminant: 189 
Discharged before sample positive = 19 
Analysis population: N=326 
3 unclassified:  
3 likely HAI in ICU 
Analysis population: N=301 
6 unclassified: 
5 likely HAI in ICU 
1 no appropriate susceptibility  
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Table 5-1. Baseline characteristics of patients 
 
N MALDITOF-MS  
n (% or IQR) 
N Control  
n (% or IQR) 
P* 
Sex 326 
 
302 
 
0.45 
 - Female 
 
121 (37) 
 
103 (34) 
 
Age (median years) 
 
47 (32–59) 
 
47 (35–58) 0.91 
Site 326 
 
302 
 
0.57 
 - Ho Chi Minh city (HCMC) 
 
187 (57) 
 
180 (60) 
 
 - Hanoi 
 
139 (43) 
 
122 (40) 
 
Source 325 
 
302 
 
0.58 
 - Direct Admission 
 
163 (50) 
 
144 (48) 
 
 - Hospital transfer 
 
162 (50) 
 
158 (52) 
 
Ward 326 
 
302 
 
0.41 
 - Critical Care 
 
79 (24) 
 
82 (27) 
 
 - Other 
 
247 (76) 
 
220 (73) 
 
Site of infection 326 
 
302 
 
0.33 
 - Central nervous system (CNS) 
 
81 (25) 
 
89 (29) 
 
 - Abdominal 
 
83 (25) 
 
81 (27) 
 
 - Respiratory 
 
31 (10) 
 
23 (8) 
 
 - Other 
 
40 (12) 
 
44 (15) 
 
 - Unknown 
 
91 (28) 
 
65 (22) 
 
ICD-10 Code 325 
 
302 
 
0.12 
 - Sepsis 
 
87 (27) 
 
81 (27) 
 
 - HIV related 
 
69 (21) 
 
59 (20) 
 
 - CNS Infection 
 
46 (14) 
 
49 (16) 
 
 - Cirrhosis 
 
28 (9) 
 
29 (10) 
 
 - Tetanus 
 
6 (2) 
 
4 (1) 
 
 - Other 
 
89 (27) 
 
80 (27) 
 
Length of illness (median days) 321 6 (3–14) 300 6 (3–14) 0.62 
Time from sample collection to 
first growth (median hours) 
 
34 (22–45) 
 
36 (22–46) 0.41 
Time from sample collection to 
Gram stain (median hours) 
287 31 (21–43) 267 33 (20–44) 0.63 
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Table 5-2. Type of eligible specimen 
Specimen type MALDITOF-MS (N=326) 
n (%) 
Control (N=302) 
n (%) 
P* 
Blood Culture 222 (68.1) 199 (65.9) 0.61 
Cerebrospinal fluid 75 (23) 79 (26.2) 
Peritoneal fluid 25 (7.7) 21 (7) 
Deep abscesses 4 (1.2) 2 (0.7) 
Pleural fluid 0 1 (0.3) 
 
In the first observed growth of specimens, 635 bacterial or fungal isolates were 
obtained (1 patient had 4 isolates in a single culture and 4 patients had 2 isolates). 
Enterobacteriaceae were the most frequently isolates (235/635, 37.0%), followed by Gram 
positive bacteria (219/635, 34.5%), fungi (105/635, 16.5%) and non-Enterobacteriaceae 
(76/635, 12%). The most common bacterial isolates were Escherichia coli (147/635, 23·1%), 
Streptococcus suis (84/635, 13.2%) and Staphylococcus aureus (58/635, 9.1%). Methicillin 
resistance was detected in 31/58 (53.4%) of S. aureus, 3rd generation cephalosporin and 
carbapenem resistance in 113/234 (48.3%) and 10/220 (4.6%) respectively of 
Enterobacteriaceae tested and carbapenem resistance in 10/24 (41.7%) of Acinetobacter 
and Pseudomonas species. Aetiology of infection and pattern of drug resistance in selected 
organism in the two arms is shown in Table 5 3 and Table 5-4. 
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Table 5-3. Aetiology of infection from the growth of eligible specimen 
 
 
MALDITOF-MS (N=329) 
n (%) 
Control (N=306) 
 n (%) 
P* 
Total Enterobacteriaceae 131 (40) 104 (34) 0.15 
 - Escherichia coli 83 (25) 64 (21) 
 
 - Klebsiella pneumoniae 29 (9) 21 (7) 
 
 - Other Enterobacteriaceae 19 (6) 19 (6) 
 
Total Non-Enterobacteriaceae 40 (12) 36 (12) 0.98 
 - Acinetobacter & Pseudomonas spp. 14 (4) 12 (4) 
 
 - Other Gram-negatives 26 (8) 24 (8) 
 
Total Gram-positive 105 (32) 114 (37) 0.18 
 - Streptococci 70 (21) 85 (28) 
 
 - Staphylococcus aureus 32 (10) 26 (8) 
 
 - Other Gram-positives 3 (1) 3 (1) 
 
Total Fungi 53 (16) 52 (17) 0.85 
 - Cryptococcus neoformans 29 (9) 34 (11) 
 
 - Talaromyces marneffei 20 (7) 16 (5) 
 
 - Other fungi 4 (1) 2 (1) 
 
 
Table 5-4. Bacteria resistance profiles (where tested) 
Resistance profile MALDITOF-MS  
n/N (%) 
Control  
n (%) 
S. aureus with methicillin resistance 16/32 (50) 15/26 (58) 
Enterobacteriaceae with 3G-C resistance 63/131 (48) 50 /103a (49) 
Enterobacteriaceae with carbapenem resistance 9/123b (7) 1/97c (1) 
Acinetobacter or Pseudomonas species with 
carbapenem resistance  
5/13d (38) 5/11e (45) 
Enterococci with vancomycin resistance 1/5 (20) 2 (33) 
a 1 isolate not tested (K. pneumoniae) 
b 8 isolates not tested (1 Klebsiella pneumoniae, 7 Salmonella spp.) 
c 7 isolates not tested (2 E. coli, 2 K. pneumoniae, 3 Salmonella spp.) 
d 1 isolate not tested (Acinetobacter sp.) 
e 1 isolate not tested (Acinetobacter baumannii) 
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5.3.2. Primary outcome 
The proportion of patients who received optimal therapy within 24 hours, was not 
different between MALDITOF-MS (135/326, 41.4%) and control arms (119/301, 39.5%) 
(Adjusted Odds Ratio (AOR) 1.17; 95% confidence interval (CI) 0.82-1.68, p=0.38) (Table 
5-5). In 9 cases (3 MALDITOF-MS, 6 control arm) the review committee recorded therapy 
as ‘unclassifiable’ and these were included in the ‘not optimal’ outcome per the analysis 
plan. The predominant reason for the committee to consider a treatment non-optimal was 
because therapy was too broad (252/373, 67.6%) (Table 5-6). The proportion of optimal 
therapy in predefined subgroups was not significantly different between the MALDITOF-
MS and control arms (Table 5-7). 
 
Table 5-5. Proportions of patients on optimal antibiotic therapy within 24 and 48 hours 
of growth 
 
MALDITOF-MS 
n/N (%) 
Control 
n/N (%) 
AOR (95% CI)a p 
Within 24 hours  135/326 (41.4) 119/301 (39.5) 1.17 (0.82 – 1.68) 0.38 
Within 48 hours 151/326 (46.3) 140/301 (46.5) 1.05 (0.74 – 1.51) 0.77 
a Adjusted odds ratio adjusted for specimen type (blood/other) and site 
 
Table 5-6. Reasons for non-optimal therapy at 24 hours after culture growth  
 MALDITOF-MS (N=191) 
n (%)  
Control (N=182) 
n (%) 
p 
Pathogen not covered 54 (28.3) 46 (25.3) 0.514 
Therapy too broad 130 (68.1) 122 (67) 0.832 
Therapy potentially effective but not 
ideal 
3 (1.6) 6 (3.3) 0.328 
Growth of second pathogen within 
48 hours that was not covered 
1 (0.5) 2 (1.1) 0.615 
No data  3 (1.6) 6 (3.3) 0.328 
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Table 5-7. Pre-specified subgroup analyses of proportion of patients on optimal therapy within 24 and 48 hours of culture growth 
 
Proportion optimal within 24 hours of culture growth Proportion optimal within 48 hours of culture growth 
 
N MALDITOF N Control AOR (95% CI)a P N MALDITOF N Control AOR (95% CI)a P 
  
n (%) 
 
n (%) 
   
n (%) 
 
n (%) 
  
Sample Type 
    
0.45b 
     
0.60b 
Blood 222 75 (33.8) 199 59 (29.6) 1.31 (0.84 – 2.07) 0.23 222 88 (39.6) 199 76 (38.2) 1.14 (0.73 – 1.78) 0.56 
Other 104 60 (57.7) 102 60 (58.8) 0.97 (0.54 – 1.74) 0.92 104 63 (60.6) 102 64 (62.7) 0.92 (0.51 – 1.67) 0.79 
Site 
     
0.61b 
     
0.96b 
HCMC 187 108 (57.8) 179 100 (55.9) 1.10 (0.72 – 1.68) 0.66 187 122 (65.2) 179 115 (64.2) 1.05 (0.68 – 1.63) 0.81 
Hanoi 139 27 (19.4) 122 19 (15.6) 1.38 (0.71 – 2.74) 0.34 139 29 (20.9) 122 25 (20.5) 1.06 (0.57 – 1.99) 0.86 
Pathogen type 
    
0.62b 
     
0.49b 
Gram-positive 103 45 (43.7) 111 41 (36.9) 1.74 (0.90 – 3.42) 0.1 103 47 (45.6) 111 47 (42.3) 1.42 (0.74 – 2.74) 0.3 
Gram-negative 167 58 (34.7) 137 47 (34.3) 1.09 (0.65 – 1.82) 0.75 167 70 (41.9) 137 62 (45.3) 0.91 (0.55 – 1.52) 0.72 
Fungi 52 31 (59.6) 51 31 (60.8) 1.11 (0.41 – 3.07) 0.83 52 33 (63.5) 51 31 (60.8) 1.38 (0.53 – 3.77) 0.51 
Admitted from 
    
0.92b 
     
0.73b 
Home 163 71 (43.6) 144 61 (42.4) 1.17 (0.72-1.90) 0.53 163 80 (49.1) 144 71 (49.3) 1.10 (0.68-1.79) 0.7 
Hospital 162 64 (39.5) 157 58 (36.9) 1.17 (0.68-2.01) 0.57 162 71 (43.8) 157 69 (43.9) 1.00 (0.58-1.70) 0.99 
Final diagnosis 
    
0.71b 
     
0.74b 
Meningitis 76 57 (75.0) 64 47 (73.4) 1.3 (0.56 – 3.04) 0.54 76 59 (77.6) 64 50 (78.1) 1.12 (0.47 – 2.69) 0.79 
Other 250 78 (31.2) 237 72 (30.4) 1.07 (0.71 – 1.63) 0.74 250 92 (36.8) 237 90 (38.0) 0.96 (0.64 – 1.45) 0.86 
a Adjusted for site and specimen type except where these are part of the subgroup. 
b Test for heterogeneity.
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5.3.3. Secondary outcomes 
There was no difference in the proportion of patients on optimal therapy within 48 
hours of growth between MALDITOF-MS (151/326, 46.3%) and control arms (140/301, 
46.5%, AOR 1.05 p=0.77) (Table 5-7) or in the time from growth to optimal antimicrobial 
therapy (HR 0.992 (95%CI 0.808– 1.217) p=0.937) (Figure 5-2). 
 
Figure 5-2. Time from growth to not optimal antimicrobial therapy (OAT). 
There was no difference in the ordinal outcome (hospital outcome grouped into 5 
categories - death, palliative discharge, survived with sequelae, transferred to another 
hospital and recovered) adjusted for site and sample type, between the MALDITOF-MS and 
control arms (AOR 0.869 (95%CI 0.65 – 1.16) p = 0.34). Although median hospital stay was 
the same for both arms, Cox proportionate hazards adjusted for site and specimen type 
demonstrated an increased hazard ratio for hospital discharge in the MALDITOF-MS arm 
Figure 5-3. Analysis in survivors only showed similar median length of stay in the 
MALDITOF-MS (15 days, IQR 11-21) and control arms (16 days, IQR 11-23). There was no 
significant difference in other pre-specified secondary outcomes (Table 5-8). 
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Table 5-8. Pre-specified secondary patient-level outcomes 
Secondary outcomes  
N 
MALDITOF-MS 
Median (IQR) 
N Control 
Median (IQR) 
P 
DDD of antimicrobial consumption 
from enrolment to discharge  
304 16.0 (8.4–33) 283 18.0 (9.0–39.3) 0.35a 
Days of antimicrobial therapy from 
enrolment to discharge  
304 10 (6–15) 282 11 (7–17.8) 0.287b 
Days in hospital 322 15 (10–21) 301 16 (10–23) 0.039c 
Days spent in Critical Care 115 5 (2–11) 100 4 (3–10.3) 0.38d 
Hours from first growth to 
pathogen identification 
324 2.2 (1.7–28.1) 298 26.6 (24.7–48) ND 
Hours from sample collection to 
pathogen identification 
324 43.2 (28.1–69.1) 298 66 (48–88.6) ND 
Days from sample collection to 
hospital discharge 
326 11 (6.1–16.3) 302 12.3 (7.2–19) ND 
a Linear regression coefficient 0.92 (95% CI 0.78–1.09) after adjustment for site and specimen 
type. 
b Hazard ratio for stopping antibiotics 1.09 (95% CI 0.92–1.29) after adjustment for site and 
specimen type. 
c Hazard ratio for hospital discharge 1.18 (95% CI 1.01–1.38) after adjustment for site and 
specimen type. 
d Hazard ratio for ICU discharge 1.13 (95% CI 0.86–1.49) after adjustment for site and specimen 
type in those that had an ICU stay 
ND statistical comparison not performed (as stipulated in the analysis plan). 
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Figure 5-3. Time from randomisation to hospital discharge. 
 
5.3.4. Subgroup analyses 
Limiting the analysis to the subgroup of patients with Gram positive organisms cultured 
showed a trend towards an increased proportion on optimal therapy at 24 hours in the 
MALDITOF-MS arm (45/103, 43.7%) compared to the control arm (41/111, 36.9%; p=0.1). 
However, there was no significant effect observed in any pre-specified subgroup analysis 
(Table 5-8). 
 
5.3.5. Exploratory analyses 
An analysis of mortality as a binary outcome (death or palliative discharge compared 
with all other outcomes) adjusted for site and sample type revealed no difference 
(MALDITOF-MS arm 52/326 (16.0%), control arm 43/301 (14.3%), AOR 1.13 (95%CI 0.73 – 
1.76, p=0.59)). 
Analysis of time spent in intensive care, amongst those that were admitted to ICU at 
any time during their admission, showed no difference between the MALDITOF arm 
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(median time in ICU 5 days, IQR 2 – 11) and the standard diagnostics arm (median time in 
ICU 4 days, IQR 3 – 10.2), (Cox proportionate hazards ratio for ICU discharge adjusted for 
site and specimen type for ICU discharge 1.13 (95%CI 0.859 – 1.49, p = 0.38)). There 
remained no significant difference in the hazard ratio for ICU discharge when the analysis 
was limited to exclude outliers or limited to survivors (HR 1.19, 95%CI 0.9-1.576, p=0.221). 
Excluding outliers (the longest staying 1% of patients) in an analysis of hospital stay to 
explain the increased hazards ratio for hospital discharge in the MALDITOF-MS arm, the 
hazard ratio for discharge in the MALDITOF-MS arm dropped to 1.16 (p=0.067). 
An analysis to determine whether results were reaching the wards more quickly in the 
MALDITOF-MS arm demonstrated that the median time from growth to the pathogen 
identification report being received on the ward was 10.1 hours (IQR 1.9 – 32.9 hours) in 
the MALDITOF-MS arm and 31.0 hours (IQR 27.4 – 54 hours) in the control arm.  
A subgroup analysis of the 146 patients not on optimal therapy at the time of culture 
growth, that subsequently did receive optimal therapy, showed that the median time to 
optimal therapy was 2.0 (IQR 0.7 – 5.6) days in the MALDITOF-MS arm and 2.6 (IQR 1.2 – 
4.8) days in the control arm. A further subgroup analysis of those patients according to 
whether they were in critical care or not when cultures were drawn showed no significant 
difference in both those in critical care (OR 0.90 (95% CI 0.5 – 1.72, p = 0.81)) or other wards 
(OR 1.16 (95%CI 0.79–1.69, p = 0.45)). 
An analysis looking at the proportion receiving an antibiotic with no activity to the 
pathogen grown per antibiotic susceptibility testing (AST) results (inadequate therapy) 
showed little difference between the two arms (54/326, 16.6% and 46/302, 15.2% in 
MALDITOF-MS and control arms respectively). 
The median total antibiotic and antifungal consumption in defined daily doses (DDD) 
from enrolment to hospital discharge was similar between the MALDITOF (15.5; IQR 8.0 – 
33.0) and control arms (18·0; IQR 8.1 – 39.5), linear regression coefficient 0.94 (95% CI 0.79 
– 1.12, p=0.482 after adjustment for site and specimen type; data only available for 294 
and 273 patients in MALDITOF and standard diagnostic arms respectively). Similarly, the 
median total duration of antibiotic or antifungal therapy from enrolment to hospital 
discharge was similar in both arms (10 days, IQR 6– 15 days in MALDITOF and 11 days, IQR 
7 – 18 days in control arm, hazard ratio for stopping antibiotics 1.09 (95% CI 0.93 – 1.29), 
p=0·287 after adjustment for site and specimen type; data only available for 282 and 304 
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patients in MALDITOF and control arms respectively). Restriction of these data to survivors 
did not result in a significant difference between MALDITOF (11; IQR 7-16) and standard 
arms (11, IQR 8-18), HR= 1.08 (95% CI 0.91 – 1.29), p=0.387.  
There was no significant difference between the hospital costs between the MALDITOF 
(median cost 16,323 USD, IQR 7,824 – 31,252) and control arms (15,928 USD, IQR 7,125 – 
33,175, p=0.641). Costs for microbiology testing were also similar between MALDITOF 
(median cost 798 USD (IQR 528 – 1,200) and the control arm (759 USD (IQR 480 – 1,104), 
p= 0.120. Data on costings were only available for 297 patients in the MALDITOF arm and 
269 in the control arm. 
5.4. Discussion 
Our study demonstrates that early identification of pathogens from cultures of blood 
and other sterile sites using MALDITOF-MS did not result in a difference in the proportion 
of patients on optimal therapy within 24 hours of first growth. Neither did MALDITOF-MS 
alter the proportion on optimal therapy by 48 hours, the time taken to provide optimal 
therapy, the duration or total antibiotic therapy, patient outcomes or time in intensive 
care. We found an association between MALDITOF-MS and earlier hospital discharge, but 
the significance was removed when outliers were excluded (very long stay patients) and 
we therefore consider it unlikely to be of clinical significance. 
Using rapid Gram staining of blood culture and notification in a matched case control 
study, quick Gram stain turnaround time (<1 hour) was associated with significantly lower 
mortality (10.1% vs. 19.2%) (Barenfanger et al., 2008). Introduction of automated 
identification systems (such as Vitek, MicroScan WalkAway or Phoenix) has offered 
advantages in early reporting of pathogen identification and antimicrobial susceptibilities. 
In a historical cohort study in all cultures from 2 periods in 1997 at a center in the United 
States using the Vitek system, quick turnaround time for the reporting of antibiotic 
susceptibility testing facilitated early appropriate antibiotic therapy initiation (94% vs 77% 
for normal manner), reduced length of stay by 2 days and reduced cost by $1,750 per 
patient (Barenfanger et al., 1999). In a randomized controlled trial of 1498 patients in the 
Netherlands with positive growth in any sterile bodily fluid (excluding urine), the 
intervention group of Vitek 2 (next generation platform) showed significant reduction in 
antibiotic use (6 defined daily doses lower per patient, p=0.012), and quicker antibiotic 
switches than in the control arm, but mortality (17.6% versus 15.2%, p=0.21) was not 
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significantly reduced in comparison to the control arm of Vitek 1 system (Kerremans et al., 
2008). However the effectiveness of MALDITOF-MS in reducing antibiotic use has not been 
explored in randomized control trials although MALDITOF-MS may have better 
performance than Vitek-2 in identifying pathogens in routine clinical isolates (Guo et al., 
2014). In a study among 155 episodes of peritoneal dialysis-related peritonitis, dialysate 
effluent fluid culture was identified by MALDI-TOF (57 isolates) and conventional standard 
method (98 isolates). MALDI-TOF reduced the time to identification of causative pathogens 
by an average time of 37-68 hours and shortened the length of hospital stay (5.2 ± 4.8 
versus 8.2 ± 4.5, p = 0.001) (Lin et al., 2016). However, the impact on targeting antibiotic 
therapy or antibiotic use was not reported. 
The rapid identification of pathogens in combination with antibiotic stewardship 
program in high income countries was seen to significantly reduce the time to targeted 
antibiotic therapy, unnecessary use of antibiotics for contaminated samples, overall length 
of stay and hospitalization cost, but mortality was not significantly reduced (Box et al., 
2015). This was seen in a multicenter, pre-post, quasi-experimental study using an 
automated nucleic acid system (Verigene Gram-Positive Blood Culture Test) combined with 
antibiotic stewardship conducted by infectious diseases physicians and pharmacists (Box 
et al., 2015). Similar designs with MALDITOF-MS and antibiotic stewardship were 
implemented among patients with bacteremia and candidemia and showed an improved 
time to optimal antibiotic therapy and mortality reduction in some studies (Huang et al., 
2013, Perez et al., 2014) but not in others (Wenzler et al., 2016, Perez et al., 2013). The 
impact of identification by MALDITOF-MS on clinical outcome in previous studies was 
summarised in Supplementary Table 2. 
De-escalation is a component of antimicrobial stewardship to replace empirical broad-
spectrum by a narrower antimicrobial therapy and shorten the duration of antimicrobial 
(Dellit et al., 2007). It is practically done by subjectively reviewing the patient's microbial 
culture results, using a ranking system based on spectrum of antimicrobial activity (Leone 
et al., 2014) or using quantitative score (Madaras-Kelly et al., 2014). In a study on 123 
physicians and pharmacist to measure the spectrum of antimicrobial activity by a numerical 
spectrum score and defining de-escalation, the optimal time after initial antibiotic therapy 
to de-escalate therapy was 24 hours at individual perspective (63% of participants), 72 
hours and 96 hours at facility-level perspective in 44% and 42% of participants respectively 
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(Madaras-Kelly et al., 2014). To explore the potential barriers in antimicrobial de-
escalation, I performed informal interviews with doctors in non-study hospitals to reveal 
explanatory factors associated with this. The reasons for not switching to optimal 
antimicrobial therapy was listed as doctors’ concerns about safety and quality of 
antimicrobials, especially the older or more narrow spectrum antibacterials and generic 
drugs, which are only procured by domestic manufactures or manufactured in other LMICs. 
Another barrier was reported as doctors’ anecdotal belief that intravenous antimicrobials 
have better bioavailability and effectiveness (usually contrary to evidence), and therefore 
they prefer to not switch to an alternative of narrow spectrum antimicrobials or an oral 
formulations of the same drug. 
In common with previous studies, we found quicker pathogen identification and 
reporting. Our study gives some indication as to why MALDITOF-MS results did not result 
in improved outcomes. In both arms Gram stain results for positive blood cultures were 
available rapidly and possibly already provided sufficient information. The most common 
cause of suboptimal therapy was use of excessively broad therapies, suggesting that there 
were delays in de-escalation of therapy. There was some evidence that the intervention 
was more successful in patients with Gram positive infections. This may relate to identifying 
Streptococcus suis, a common cause of both meningitis and severe sepsis which has always 
been susceptible to penicillin (Huong et al., 2014) and exclusion of listeriosis through 
identification of an alternative pathogen.  
It has been suggested that research on ASP should evaluate its effectiveness on 
healthcare provider and patient centred outcomes, as well as microbiological ones 
(McGregor and Furuno, 2014). Rapid diagnostics, including MALDITOF-MS, in combination 
with ASPs have been proposed to optimise therapy faster and improve clinical outcomes 
(Barlam et al., 2016). In a meta-analysis of the effectiveness of test result notification to 
clinicians on targeted therapy for patients with bloodstream infection, it was suggested 
that a combination of rapid molecular or phenotypic methods with result notification may 
be more effective than traditional identification techniques in shortening delays in 
achieving targeted therapy (Buehler et al., 2016). However, ASPs require resources that are 
often lacking in low- and middle-income settings. Our study and others indicate that the 
process of reporting and acting on results is likely to be as important as the speed with 
which results are generated. 
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There have been few randomised controlled trials exploring the impact of these 
technologies (Holtzman et al., 2011, Banerjee et al., 2015) and no such evidence for 
MALDITOF is available at the time of writing. One trial of MALDITOF-MS compared with 
conventional microbiology with 28 day mortality as the primary endpoint has completed 
recruitment in the UK but has yet to be reported (the RAPIDO trial, 
https://doi.org/10.1186/ISRCTN97107018). Whilst studies have established that 
MALDITOF-MS can identify pathogens in the tropics (Lo et al., 2015) (see Supplementary 
Table 1), all eight publications that explored the clinical impact of MALDITOF-MS (Vlek et 
al., 2012, Huang et al., 2013, Lin et al., 2016, Osthoff et al., 2017, Wenzler et al., 2016, Perez 
et al., 2013, Perez et al., 2014, Lockwood et al., 2016) were conducted in HICs (4 USA, 1 
Taiwan, 1 The Netherlands, 1 Switzerland). Three studies explored the impact of 
MALDITOF-MS compared with conventional diagnostics (Lin et al., 2016, Osthoff et al., 
2017, Vlek et al., 2012) without an ASP component. One was restricted to peritoneal 
dialysis fluid (Lin et al., 2016), showing a significant reduction in hospital stay. The others 
recruited patients with bloodstream infections (Osthoff et al., 2017, Vlek et al., 2012). One 
showed a significant improvement in the proportion with appropriate therapy within 24h 
of growth (from 64% to 75.3%, p=0.01)(Vlek et al., 2012), whilst the other found a non-
significant difference in the proportion of patients receiving active treatments within 48 
hours of blood cultures being drawn between the MALDITOF-MS (95.6%) and control arms 
(89.8%, p=0.09) (Osthoff et al., 2017). Five studies examined the impact of MALDITOF-MS 
plus ASP with conventional diagnostics without ASP (Huang et al., 2013, Lockwood et al., 
2016, Perez et al., 2013, Perez et al., 2014, Wenzler et al., 2016). These studies all showed 
improvements in time to active or appropriate therapy and two showed improvements in 
mortality (Huang et al., 2013, Perez et al., 2014).  
Our study has the advantage of addressing the single intervention of MALDITOF 
diagnostics, thereby highlighting the need to investigate the addition of other supports, 
such as ASP, if clinically significant impacts are to be achieved. It is consequently not 
generalisable to settings where ASP interventions are already in place, where studies in 
HICs have shown good results. The individually randomised nature of the study is robust 
but a potential limitation is that this design may not account for changes in prescribing that 
could arise from a ‘cultural shift’ resultant from a wholesale change in diagnostic practice. 
Although the use of two sites and the large sample size is a strength, the use of specialist 
infectious diseases hospitals could cause bias and poor generalisability. However, it seems 
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unlikely that MALDITOF-MS alone would be more effective at changing prescribing practice 
in a setting where staff are less experienced in managing infection and the uniformity of 
the results across different pathogen groups makes it unlikely that the case mix seen is 
responsible for the negative results. Our study did not achieve the prespecified sample size. 
The discrepancy being due to a higher than anticipated number of patients having 
contaminated cultures. However, this large sample size was determined to accurately 
assess if the intervention was effective for blood cultures in each hospital, we surpassed 
the sample size necessary for the primary outcome and it is thus unlikely we missed a 
relevant positive result. Our data relate to a setting where antibiotic resistance is 
particularly high and may not be generalisable to LMIC settings where resistance rates are 
lower. The high contamination rate during the study was noted during the study. Whilst 
there was a desire to avoid undue interference with hospital practice, attempts were made 
to reduce this through additional education for those responsible for bloodletting, 
replacement of liquid disinfection fluids with disposable sterile alcohol wipes and ongoing 
audit and feedback. As a limitation of this study, we were not able to report the exact time 
of identified pathogen and antimicrobial susceptibility testing results reported to the 
doctor due to inconsistent and incomplete reporting: the time was often reported in days 
rather than hours. 
Despite these negative findings there are several positive aspects to MALDITOF-MS that 
should not be overlooked. Firstly, even speedier identification can be achieved by both 
processing samples direct from blood culture (La Scola and Raoult, 2009) (without the 
subculture onto blood agar) and by running the machine more frequently than twice daily. 
However, this requires changes to work flow that were not possible within the trial and, 
based on the results we obtained, would be unlikely to have had an impact on the results. 
Rapid AST, either through short incubation with antibiotics or through analysis of the 
spectra obtained has also now been described using MALDITOF-MS (Lange et al., 2014). 
Though more technically difficult, such results may have been more compelling in this 
setting and warrant further evaluation. We planned to analyse the cost effectiveness of 
MALDITOF-MS, however neither hospital changed their pricing structure dependent on the 
diagnostic modality and we were thus unable to. Finally, rapid detection of contaminants 
(not explored in this study) can result in reductions in antibiotic use, save laboratories time 
and money and increase the throughput of the labs. 
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5.5. Conclusion 
Our study showed no improvement in antimicrobial prescribing or other patient or 
provider centred outcomes through MALDITOF-MS. MALDITOF-MS did produce results 
rapidly in our setting. Our findings suggest that whilst MALDITOF-MS may have other 
compelling advantages, it is unlikely to lead to improvements in prescribing without 
investment in ASPs and education of the diagnostic and prescribing workforce.
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: Hospital acquired blood stream infection in 
intubated patients in 3 Vietnamese ICUs 
6.1. Introduction 
In chapter 5, I showed that advanced technology of microbiological diagnostics alone 
did not improve antimicrobial use in patients with bloodstream infections (BSI). In this 
chapter, we examined the diagnosis of BSI in a prospective randomised controlled trial to 
measure the burden of hospital acquired BSI in critical care units in Vietnam. 
Since their first introduction in 1929 (Sette et al., 2012), intravascular catheter 
placement has been a very common procedure in ICUs, with a rate of arterial catheter and 
central venous catheter use ranging from one-third to nearly all patients in ICUs 
(Gershengorn et al., 2014). Intravascular catheters are used for different indications, 
including fluid replacement, transfusion, parenteral nutrition, antimicrobial therapy, 
monitoring of hemodynamic status and hemodialysis (Mermel et al., 2009). However, the 
use of intravascular catheters is associated with a risk of intravascular catheter-related 
bloodstream infections (CRBSI), caused by microorganisms that colonise the catheter or 
contaminate the fluid administered through the catheter. These are mostly coagulase-
negative staphylococci, S. aureus, Candida species, and enteric Gram-negative bacilli 
(Mermel et al., 2009). Central line-associated BSI often ranked third among the most 
common HAIs. In ICUs in LMICs, the incidence density of catheter-related bloodstream 
infections was 1.7 – 44.6 per 1000 catheter-days whilst for catheter-related urinary-tract 
infections this was 1.4 – 23.0 per 1000 urinary catheter-days and for ventilator-associated 
pneumonia 3.2 – 56.9 per 1000 ventilation-days (Allegranzi et al., 2011).  
The burden of HAIs, including specific type of HAIs in SEA is not well documented (Ling 
et al., 2015). The incidence density by specific type of HAIs in SEA was 14.7 per 1000 
ventilator-days (95% CI, 11.7–17.7) for ventilator-associated pneumonia, 4.7 per 1000 
catheter-days (95% CI, 2.9–6.5) for central line–associated bloodstream infection and 8.9 
per 1000 catheter-days (95% CI, 6.2–11.7) for catheter-associated urinary tract infection 
(Ling et al., 2015). In a meta-analysis of studies from 2009 to 2016, patient’s characteristics 
on admission including diabetes (relative risk (RR), 1.76; 95% CI, 1.27-2.44), 
immunosuppression (RR, 1.24; 95% CI, 1.04-1.47), and body temperature (mean difference 
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(MD), 0.62; 95% CI, 0.41-0.83) and treatment-related factors, including surgery time (mean 
difference 34.53; 95% CI, 22.17-46.89), reoperation (RR, 7.94; 95% CI, 5.49-11.48), 
exposure to cephalosporin (RR, 1.77; 95% CI, 1.30-2.42), days with central venous catheter 
(MD, 5.20; 95% CI, 4.91-5.48), intensive care unit (ICU) admission (RR, 3.76; 95% CI, 1.79-
7.92), days of ICU stay (MD, 21.30; 95% CI, 19.81-22.79), and mechanical ventilation (OR, 
12.95; 95% CI, 6.28-26.73) were associated with HAIs (Rodriguez-Acelas et al., 2017). 
In a prospective observational study in the Hospital for Tropical Diseases in southern 
Vietnam, the incidence density of HAIs in ICU were 23/1000 patient days and pneumonia 
was the most common HAIs (49.1%) followed by UTIs (36.8%) and BSI (14.1%) (Thuy et al., 
2018). Whilst the incidence density of VARI was quite consistent among studies, the data 
of CRBSI in Vietnam was limited. A point prevalence study in ICUs in 14 provincial and 
national level hospitals in the VINARES network in Vietnam showed a HAI prevalence of 
29.5% (965/3266). The majority (79%, 804) were hospital acquired pneumonia, with 73% 
(589) being ventilator associated. HABSI ranked second with 44 cases (4.4%), 27 of which 
(61.3%) were catheter associated (Phu et al., 2016). 
This chapter aims to estimate the incidence density rate of HABSI (which is the ratio of 
the number of cases to the total time the patient population is at risk of BSI and presented 
in per 1000 patient-days) and factors associated with CRBSI in intubated patients in ICUs in 
Vietnam using data from patients enrolled in the trial to study the effects of continuous 
endotracheal cuff pressure control on preventing ventilator associated respiratory 
infections (VARI) in newly intubated patients (Chapter 2) 
6.2. Methods 
6.2.1. Study population 
This study used data from an open-label randomised controlled trial (RCT) to study the 
effects of continuous endotracheal cuff pressure control on preventing VARI in newly 
intubated patients (Chapter 2). Six hundred patients aged 18 years and older who were 
admitted to the ICUs in 3 hospitals in Vietnam were included and randomised in control 
group (manual cuff pressure control) or intervention group (automated cuff pressure 
control). The patients in both arms received diagnostics for hospital acquired infections 
when a new antimicrobial was started or the treating doctor suspected a new infection. All 
patients were followed during hospitalisation and at 30 days and 90 days after 
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randomisation. In this chapter, patients from both assigned groups were included in the 
analysis. Details on the methods are presented in Chapter 2. 
6.2.2. Case definitions of hospital acquired bloodstream infection 
Hospital acquired bloodstream infection (HABSI) were defined as the first episode of a 
new infection in a patient admitted to ICU for at least 48 hours by the European network 
for the surveillance of healthcare-associated infections (European surveillance of 
healthcare-associated infections in intensive care units, 2015). Bloodstream infection was 
defined as a patient having at least one positive blood culture for a recognised pathogen 
OR a patient having at least one of the following signs or symptoms: fever (> 38 °C), chills, 
or hypotension and two positive blood cultures for a common skin contaminant (coagulase-
negative staphylococci, Micrococcus spp., Propionibacterium acnes, Bacillus spp., 
Corynebacterium spp.) (from two separate blood samples, usually within 48 hours) 
(European surveillance of healthcare-associated infections in intensive care units, 2015). 
Central line-associated BSI (CLABSI) was defined as a patient with a laboratory confirmed 
bloodstream infection and an central venous line (subclavian veins, internal jugular veins 
or femoral veins) present on the date of laboratory confirmed BSI or the day before 
(Centers for Disease Control and Prevention/ National Healthcare Safety Network, 2019). 
6.2.3. Statistical Analysis 
The incidence density rate of hospital acquired bloodstream infection in ICU was 
calculated by dividing the number of cases with HABSI by the total number of patient-ICU 
days and multiplying with 1000 (per 1000 patient-days). The incidence density rate of a 
CLABSI was calculated by dividing the number of CLABSI by the number of patient-days with 
central venous catheter during ICU stays (per 1000 device days (Centers for Disease Control 
and Prevention/ National Healthcare Safety Network, 2019).  
All data were analysed using R (Version 3.6.2). Factors associated with HABSI were 
compared between patients with and without HABSIs using Cox’s proportional hazards 
regression. Variables were selected by review of the literature (demographic, severity, 
interventions age) and were included in Cox proportional hazards model. All tests were 
two-tailed and differences were considered statistically significant at p values ≤0.05.
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Table 6-1. Participant’s characteristics  
Characteristics  All patients 
n=591 
Patients with 
HABSI (n=44) 
Patients without 
HABSI (n =547)  
P value 
Male sex (n, %) 408/591 (69.0%) 34/44 (77.3%) 374/547 (68.4%) 0.219 
Age (years), (median, IQR)  58.0 (42.0-70.0) 60.0 (43.0-74.2) 58.0 (42.0-70.0)  
Place of enrolment (n,%)    0.922 
TVH 135/591 (22.8%) 10/44 (22.7%) 125/547 (22.9%)  
HCM 294/591 (49.7%) 23/44 (52.3%) 271/547 (49.5%)  
NHTD 162/591 (27.4%) 11/44 (25.0%) 151/547 (27.6%)  
Transferred from other 
hospital (n,%) 
422/591 (71.4%) 30/44 (68.2%) 392/547 (71.7%) 
0.623 
Central venous catheter 
placement (n,%) 
333/591 (56.3%) 33/44 (75.0%) 300/547 (54.8%) 
0.001 
Arterial catheter 
placement (n,%) 
167/591 (28.3%) 22/44 (50.0%) 145/547 (26.5%) 
<0.001 
Charlson Comorbidity 
Index (n,%) 
   0.143 
 0 361/591 (61.1%) 28/44 (63.6%) 333/547 (60.9%)  
 1-2 133/591 (22.5%) 5/44 (11.4%) 128/547 (23.4%)  
 3-4 44/591 (7.4%) 6/44 (13.6%) 38/547 (6.9%)  
 ≥5 53/591 (9.0%) 5/44 (11.4%) 48/547 (8.8%)  
APACHE II score at 
enrolment (median, IQR) 
17.0 (13.0-22.0) 16.0 (12.8-22.0) 18.0 (14.0-22.0) 0.245 
Cause of admission (n,%)     
Tetanus 180/591 (30.5%) 22/44 (50.0%) 158/547 (28.9%) 0.003 
Pneumonia (any) 167/591 (28.3%) 8/44 (18.2%) 159/547 (29.1%) 0.123 
Sepsis/septic shock 141/591 (23.9%) 6/44 (13.6%) 135/547 (24.7%) 0.098 
CNS Infection 127/591 (21.5%) 5/44 (11.4%) 122/547 (22.3%) 0.089 
COPD 10/591 (1.7%) 0/44 (0.0%) 10/547 (1.8%) 0.366 
Cerebrovascular disease 9/591 (1.5%) 0/44 (0.0%) 9/547 (1.6%) 0.391 
Myocardial infarction 27/586 (4.6%) 1/44 (2.3%) 26/542 (4.8%) 0.442 
Others 66/591 (11.2%) 2/44 (4.5%) 64/547 (11.7%) 0.147 
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6.3. Results 
6.3.1. Demographic and clinical characteristics of the patients 
From November 2016 to December 2018, we recruited a total of 597 patients for the 
randomised controlled trial of the effectiveness of continue cuff pressure control and 591 
patients who had been hospitalised for more than 48 hours were included in this analysis. 
The median age of patients was 58 years (IQR 42-70) and most were male (408/591 or 
69%). The demographics of patients were summarised in Table 6-1. Of the patients studied, 
all patients were intubated at the time of enrolment, 153/591 (25.9%) had a tracheostomy 
at randomisation, 318/591 (53.8%%) had central venous catheters (CVC), and 153/591 
(25.9%) had an arterial catheter during their ICU stay. 
6.3.2. Incidence density rate of hospital acquired bloodstream infection  
Among 591 patients who were admitted to ICUs, 44/591 patients (7.4%) had at least 
one episode of HABSI. There were 333/519 patients with central line placement and a total 
number of central catheter days of 3677. Thirty-one patients with HABSI (31/44 or 70.5%) 
was identified as CLABSI. The overall rate of CLABSI was (31/333) was 9.3%. The incidence 
density rates of HABSI and CLABSI were not significantly different between hospitals sites 
or patients with or without tetanus diagnosis (Table 6-2). The median time from ICU 
admission to diagnosis of HABSIs was 13 days (IQR 8-21 days). 
Table 6-2. Incidence density rate of hospital acquired bloodstream infections 
Group HABSI rate (IQR) (per 1000 
patient-days) 
CLABSI rate (IQR) (per 1000 catheter-
days) 
All patients 3.76 (2.77-5.1) (44/11688) 8.43 (5.83-12.1) (31/3677) 
Hospital 
  
TV 4.16 (2.12- 7.91) (10/2403) 9.51 (4.65- 18.67) (9/946) 
HTD 3.52 (2.28- 5.36) (23/6539) 10.32 (5.75- 18.07) (13/1260) 
NHTD 4.01 (2.11- 7.39) (11/2746) 6.12 (2.99- 12.03) (9/1471) 
Tetanus diagnosis 
  
No tetanus 3.06 (1.97- 4.71) (22/7192) 8.06 (5- 12.81) (19/2358) 
Tetanus 4.89 (3.15- 7.53) (22/4496) 9.1 (4.94- 16.31) (12/1319) 
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6.3.3. Aetiology of hospital acquired infections 
Among the 44 patients with HABSIs, 47 isolates were identified from 44 blood cultures, 
including 41 patients with a single organism and 3 patients with dual organisms (1 case of 
co-infection with Enterococcus faecalis and Proteus mirabilis; 1 case with Klebsiella 
aerogenes and Pseudomonas aeruginosa, and 1 case with A. baumannii and P. aeruginosa). 
Of 47 isolates, 36.2% (17/47) were Enterobacteriaceae, 40.4% (19/47) were non-
Enterobacteriaceae Gram-negative bacteria and 23.4% (11/47) were Gram-positive 
bacteria. The distribution of pathogens is shown in Table 6-3. The most common blood 
isolates were K. pneumoniae (11/47 or 23.4%) followed by P. aeruginosa (9/47 or 19.1%), 
A. baumannii and CoNS (each of 4/47 or 8.5%). 
 
Table 6-3. Aetiology and resistance of hospital acquired infections in patients with 
laboratory confirmed HAIs 
Pathogen Number of isolates Proportion (%) 
Klebsiella pneumoniae 11 23.4% 
Pseudomonas aeruginosa 9 19.1% 
Coagulase-negative staphylococci 5 10.6% 
Acinetobacter baumannii 4 8.5% 
Staphylococcus aureus 4 8.5% 
Proteus mirabilis 3 6.4% 
Enterococcus faecalis 2 4.3% 
Stenotrophomonas maltophilia 2 4.3% 
Elizabethkingia meningoseptica 1 2.1% 
Burkholderia seminalis 1 2.1% 
Serratia marcescens 1 2.1% 
Escherichia coli 1 2.1% 
Klebsiella aerogenes 1 2.1% 
Providencia stuartii 1 2.1% 
Klebsiella oxytoca 1 2.1% 
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6.3.4. Risk factors for hospital acquired bloodstream infections 
In univariate analysis, factors significantly associated with the occurrence of HABSI 
were central catheter placement (OR 2.087 95%CI 1.051, 4.142, p=0.036), arterial catheter 
placement (OR 2.287, 95%CI 1.264, 4.139, p=0.006) and CNS infection (OR 0.38, 95%CI 
0.149, 0.967, p=0.042) (Table 6-4). In multiple logistic regression analysis, arterial catheter 
placement was the only independent risk factor for the occurrence of HABSI. Patients who 
had an arterial catheter placement showed a 3.37-fold (CI 95%: 1.483, 7.657) greater 
chance of developing HABSI compared with patients who had no arterial catheter 
placement.  
The all-cause ICU-mortality rate was 189/591 (32.0%). Among 44 patients with HABSI, 
16/44 (36.4%) died. 
 
6.4. Discussion 
This is the first prospective report of incidence density rates of HABSI and CLBSI, in a 
cohort of ventilated patients on three ICUs in Vietnam. We found a high incidence density 
rate of CLBSI among newly intubated patients admitted to ICUs in Vietnam with the top 3 
most common pathogens being K. pneumoniae, P. aeruginosa and CoNS.  
In the period of 1995-2010, the incidence rate of CLABSI in LMICs was much higher than 
in HICs (12.2 per 1000 catheter-days vs 3.5 per 1000 catheter-days) (World Health 
Organization., 2011). In high income countries, a systematic review of 4109 central lines in 
ICUs in the US and Korea reported an incidence rate of CLABSI from 9.8% to 20.9% (Larsen 
et al., 2019). In a systematic review of 200 prospective studies in adult patients with 
intravascular devices between January 1966 and July 2005, the incidence density rate of 
BSI varied by specific type of intravenous device and among short-term intravenous 
devices. It was lowest with peripheral intravenous catheters (0.5 per 1000 catheter-days) 
and highest in central venous catheters (2.7 per 1000 catheter-days) and the incidence 
rates were 0.1% and 4.4% respectively (Maki et al., 2006).
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Table 6-4. Risk factors associated with hospital acquired bloodstream infections 
 
Characteristics  Patients without 
HABSI (n = 547)  
Patients with 
HABSI (n = 44)  
Unadjusted OR (95% CI)  P Value  Adjusted OR (95% CI)  P value  
Sex Female 173 (29.3 %) 10 (1.7 %)     
 Male 374 (63.3 %) 34 (5.8 %) 1.838 (0.903, 3.741) 0.093 2.046 (0.95, 4.408) 0.068 
Age 18-47 yrs 191 (32.3 %) 13 (2.2 %)     
 48-65 yrs 182 (30.8 %) 11 (1.9 %) 1.028 (0.458, 2.307) 0.947 0.782 (0.317, 1.931) 0.594 
 ≥66 yrs 174 (29.4 %) 20 (3.4 %) 1.473 (0.731, 2.969) 0.279 1.294 (0.529, 3.169) 0.572 
Hospital  BVTV 125 (21.2 %) 10 (1.7 %)     
 HTD 271 (45.9 %) 23 (3.9 %) 0.782 (0.371, 1.649) 0.519 0.334 (0.076, 1.468) 0.147 
 NHTD 151 (25.5 %) 11 (1.9 %) 0.915 (0.385, 2.176) 0.84 0.833 (0.218, 3.183) 0.789 
APACHE II score <16 198 (34.1 %) 21 (3.6 %)     
 16-20 160 (27.5 %) 9 (1.5 %) 0.59 (0.27, 1.29) 0.186 0.628 (0.24, 1.641) 0.342 
 ≥21 179 (30.8 %) 14 (2.4 %) 1.001 (0.507, 1.974) 0.999 1.343 (0.431, 4.184) 0.611 
Charlson index 0 333 (56.3 %) 28 (4.7 %)     
 1-2 128 (21.7 %) 5 (0.8 %) 0.637 (0.246, 1.65) 0.353 0.6 (0.206, 1.742) 0.347 
 3-4 38 (6.4 %) 6 (1 %) 2.324 (0.957, 5.641) 0.062 1.49 (0.403, 5.509) 0.55 
 ≥5 48 (8.1 %) 5 (0.8 %) 1.507 (0.581, 3.908) 0.399 1.387 (0.404, 4.755) 0.603 
Sepsis and septic 
shock  
No 412 (69.7 %) 38 (6.4 %)     
Yes 135 (22.8 %) 6 (1 %) 0.862 (0.363, 2.05) 0.737 0.576 (0.192, 1.725) 0.324 
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Characteristics  Patients without 
HABSI (n = 547)  
Patients with 
HABSI (n = 44)  
Unadjusted OR (95% CI)  P Value  Adjusted OR (95% CI)  P value  
Tetanus No 389 (65.8 %) 22 (3.7 %)     
 Yes 158 (26.7 %) 22 (3.7 %) 1.599 (0.875, 2.924) 0.127 1.294 (0.378, 4.428) 0.681 
CNS infection No 425 (71.9 %) 39 (6.6 %)     
 Yes 122 (20.6 %) 5 (0.8 %) 0.38 (0.149, 0.967) 0.042 0.498 (0.126, 1.973) 0.321 
Diabetes No 378 (68.1 %) 34 (6.1 %)     
 Yes 133 (24 %) 10 (1.8 %) 1.157 (0.57, 2.349) 0.687 0.941 (0.373, 2.377) 0.898 
Moderate and severe 
liver disease 
No 519 (89.9 %) 42 (7.3 %)     
Yes 14 (2.4 %) 2 (0.3 %) 2.069 (0.498, 8.589) 0.317 1.604 (0.268, 9.605) 0.605 
Central catheter 
placement 
No 247 (41.8 %) 11 (1.9 %)     
Yes 300 (50.8 %) 33 (5.6 %) 2.087 (1.051, 4.142) 0.036 1.368 (0.628, 2.98) 0.431 
Arterial catheter 
placement 
No 402 (68 %) 22 (3.7 %)     
Yes 145 (24.5 %) 22 (3.7 %) 2.287 (1.264, 4.139) 0.006 3.369 (1.483, 7.657) 0.004 
Time from admission 
to ICU discharge 
<12 days 205 (34.9 %) 4 (0.7 %)     
12-25 days 180 (30.7 %) 13 (2.2 %) 0.846 (0.258, 2.768) 0.782 0.624 (0.183, 2.13) 0.452 
>25 days 158 (26.9 %) 27 (4.6 %) 0.912 (0.28, 2.971) 0.879 0.603 (0.175, 2.079) 0.423 
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Whilst we still found Gram negative bacteria as the most common causes of HABSI in 
Vietnam, Gram positive bacteria have overtaken Gram negative bacteria as the 
predominant cause of HABSI in the US from 1987 (Karchmer, 2000). In a large surveillance 
study in US hospitals between 1995 and 2002 with 24,179 cases of hospital acquired BSI, 
the proportion of polymicrobial infection was 13% and among monomicrobial infection, 
Gram-positive bacteria (65%) were predominant over Gram-negative bacteria (25%) 
(Wisplinghoff et al., 2004). Among 20,978 isolates HABSI in 49 US hospitals, the most 
common pathogens were coagulase-negative staphylococci (CoNS) (21.3%) followed by 
Candida species (10.2%) and Enterococcus species (9.8%). A. baumannii ranked 10th among 
the most common isolates (1.6%) (Wisplinghoff et al., 2004). In a large cohort of 5,648 
patients for nearly 20 years (1995-2013) in a paediatric tertiary center in Canada, the most 
common cause of central venous catheter–associated bloodstream Infection was Gram-
positive bacteria (72% of all CLABSI) with the predominant pathogens of CoNS (54% of all 
CLABSI), following by S. aureus (9%) and Enterobacter sp. (7.2%) (Carter et al., 2016). 
In a surveillance of 1121 HABSI episodes in 1004 patients in Brazil, an upper middle 
income country, the incidence of HABSI remained unchanged at 11.2-10.2 per 1000 
catheter days over 5 years with the most common pathogen being S. aureus (24.4%), 
followed by A. baumannii (19.2%) and CoNS (11.3%) (Girao et al., 2008). 
HABSI is associated with poor outcomes, also in high income settings. In above 
mentioned studies, the overall mortality rate was 27% in US (Wisplinghoff et al., 2004), 38 
% in Brazil. Among European countries, the overall mortality rates was lowest in France at 
12% and highest in Belgium at 31.8% and in the middle for Finland (16%) and Spain (24-
27.3%) (Goto and Al-Hasan, 2013). In a case control study of patients with HABSI matched 
by diagnosis, age, sex and length of stay before HABSI, the overall mortality rates in cases 
and controls was 50% and 15% respectively, corresponding to an attributable mortality of 
35% (Pittet et al., 1994).  
The data from LMICs was limited. In my previous retrospective study on patients with 
bloodstream infection in the National Hospital for Tropical Diseases from 2011 to 2013 
((Dat et al., 2017b)), I identified 77 patients with hospital acquired BSI (defined as a positive 
blood culture after >48h of admission). Among pre-defined patients with HABSI, the most 
common pathogens were K. pneumoniae (28.6%, followed by E. coli (11.7%), 
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Stenotrophomonas maltophilia (10.4%), Acinetobacter species (9.1%) and S. aureus (9.1%). 
The proportions of ESBL production in Enterobacteriaceae pathogens causing HASBI were 
marginally-significant higher than in community acquired BSI (4/19, 21.1% vs 5/82, 6.1%, 
p= 0.062) for K. pneumoniae and were similar for E. coli (5/9, 55.6% vs 28/52, 53.8%, p=1) 
(Dat et al., 2017b). However, without clinical judgment, my previous retrospective study 
may overestimate number of HABSI cases.  
A strength of this study was that it was conducted within a multi-center randomised 
control trial for preventing VARI. Suspected HAI episodes were evaluated followed by 
standard procedures which helped to reduce the inter-hospital variability in timing and 
indication of diagnostic investigations. Additionally, it makes our results generalizable to 
intubated patients in other ICUs in Vietnam. A limitation of our study is the 
representativeness of our sample of intubated patients of ICU patients in Vietnam and 
elsewhere. As reported in a previous study, the rate of intubation among patients in critical 
care units in Vietnam was 52.3% (Phu et al., 2016) and tetanus patients in Vietnam are 
mostly treated in 2 study hospitals (NHTD and HTD) and are therefore overrepresented, 
which we addressed by analysing them separately. 
6.5. Conclusion 
Based on data of an RCT, we reported a relatively high incidence of CLABSI, risk factors 
for HABSI and a complex aetiology of HABSI in critical care units in Vietnam. The findings of 
my study suggest a necessity for national surveillance for benchmarking to measure the 
impact of interventions through national guidelines / prevention bundles for management 
of intravascular catheter-related infection. 
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: Descriptive analysis of ventilator associated 
respiratory infections in a randomised controlled trial in 
the ICUs in Vietnam  
7.1. Introduction 
Ventilator associated respiratory infections (VARIs) are the most common type of 
hospital acquired infection in ICUs worldwide, with an incidence density ranging from and 
3.2 to 56.9 per 1000 ventilator days in low to middle income countries (LMIC) (Allegranzi et 
al., 2011). Prevention of VARI would benefit individual patients in terms of reducing the 
length of ICU stay, cost of care and the exposure to broad spectrum antibiotics and in turn, 
antimicrobial drug resistance. At institutional level, it also provides benefits to the ICUs in 
terms of reducing use and cost of broad-spectrum antimicrobials and reducing the 
exposure of environmental bacteria (such as A. baumannii) to these agents, which may 
drive down antimicrobial resistance on the units. And therefore, at national level, 
prevention of VARI substantially reduces morbidity and VARI-related mortality, as well as 
the national health budget (see Chapter 4). As I estimated in Chapter 4, efforts to reduce 
VARI incidence density by 1% can result in a decrease of 1,578 VARI episodes per year and 
a saving of US$ 1.86 million nationally. 
Care bundles are a group of interventions usually consisting of 3-5 evidence-based 
interventions to improve patient care (Fulbrook and Mooney, 2003, Horner and Bellamy, 
2012). They have gained interest for over 20 years because the clinical outcome 
improvement is likely a result of implementation of several different elements at the same 
time rather than a single intervention (Lavallee et al., 2017). Interventions incorporated 
into care bundles may be based on different levels of evidence, from expert opinion to 
proper RCTs (Camporota and Brett, 2011). As evidence is ever evolving, elements of care 
bundles are required to be continuously re-evaluated and updated. 
Care bundles are important for VARI prevention and largely focus on the general 
strategies of training and education, hand hygiene, bed head elevation and early mobility, 
strategies to prevent aspiration and strategies to reduce colonization and contamination 
(Klompas et al., 2014). However, data on the effectiveness of the components of such 
bundles in resource constrained settings are limited and their implementation is 
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challenging due to inadequate staffing levels, the low rate of adherence and the findings 
that some interventions proven to work in developed world settings, such as semi-
recumbent patient positioning, have failed to demonstrate effectiveness when scrutinized 
in these settings (Loan et al., 2012).  
Maintenance of adequate endotracheal cuff pressure (at least 20 mmHg) is a 
component of VARI prevention bundles, acting in theory by diminishing the aspiration of 
contaminated oropharyngeal secretions (Rello et al., 1996). Utilisation of continuous 
control of endotracheal cuff pressure could be an ideal approach in LMIC as this 
intervention requires less nursing workload and has little cost in terms of disposable items 
(as compared to innovative endotracheal tubes, which carry a high disposable cost 
(Fernandez et al., 2012)). One individual patient data meta-analysis evaluated 2 
randomized controlled trials (RCTs) and 1 quasi-randomised study in a high resourced 
settings with a total of 543 patients and found that continuous control of cuff pressure 
significantly reduced the incidence of ventilator associated pneumonia (VAP) (HR of 0.47, 
95 % CI 0.31–0.71) (Nseir et al., 2015, Lorente et al., 2014, Nseir et al., 2011, Valencia et al., 
2007). A more recent systematic meta-analysis included the 3 abovementioned studies and 
4 other RCTs (1 study from France and 3 studies from China) and showed a lower incidence 
of VAP in the group of continuous cuff pressure control (CPC) (OR=0.39, 95% CI: 0⋅28–0⋅55) 
(Wen et al., 2018). However, there were no differences in the duration of mechanical 
ventilation, in-hospital mortality and duration of antimicrobial therapy (Wen et al., 2018, 
Nseir et al., 2015). Limitations of these RCTs were that only one study looked at 
antimicrobial prescription (Nseir et al., 2011) and additional major limitations in findings in 
RCTs were the heterogeneity among small sample size trials using different devices and the 
unblinded assessment of VAP (except in 1 trial in Spain (Lorente et al., 2014)).  
Because the current evidence is insufficient to recommend the automated continuous 
or manual control of cuff pressure, we aimed to evaluate the impact of continuous pressure 
control on the incidence of VARI and the number of antibiotic-free days during ICU stay. 
However, although I have led the trial to completion of enrolment and follow-up, unblinded 
results were not available yet at the time of the deadline for submission of the thesis. 
Because of the time limitation for analysis, I have described here only the characteristics of 
patients with VARI in 4 intensive care units across 3 sites in Vietnam and a summary of the 
statistical analysis plan for the trial.  
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7.2. Methods 
7.2.1. Study design  
This was an open-label, randomised, controlled trial conducted at ICUs in 3 referral 
hospitals in Vietnam, namely the Hospital the National Hospital of Tropical Diseases (NHTD) 
in Hanoi and the Hospital for Tropical Diseases (HTD) and Trung Vuong Emergency Hospital 
(TVH) in Ho Chi Minh City. For the purpose of this study, we used a manual cuff pressure 
manometer (VBM Cuff Pressure Gauges, reference 54-05-000, VBM Medizintechnik GmbH, 
Sulz am Neckar, Germany) for the control and a stand-alone CPC device (reference 701; 
TRACOE medical GmbH, Nieder-Olm, Germany) for the intervention. 
The inclusion criteria were patients who were at least 18 years of age, received 
endotracheal or tracheostomal intubation or tracheostomy for less than ≤ 24 h at the time 
of randomisation and for active treatment (i.e., physician caring for patient would prescribe 
an antibiotic if the patient developed an infection). Exclusion criteria were previous 
enrolment in the study or previous intubation within the last 14 days or known or suspected 
tracheal stenosis, tracheomalacia or stridor secondary to physical tracheal injury. The 
written informed consent was required to be enrolled for all participants. 
The trial was registered at ClinicalTrials.gov (NCT02966392) before initiation of patients 
enrolment (Dat et al., 2018). 
 
7.2.2. Sample size and randomisation 
We calculated the sample size to detect a 40% reduction of VARI prevalence at the 
power of 80% and the significance level of 5% (two-sided test). In the setting of high burden 
of tetanus among patients admitted to participating ICU, we stratified the study population 
at a ratio of 3:7 by the admission diagnosis of tetanus and non-tetanus to generalise our 
study for other settings. We assumed that “lost to follow up” or “extubation within 48 
hours” would account for more than 8% of participants, that the required sample size was 
therefore 600 patients, including 420 non-tetanus and 180 tetanus. All patients were 
randomly assigned in a 1:1 ratio by site and admission diagnosis to receive manual, 
intermittent CPC (control group) or automatic, continuous CPC (intervention group) using 
computer-generated block randomisation. 
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7.2.3. Intervention 
The cuff pressure was targeted to 25 cm H2O and recorded every 8 hours in all patients 
on mechanical ventilation. The control group received manual cuff pressure check and 
adjustment at the above schedule whilst the intervention group required no additional 
action. On a daily basis, the attending doctors evaluated patients until 2 days after 
extubation for new hospital acquired infection. When an infection was suspected, a 
standard panel of testing was performed with complete blood count, procalcitonin, arterial 
blood gas, blood culture, sputum/endotracheal aspirate microscopy and culture, urine 
culture and chest x-ray. Participants were followed up until discharge from ICU, and at 28 
days and 90 days after randomisation (whichever happened first). 
7.2.3.1. Endpoints 
The primary endpoint was the prevalence of VARI (defined as VAP or ventilator-
associated tracheobronchitis (VAT) during ICU stay). An independent reviewer reviewed all 
suspected hospital acquired infections at the end of the study and conclusively made a 
diagnosis of VARI. The VARI diagnosis required 2 core criteria: the first criterion was that 
the patient had to be on intubated for at least 48 hours and the second criterion was that 
new antibiotics(s) were started or the antibiotic regimen was changed to treat a new 
infection. When those two core criteria were met, VARI was defined as VAT if there was a 
new onset of purulent respiratory secretions or a change in the appearance of sputum or 
an increase in volume of sputum plus either a temperature >38 °C or < 36°C or a white 
blood cell count <4.0 x 109/L or ≥12 x 109/L with no other recognised cause. VARI was 
defined as VAP if a patient had a new infiltration or progressive changes on chest 
radiography and 2 of 3 the following criteria: (1) temperature >38 °C or < 36 °C; (2) white 
blood cell count <4.0 x 109/L or ≥12 x 109/L with no other recognised cause and (3) a new 
onset of purulent respiratory secretions or a change in appearance of sputum or increase 
in volume of sputum. 
Secondary endpoints included microbiologically confirmed VARI and VAP, duration of 
intubation and mechanical ventilation in ICU, number of intubation days with 
antimicrobials, incidence of other HAIs, the length and cost of ICU/hospital stay, cost of 
antibiotics during ICU/hospital stay, in-hospital mortality and mortality at 28 and 90 days 
after randomisation. The definitions for secondary endpoints were detailed in our 
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published protocol (Dat et al., 2018). Safety endpoints included the incidence of in-hospital 
re-intubation and complications of intubation. 
7.2.4. Statistical Analysis 
Data was managed in a computerised data entry system with double data entry and 
analysed using R. The primary and secondary endpoints will be analysed using intention-
to-treat, per-protocol and logistic regression model approaches, with an adjustment for 
tetanus diagnosis. For the primary endpoint patients who were intubated for less than 48 
hours were excluded. The cumulative incidence of VARI was plotted by predefined 
subgroups, including tetanus vs. non-tetanus, with death, extubation and ICU discharge as 
combined competing risks. For VARI episodes, curves will be compared using log-rank test 
and fitted cause-specific proportional hazards model with adjustment for tetanus status as 
main effect. For both the logistic regression model and the cause-specific hazards 
regression model, I will test for heterogeneity of the intervention effect by tetanus status 
and report the hazard ratios. All secondary outcomes will be adjusted for tetanus status as 
main effect. Binary secondary endpoints (clinical and microbiologically confirmed VAP and 
any HAI) will be analysed in the same way as the primary endpoint. The distribution of 
duration of ventilation and intubation and the time of ICU stay were estimated; death will 
be considered as a competing event. Non-parametrical estimation will be used for the 
cause-specific cumulative incidence for both event types. The cause-specific cumulative 
incidence of death will be compared between 2 arms using the Fine-Gray competing risk 
regression model and will be adjusted for tetanus status. We also will fit a cause-specific 
proportional hazards model.  
The proportion of intubated days free of antibiotics will be analysed using a Poisson 
regression model with the number of intubated days without antibiotics as the outcome, 
the randomized arm as the main covariate, and the (log-transformed) total number of 
intubated days as an offset. Quasi-likelihood will be used to account for potential over-
dispersion. Mortality will be compared by Kaplan Meier curves and modelled by Cox 
proportional hazards regression. The proportion of patients with at least one adverse event 
will be compared using Fisher’s exact test. 
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7.3. Results 
Five hundred ninety-seven patients were enrolled into the trial between November 
2016 and December 2018. Two hundred ninety-five were allocated to the first arm and 302 
patients to the second arm to receive either automated continuous cuff pressure control 
or manual cuff pressure control. Six patients (6/597 or 1%) were excluded from this 
analysis, including 2 patients who had received intubation within 14 days before study 
enrolment, 2 cases with wrong arm allocations, 1 patient intubated for more than 24 hours 
before enrolment, and 1 case with technical issues of the study device. In this chapter, a 
total of 591 patients were included and there were a total of 180 (%) patients with tetanus. 
Among 591 eligible patients recruited in the RCTs, 140/591 patients (23.7%) developed 
VARI, among whom 102/140 (72.9%) patients had VAP as defined by an independent 
endpoint reviewer. The baseline characteristics of patients were shown in  
. The final analysis with unblinding of treatment arms is ongoing.  
7.4. Discussion 
My preliminary results showed that VARI is a common problem among intubated 
patients in ICU in Vietnam with the proportion of VARI in patients with mechanical 
ventilation (23.7%) similar to our previous report (92/374, or 24.6%) from 4 study ICUs in 
Vietnam from between 2013 and 2015 (Phu et al., 2017). In this prospective study, 37/92 
(40.2%) patients with VARI were diagnosed with VAP and the in-hospital mortality rate was 
not statistically increased among patients with VAP (HR 1.79, 95% CI 0.84–3.82, p = 0.13) 
and VAT (HR 0.43, 95%, CI 0.13–1.38, p = 0.15) (Phu et al., 2017).  
In a prospective, multicentre study in 13 ICUs from 8 European countries, 84 VARI 
episodes were diagnosed in 244 adult patients (34.4%), including 33 episodes of VAP 
(39.3%) and 51 episodes of VAT (Ramirez-Estrada et al., 2018) using the same 2008 CDC 
criteria as my study and the previous study in Vietnam. Participants in the European study 
were 63.1% male, had a median age of 56 (95%CI 49-69) and a median APACHE II score at 
admission of 20 (95% CI 14–27). The tracheostomy rate was 29% (44/244) and the median 
length of stay on ICU was 14 days (95% CI 8–26). Patients with VAP had a higher mortality 
than patients with VAT (42.8 vs 19.6%, p = 0.007) (Ramirez-Estrada et al., 2018). 
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Table 7-1. Baseline characteristics of participants 
 
All patients 
(n=591) 
Patients with VARI 
(n=140) 
Patients with VAP 
(n=102) 
Male sex (n, %) 408/591 (69.0%) 110/140 (78.6%) 81/102 (79.4%) 
Age (years), (median, IQR)  58.0 (42.0-70.0) 58.0 (39.8-68.0) 59.0 (39.2-69.0) 
Place of enrolment (n,%) 
   
TVH 135/591 (22.8%) 11/140 (7.9%) 9/102 (8.8%) 
HCM 294/591 (49.7%) 83/140 (59.3%) 62/102 (60.8%) 
NHTD 162/591 (27.4%) 46/140 (32.9%) 31/102 (30.4%) 
Transferred from other 
hospital (n,%) 
422/591 (71.4%) 111/140 (79.3%) 75/102 (73.5%) 
Initial intubation  
   
endotracheal intubation 438/591 (74.1%) 83/140 (59.3%) 53/102 (52.0%) 
 tracheostomy  153/591 (25.9%) 57/140 (40.7%) 49/102 (48.0%) 
APACHE II score at 
enrolment (median, IQR) 
17.0 (13.0-22.0) 15.5 (13.0-19.0) 14.0 (12.0-19.0) 
Charlson Comorbidity Index 
   
0 361/591 (61.1%) 111/140 (79.3%) 80/102 (78.4%) 
1-2 133/591 (22.5%) 19/140 (13.6%) 14/102 (13.7%) 
3-4 44/591 (7.4%) 6/140 (4.3%) 5/102 (4.9%) 
≥5 53/591 (9.0%) 4/140 (2.9%) 3/102 (2.9%) 
Cause of admission (n,%) 
   
Tetanus 180/591 (30.5%) 70/140 (50.0%) 59/102 (57.8%) 
Pneumonia (any) 167/591 (28.3%) 22/140 (15.7%) 15/102 (14.7%) 
Sepsis/septic shock 141/591 (23.9%) 16/140 (11.4%) 11/102 (10.8%) 
CNS Infection 127/591 (21.5%) 33/140 (23.6%) 18/102 (17.6%) 
COPD 10/591 (1.7%) 0/140 (0.0%) 0/102 (0.0%) 
Cerebrovascular disease 9/591 (1.5%) 1/140 (0.7%) 1/102 (1.0%) 
Myocardial infarction 27/586 (4.6%) 2/140 (1.4%) 2/102 (2.0%) 
Others 66/591 (11.2%) 11/140 (7.9%) 8/102 (7.8%) 
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Characteristics of patients admitted to ICUs were similar previous reports, in terms of 
age, sex distribution and severity. Characteristics of patients admitted to ICUs are 
recognised as a non-modifiable risk factor for the development of VAP and for mortality 
(Bonten et al., 2004, Blot et al., 2014). These patients related factors included comorbidities 
(chronic diseases, head trauma, coma, organ failure), and age > 60 years old (Bonten et al., 
2004). As I have discussed in 1.2.1.Overview of hospital acquired infections (HAIs) and 
Figure 1-3, VAT and VAP are considered a continuum of ventilator-associated respiratory 
tract infections and the differentiation of these 2 entities is challenging. A recent review 
hypothesised that the continuum and severity of VARI was modulated by host immunity, 
inflammation and causative pathogens (Wu et al., 2019). In patients with intact immunity, 
VARI can be limited to local inflammation as VAT whilst patients with immunosuppression 
are at higher risk of VAP development. Therefore, the information of patient characteristics 
was important for generalising findings to other settings and better understanding the risk 
of HAIs acquisition. 
To my best knowledge, this trial is the first study with a large sample size in an LMIC to 
evaluate the effectiveness of endotracheal cuff CPC in preventing VARI. Because of the 
limitation of human resources in LMICs, besides reducing the nursing workload for 
maintaining cuff pressure, the intervention should show a beneficial impact on patients 
outcomes, e.g. reducing mortality, duration of mechanical ventilation and ICU stay, cost of 
admission etc. The intervention will likely be considered of questionable benefit should it 
result only in a reduction in VARI episodes without corresponding reductions in at least 
patient-centred or antibiotic stewardship outcomes (Barlam et al., 2016). 
The drop of cuff pressure in intermittent measurement can lead to leakage of secretions 
through the endotracheal tube cuff (Carter et al., 2014). Current available evidence in 
small, non-RCT studies are insufficient to recommend CPC routinely (Tablan et al., 2004). 
My study provides an opportunity to evaluate the impact of CPC in preventing VARI and in 
reducing antibiotic use as an aspect of infection prevention and control and antimicrobial 
stewardship in a resource-constrained setting with established high levels of antibiotic use 
and resistance. 
Both VAT and VAP share common clinical manifestations of fever, purulent respiratory 
secretions, and leucocytosis. The chest x-ray is the usual common method to diagnose VAP 
based on the presence of pulmonary infiltrates. In a prospective study in 10 countries with 
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114 ICUs, the incidence of VAT was similar to VAP (11% vs 12%) (Martin-Loeches et al., 
2015). In a survey of perceptions of international physicians, nearly 80% of respondents 
diagnosed VAT on the basis of both clinical and microbiological criteria, and the remaining 
respondents used clinical criteria alone or as a diagnosis of exclusion. Half of the 
respondents agreed to antibiotic use in patients with VAT (Rodriguez et al., 2014). In 
Vietnam it is common practice to treat VAT with antimicrobials, and in view of these 
considerations, we constructed our trial around an endpoint of VARI that encompassed 
both VAT and VAP.  
In an open-label study where the treating doctor is not blinded to the intervention, 
there is a risk of clinical ascertainment bias of the study endpoint (Schulz and Grimes, 2002). 
Whilst death or microbiological results are hard endpoints which are unlikely to be biased 
by a lack of blinding, VARI diagnostic categories and antibiotic use are more subjective and 
vulnerable to misclassification bias in non-blinded trials (Dechartres et al., 2009). For this 
reason an independent endpoint committee is recommended for multicentre clinical trials 
to judge complex, multi-aspect definitions and outcomes (Naslund et al., 1999, Moher et 
al., 2001). In our study treating doctors know the allocated arm of the patient and perform 
assessments for HAI as part of routine care; therefore, the use of a blinded endpoint 
reviewer will reduce bias in the primary endpoint evaluation. The study may also offer an 
opportunity to understand inconsistencies in the assessment of VARI diagnoses between 
treating doctors and the endpoint reviewer, as well as how this impacts the significance of 
results. 
7.5. Conclusion 
The rate of VARI in my study was high as 23.7% and similar to previous study in Vietnam 
in the period of 2013-2015. The final analysis for the effectiveness of continuous cuff 
pressure control vs manual cuff pressure control is ongoing. Patient recruitment and follow 
up is completed with a low rate of withdrawal, ensuring the validity of clinical data and the 
acceptability for participants.
135 
 
: Discussion 
Vietnam has made substantial progress over the past decade regarding the growth of 
the healthcare workforce, but the national capacity of critical care was still remarkably 
lower than in other countries in Southeast Asia and other low- and middle-income regions 
(Dat et al., 2017a). Implementation of infection prevention and control and antimicrobial 
stewardship in Vietnam, like in other LMICs, is limited by the capacity of healthcare 
infrastructures, microbiological diagnostics, effective interventions, political action and 
insufficient financial resources (Cox et al., 2017, Nguyen et al., 2013). 
Because the understanding of antimicrobial use is important when addressing 
antimicrobial drug resistance whilst the data of antimicrobial consumption in Vietnam was 
dispersed in different sources, my thesis started by analysing the availability and use of 
antimicrobials in the country. My findings in Chapter 3 and Chapter 4 showed that the high 
drug resistance rate in Vietnam required the use of last resort high-price antimicrobials and 
it was associated with high cost of treatment. Under the current the economic situation, 
the prevention of hospital acquired infections (HAIs) is of importance to the country in 
terms of saving health expenditures and improving the affordability of ICU services. Results 
presented in Chapter 4,Chapter 6 and Chapter 7 confirmed that ventilator associated 
respiratory infections (VARI) and central line-associated BSI (CLABSI) were important 
hospital acquired infections in intubated patients in critical care units in Vietnam. To 
address the burden of HAIs, my thesis aimed to explore the potential interventions which 
have the potential to reduce antimicrobial use, focusing on diagnostics and medical devices 
in 2 randomised control trials. The key messages of my thesis were further discussed below. 
8.1. Hospital acquired infections are pressing on critical care 
services in Vietnam  
The cost of antimicrobials relative to total medication and healthcare cost in Vietnam 
was high in comparison to high income settings (Chapter 4), especially the antimicrobials 
of last resort. Currently, the medication budget of public hospitals is spent for a substantial 
proportion on antimicrobials (28.5% of hospital budget), which is higher than high income 
countries (nationally 9% of a hospital’s drug acquisition budget in Canada (Nault et al., 
2008)).  
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Because hospital acquired infections result in additional use of resources, including 
antimicrobial therapy and diagnostics, policy decisions on infection prevention and control 
and antimicrobial stewardship, including conserving antibiotic effectiveness and 
accessibility and utilising microbial diagnostics need to be supported by evidence in a 
resource limited setting. 
My thesis is the first work presenting the high economic burden of VARI, the most 
common HAIs in critical care units in Vietnam. Based on available data and resources, we 
carried out a modelling study to estimate the cost of management of VARI throughout 
Vietnam. At the time of writing this thesis, the cost of VARI to the national healthcare 
system in Vietnam was unavailable and therefore the magnitude of the economic burden 
of HAIs was lacking. My study showed the cost spent for treatment of each VARI episode 
was US$ 1,174.9 per episode, including US$ 600 for antimicrobials, US$ 268.2 for 
ventilation support, US$ 262.5 for hospital bed and US$ 43.9 for diagnostics. At the country 
level and current VARI incidence of 21.7/1000 ventilation days, the annual total lost cost 
for management of VARI was calculated at US$ 40,447,469. Whilst the VARI incidence was 
quite consistent across studies in Vietnam, the data on the incidence of BSI in critical care 
units is limited. Using data from my intervention trial I also report as the first study in 
Vietnam the incidence rate of BSI in (ventilated) patients in 3 ICUs in the country. The high 
rate and incidence of CLABSI (9.3% and 8.43 per 1000 catheter-days, respectively) 
confirmed the burden of HAIs in critical care units and the importance to implement 
surveillance and interventions for different HAIs types. 
The same methods used in Chapter 4 can be applied to estimate the excess cost of 
management of other HAIs, when an alternative approach using the detailed cost of 
individuals to modelling the total cost or an analysis controlling for potentially confounders 
(e.g. age, sex, or number of co-morbidities or admission type) is not available. Regarding 
the methods presented in the Chapter 6, for LMICs, when national active surveillance is not 
established, the reports of HAIs incidence from prospective clinical trials as these can be 
used to inform decision making and allocating local resources to infection control 
programmes. Currently, multiple-partner efforts are being made in Vietnam to track HABSI 
and hospital acquired urinary tract infections. It is considered the first sentinel surveillance 
in country conducted in 6 model hospitals (Centers for Disease Control and Prevention 
(CDC), 2019) . 
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The results of HAIs burden presented in my thesis have important implications for policy 
and medical practice. The estimate of the economic burden of VARI and the incidence rate 
of BSI is evidence for the urgency of implementation of care bundles for HAIs prevention 
nationwide and indicates potential financial benefits of these preventions.  
 
8.2. Advanced technology alone is not effective without human 
action 
Among advanced microbiological diagnostics, we chose MALDITOF-MS, which is a 
relatively recent innovation with advantages of early identification of pathogens (Chapter 
5). We searched PubMed between October 1, 2007, and October 1, 2018 with the terms 
“time-of-flight mass spectrometry" or “MALDI-TOF” combined with "identification" and 
"patients". There were 2 systematic reviews assessing MALDI-TOF performance, in terms 
of microbiological diagnostics accuracy in bloodstream infection by comparison between 
MALDI-TOF and routine microbiological methods (Scott et al., 2016, Dixon et al., 2015). 
There were no randomised controlled trials when we started our study. All previous clinical 
studies of MALDI-TOF were conducted in HIC settings. My study was the first to explore the 
impact of MALDI-TOF diagnostics alone on antimicrobial use and clinical outcomes in an 
LMIC, where antimicrobial resistance and antibiotic consumption are high. Our findings 
showed that advanced diagnostics alone did not improve antimicrobial use. The impact of 
transferring novel techniques to LMICs may need to be evaluated by the highest quality of 
evidence. The communication and multidisciplinary teamwork in this setting should be 
improved by training and education and further explored in clinical trials. Research on 
antimicrobial stewardship is advocated to evaluate its effectiveness on healthcare provider 
and patient perspectives as well as microbiological endpoints (McGregor and Furuno, 
2014). Antimicrobial stewardship programs often include multiple simultaneous 
interventions (“a bundle”) which leads to difficulty in measuring the effect of individual 
relevant components. Recently, rapid diagnostics, including MALDITOF, in combination 
with active reporting systems have been advocated for antimicrobial stewardship to 
optimise antimicrobial therapy and improving clinical outcomes (Barlam et al., 2016). 
However, our study and a small number of other studies on other rapid diagnostic 
technologies indicate that the process of reporting results is likely to be as important as the 
speed with which results can be generated. 
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Chapter 5 showed that the early identification of pathogens from culture of blood and 
other sterile sites using MALDI-TOF, in the absence of any concurrent antimicrobial 
stewardship programme, did not result in a difference in the proportion of patients on 
optimal antimicrobial therapy within 24 or 48 hours of growth of the first clinically 
significant isolate, the time taken to provide optimal therapy, duration or total antibiotic 
therapy, outcome or time in intensive care. We did find a small improvement in the rate of 
hospital discharge, however in the context of other results and the impact of the exclusion 
of outliers on this result, it is unlikely to be of clinical significance. 
In common with most studies, we found a significant shortening of the time from 
specimen growth to identification and reporting. Our study gives some hints as to why this 
did not result in an improvement in optimal therapy. The most common cause of 
suboptimal therapy at 24 hours was use of excessively broad therapies, suggesting that 
there were delays in de-escalation of therapy. Analysis of the rationale for failure to de-
escalate found that most clinicians felt that the broad therapy was adequate and wished 
to review antibiotic susceptibility results before making decisions on therapy.  
To support Vietnam to address the AMR burden, country and regional grants from the 
Fleming Fund, a global investment of £265 million in 24 LMICs from 2015 to 2021, totalling 
around £15 million, have been made available for Vietnam to establish a National AMR 
reference laboratory and a National AMR hospital surveillance network (Kinh et al., 2017) 
and for building capacity for laboratory diagnostics for AMR in hospital and veterinary 
laboratories. The findings of the MALDITOF-MS study implicate that the laboratory capacity 
for microbiological diagnosis needs to be sustained by trained human resources. 
Antimicrobial stewardship in participating hospitals should be implemented prior to or 
alongside the equipment investments. 
8.3. Evidence based intervention is required for adaptation of 
bundle of care in prevention of HAIs in resource limited settings  
In Chapter 7, I presented the methods used to evaluate the effectiveness of a medical 
device on antimicrobial use and HAI incidence. By focusing on VARI, which is the most 
common HAI in critical care units in Vietnam, my work evaluated the effectiveness of 
continuous cuff pressure control in preventing VARI. At the time of thesis submission, this 
was the largest study with an RCT design and the first study in an LMIC setting to evaluate 
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this method. Because of the deadline for thesis submission, the results of this study could 
not yet be presented here and final results will likely become available prior to the viva and 
will subsequently be published in an open access, peer reviewed journal.  
8.4. Recommendations 
Whilst the global health expenditure grows faster than GDP (World Health 
Organization, 2017b), our findings in the costing study illustrate the significance of HAIs 
prevention in saving national cost. In consideration of the findings of our MALDITOF-MS 
trial, studies to assess the implementation of advanced technology and medical devices are 
an important part of the process to improve patient care and to determine whether such 
investments are cost-effective in supporting antimicrobial stewardship interventions and 
prevention and control of HAIs. Results of these studies provide evidence to help guide 
policy decisions on prioritising investments for preventing HAIs and promoting 
antimicrobial stewardship with limited budgets. 
Based on findings in my thesis, I recommend further studies to be performed to (1) 
evaluate the economic benefit of MALDITOF-MS as part of an antimicrobial stewardship 
intervention in reducing antimicrobial use; (2) measure the incidence and economic burden 
of different HAIs types as part of a national surveillance programme and (3) evaluate the 
roll-out of the continuous cuff pressure control devices to reduce HAI in resource limited 
settings (pending results of our trial). 
Future studies of medical devices should evaluate the impact of successful 
interventions at the ICU level and benefits to patient’s outcomes with the hope that a 
substantial reduction in the use of antibiotics will in turn lead to a reduction of the 
emergence and transmission of resistance in the ICU. Because RCTs are time and cost 
consuming, alternative approaches (cluster-randomised or stepped-wedge design) may be 
considered for any potential rollout of a successful intervention. 
8.5. Conclusions 
My thesis showed that whilst the burden of HCAI is severe and the high cost of 
treatment for multidrug resistant infections placed an economic burden on health systems 
and both served as a barrier to the uptake of ICU services, advanced diagnostic technology 
alone was not a solution for reducing antimicrobial use or improving patient’s clinical 
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outcomes. Evaluation of interventions in clinical trials is important to understand how well 
technology and devices works in reality of clinical settings. 
My thesis highlighted the necessity of addressing the burden of hospital acquired 
infections in Vietnam, where the incidence of HAIs is high but technology, financial and 
human resources are inadequate. The described approach to evaluate the cost of care in 
this thesis can be applied to explore the economic burden of anatomical site-specific HAIs 
types, while national registration is not established. Understanding the effectiveness stand-
alone implementation of advanced diagnostic technology (MALDITOF) and the HAI 
prevention recommendations that will follow from my clinical trial will have wide 
applicability in other LMICs. 
The findings in my thesis are relevant to healthcare professionals and policy 
stakeholders. It demonstrates the magnitude of HAI burden and creates awareness of 
potential beneficial interventions. Results of my trials will be helpful to inform decisions to 
establish the antimicrobial stewardship programmes and infection prevention and control 
bundles to improve patients’ outcomes.  
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Appendix 
Appendix 1: Supplementary review data for the Chapter 5 
Supplementary Table 1. Review of identification of pathogens from blood culture using MALDITOF-MS  
 MALDI-TOF System  Samples Accuracy Limitation Ref 
Schubert et 
al 
MALDI Sensityper 
kit (Bruker 
Daltonik) 
500 positive BC 86.5% of all, 89.8% of GNB, 86.3% 
GPB, 70.6% of yeasts at the species 
level 
Streptococcus mitis isolates have been 
misidentified as Streptococcus pneumoniae 
(Schubert 
et al., 
2011) 
Jo et al MALDI-TOF Vitek 
MS (bioMérieux, 
France) 
254 blood 
cultures: 235 
from adult 
patients, and 19 
from pediatric 
patients 
81.8% (208/254) of all, 73.9% of 
GPB and 92.6% of GNB. Correct 
identification for 
Enterobacteriaceae, non-
fermentative GNB, and 
staphylococci was 81/83 (97.6%), 
12/15 (80.0%), and 72/85 (84.7%), 
respectively. 
 
45 isolates was not identified, included 37 
Gram-positive isolates (14 streptococci, 11 
coagulase-negative staphylococci (CoNS), three 
enterococci, 2 Staphylococcus aureus, 2 
Micrococcus spp., 2 Bacillus spp., and one each 
of Actinomyces odontolyticus, Finegoldia 
magna, and Peptostreptococcus spp) and 8 
pediatric bottles (2 Staph capitis, 2 
Staphylococcus epidermidis, and one each of 
Streptococcus pneumoniae, Micrococcus spp., 
Streptococcus constellatus, and Burkholderia 
cepacia). 
(Jo et al., 
2016) 
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 MALDI-TOF System  Samples Accuracy Limitation Ref 
Chen et al Bruker Microflex LT 
with Biotyper 3.0 
system 
202 positive 
blood cultures, 
included 181 
monomicrobial, 
(75 of GPB and 
106 of GNB) 
and 21 
polymicrobial. 
97.8% (177/181) of monomicrobial, 
23.8% (5/21) of mixed-culture 
specimens and only the major 
composition of the remaining 16 
mixed cultures 
Streptococcus anginosus was miss-identified as 
Streptococcus constellatus and Streptococcus 
bovis identified as Streptococcus gallolyticus. 
Neither system was ready for direct use with 
polymicrobial blood culture 
(Chen et 
al., 2013) 
 bioMérieux Vitek 
MS IVD 
92.3% (67/181) of monomicrobial, 
only the major composition of 
mixed cultures 
 
La Scola et 
al 
MALDI-TOF MTP 
384 target plate 
(Bruker Daltonik 
GmbH, Leipzig, 
Germany 
584 positive 
blood cultures, 
562 
monomicrobial 
and 22 
polymicrobial.  
Protocol 1: 59% (189/322) of all, 
94% (117/125) of GNB and 37 
(72/192) of GPB. 
Protocol 2: 76% (181/240) of all, 
87% (87/100) of GNB and 67% 
(94/140) of GPB 
Streptococcus spp. were poorly identified. 
Serratia marcescens was misidentified as 
Aeromonas hydrophila. 2/22 polymicrobial 
positive blood was not identified, 18 with only 
one of the two isolates was identified, 2 
specimens (including one with three different 
species) was erroneous identification 
(La Scola 
and 
Raoult, 
2009) 
Pulcrano et 
al. 
Vitek II system 
(bioMérieux, Marcy 
L’Étoile, France) 
82 blood 
culture of 
Candida non-
albicans 
99% (74/82)  Candida parapsilosis was misidentified as 
Lodderomyces elongisporus and Candida 
tropicalis as Saccharomyces cerevisiae. 
misidentifying most of Candida guillermondii 
isolates  
(Pulcrano 
et al., 
2013) 
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 MALDI-TOF System  Samples Accuracy Limitation Ref 
Barnini et 
al. 
MALDI-TOF (Bruker 
Daltonics, Bremen, 
Germany) 
133 positive 
Gram-negative 
bacteria blood 
cultures, 118 
monomicrobial 
and 15 
polymicrobial 
99.2% (117/118) of GNB 
monomicrobial, 86.6 % (13/15) 
polymicrobial was correctly 
identified 
90% (70/82) of monomicrobial 
GPB,  
7/7 positive GPB mixtures with one 
microorganism of the mixture was 
correctly identified 
Stenotrophomonas maltophilia strain was not 
identified. All microorganisms of 2 mixture 
cultures were unidentified. Unidentified strains 
were 3 Staphylococcus epidermidis, 1 
Staphylococcus haemolyticus, and 1 
Micrococcus luteus, 3 misidentified strains by 
the direct method were: 1 S. haemolyticus 
erroneously identified as Staphylococcus 
hominis, 1 E. faecium as Enterococcus faecalis, 
and 1 Streptococcus oralis group mitis as 
Streptococcus pneumoniae. 
(Barnini 
et al., 
2015) 
GPB, Gram-positive bacteria 
 
Supplementary Table 2. Review of effect of rapid identification of pathogens using MALDI-TOF on clinical outcome 
Study design Study population  Intervention Outcome Mortality  Length of stay Ref  
Retrospective, 
quasi-
experimental 
single-center 
study 
119 patients with A. 
baumannii pneumonia and/or 
bacteremia. 66 patients in pre-
intervention arm and 53 
patients in intervention arm 
MALDI-TOF 
and antibiotic 
stewardship  
19% increase in clinical 
cure (15% vs. 34%, 
p=0.016)  
No significant 
difference in 14-day 
mortality (20% vs. 
25%, p=0.526).  
Decreased infection-
related length of stay (13 
[8-18] vs. 11 [7-15] days, 
p=0.021). 
(Wenzler 
et al., 
2016) 
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Study design Study population  Intervention Outcome Mortality  Length of stay Ref  
Retrospective 
study 
155 episodes of peritoneal 
dialysis-related peritonitis, 98 
isolates using a conventional 
method and 57 isolates using 
the MALDI-TOF MS  
MALDI-TOF  No difference in 
improvement of 
peritonitis, 
(the time to WBC < 
100/mm3) 
No significant 
difference in in 
hospital mortality (4.4 
vs. 10%, p= 0.52) 
Decreased hospital stay 
(8.2 ± 4.5 versus 5.2 ± 4.8 
days, P = 0.001) 
(Lin et al., 
2016) 
quasi-
experimental 
single-center 
study 
317 with Gram-negative 
bloodstream infections, final 
analysis included 112 patients 
in the pre-intervention arm 
and 107 patients in the 
intervention arm 
MALDI-TOF 
and antibiotic 
stewardship 
The time to an active 
agent initiation was 
shorter than in 
intervention group 
(n=5, 36.5 hours vs 
n=22, 73.2 hours, P 
<0.001 )  
No significant 
difference in all-cause 
30-day mortality rates 
(5.6% versus 10.7%; 
P=0.19) 
No significant difference in 
ICU length of stay (6.1 vs. 
4.9). The mean hospital 
length of stay was 11.9 
versus 9.3 days in the 
intervention group (n= 101; 
P <0.01) 
 (Perez et 
al., 2013) 
A pre–post 
quasi-
experimental 
study 
501 patients with bacteremia 
or candidemia included in final 
analysis 
MALDI-TOF 
and antibiotic 
stewardship 
Improved time to 
effective antibiotic 
therapy (30.1 vs 20.4 
hours) and optimal 
antibiotic therapy 
(90.3 vs 47.3 hours) 
30-day all-cause 
mortality 
preintervention 20.3% 
versus with MALDI-
TOF 12.7% (p=0.021) 
Length of hospitalization 
14.2 ± 20.6 days versus 
11.4 ± 12.9 days. Length of 
ICU stay was 14.9 ± 24.2 
days versus 8.3 ± 9.0 day  
(Huang et 
al., 2013) 
A pre–post 
quasi-
153 patients with antibiotic-
resistant Gram-negative 
bacteremia hospitalised and 
MALDI-TOF 
and antibiotic 
stewardship  
Improved time to 
optimal antibiotic 
therapy (80.9 versus 
Mortality among 
patients during the 
Intervention decreased 
duration of hospitalization  
(Perez et 
al., 2014) 
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Study design Study population  Intervention Outcome Mortality  Length of stay Ref  
experimental 
study 
112 patients treated post-
implementation. 
23.2 h) and effective 
antibiotic therapy 
(89.7 h versus 32 h) 
intervention period 
was lower (21% versus 
8.9%, P < 0.01) 
(15.3 days vs 23.3 days, P < 
0.0001) and shorter ICU 
 length of stay (10.7 vs 16 
days, P<Z 0.008).  
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Appendix 2: Case report form – MALDI-TOF trial 
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Appendix 3: Case report form – VARI trial 
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Appendix 4: Published papers 
− Dat VQ, Nadjm B, Campbell JI, Dung VTV, Torre A, Tu NTC, Van NTT, Trinh 
DT, Lan NPH, Trung NV, Hang NTT, Hoi LT, Baker S, Wolbers M, Chau NVV, 
Van Kinh N, Thwaites GE, van Doorn HR, Wertheim HFL. 2019. A randomised 
controlled trial of matrix-assisted laser desorption ionization-time of flight 
mass spectrometry (MALDITOF-MS) versus conventional microbiological 
methods for identifying pathogens: Impact on optimal antimicrobial therapy 
of invasive bacterial and fungal infections in Vietnam. J Infect 
doi:10.1016/j.jinf.2019.03.010. 
− Dat VQ, Geskus RB, Wolbers M, Loan HT, Yen LM, Binh NT, Chien LT, Mai 
NTH, Phu NH, Lan NPH, Hao NV, Long HB, Thuy TP, Kinh NV, Trung NV, Phu 
VD, Cap NT, Trinh DT, Campbell J, Kestelyn E, Wertheim HFL, Wyncoll D, 
Thwaites GE, van Doorn HR, Thwaites CL, Nadjm B. 2018. Continuous versus 
intermittent endotracheal cuff pressure control for the prevention of 
ventilator-associated respiratory infections in Vietnam: study protocol for a 
randomised controlled trial. Trials 19:217 
− Dat VQ, Huong VTL, Turner HC, Thwaites L, van Doorn HR, Nadjm B. 2018. 
Excess direct hospital cost of treating adult patients with ventilator 
associated respiratory infection (VARI) in Vietnam. PLoS One 13:e0206760 
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